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Early identification of malignancy has the ability to improve long term morbidity and mortality.  This 
is certainly the case for colorectal cancer and hepatocellular carcinoma (HCC), two of the 
commonest gastrointestinal malignancies.  Both diseases are subject to screening programmes.  The 
UK national Bowel Cancer Screening Programme (BCSP) has been shown to significantly improve 5 
year cancer survival by identifying colorectal cancer at an earlier stage, but also by identifying 
advanced, pre-malignant adenomatous disease and removing it.  Screening of cirrhotic patients at 
risk of HCC is a bit more controversial but is recommended by national and international bodies, 
with some evidence to suggest an improved survival from cancer associated death.  Biomarkers are 
currently employed in the diagnosis and patients selection process for these screening programmes, 
in particular alpha fetaprotein (AFP) for HCC.  The sensitivity and specificity, and thus the valid 
application of these biomarkers has been brought in question, in the case of alpha feta protein, 
leading to its removal from screening protocols.  Volatile organic compounds have been proposed as 
biomarkers for various disease processes, including gastrointestinal malignancies.  They may 
therefore have an application in disease screening and/or monitoring. 
The work presented here explores volatile organic compounds (VOCs) emitted from stool and urine, 
in order to detect disease specific differences that may be utilised as biomarkers for colorectal 
cancer and hepatocellular carcinoma.  It also explores the driver-passenger model of colorectal 
cancer and biological plausibility via the detection of volatile organic compounds emitted from 
cultures of Fusobacterium nucleatum and Campylobacter showae.  Finally, it assesses the utility of 
the stool based tM2-PK assay as a marker of colorectal neoplasia in a novel secondary care cohort.  
Solid phase micro-extraction of headspace gas followed by gas chromatography mass spectrometry 
was used to isolate and identify candidate volatile organic compounds.  Statistical analysis, including 
logicistic regression modelling and 10 fold cross validation, were applied to assess biomarker utility. 
Analysis of VOCs emitted from stool was able to differentiate those with higher risk neoplastic 
disease with the greatest confidence, including established colorectal cancer.  When comparing 
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those with cancer to no neoplasia isopropyl alcohol was significantly more abundant in the 
colorectal cancer samples (p=<0.0001, q=0.004), producing an AUROC curve of 0.76.  When 
isopropyl alcohol is combined with butanoic acid, 3-methyl, the AUROC was 0.82, sensitivity 87.9% 
(95% CI 0.87-0.99) and specificity 84.6% (95% CI 0.65-1.0).  Further logisitic regression analysis of 
VOC presence identified a three VOC panel (isopropyl alcohol, 2-Hexanone and butanoic acid,3-
methyl-,ethyl ester) with an AUROC of 0.86: a person being 6 times more likely to have cancer if all 3 
VOCs were present in their stool(p=<0.0001).  A number of the VOCs identified as important in those 
with colorectal neoplasia were also identified in the assessment of Fusobacterium nucleatum and 
Campylobacter showae, namely butanoic acid based compounds and isopropyl alcohol.  VOCs 
emitted from urine failed to demonstrate any candidate biomarkers for colorectal neoplasia. 
With regards VOCs emitted from urine as biomarkers for HCC, AUROC comparing all those with and 
without HCC was 0.76 (Sensitivity 65% [95% CI 0.61-0.69] Specificity 74% [95% CI 0.69-0.78]).  When 
assessing treatment naive HCC patients, 3 compounds were found to have significantly different 
abundance (p=<0.01), when combined and modelled these VOCs demonstrated a superior AUROC of 
0.81 (Sensitivity 77% [95% CI 0.71-0.83], Specificity 75% [95% CI 0.71-0.79]).  Of this treatment naive 
group patients defined by Barcelona Clinic Liver Cancer (BCLC) staging as having early disease and 
therefore potentially curative, demonstrated an AUROC of 0.82. 
VOC emitted from stool and urine show a clear ability to act as biomarkers for the diagnosis of 
colorectal cancer and hepatocellular carcinoma respectively. 
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1.1 Colorectal cancer: epidemiology and statistics 
Colorectal cancer is a major cause of mortality and morbidity in Europe and North America, with an 
estimated European incidence of 43.5 per 100,000 and a mortality of 19.5 per 100,000 in 2012[1].  
The incidence of colorectal cancer has increased by 6% in the last decade: it is now the third most 
common malignancy in the UK[2].  The UK lifetime risk is 1 in 15 for men and 1 in 19 for women[3].  
Colorectal cancer accounts for approximately 15,000 deaths per annum in the UK, with a 50-55% 5-
year mortality rate[2].  It is associated with a significant financial burden on the UK National Health 
Service (NHS): the mean annual cost of treating a patient with rectal cancer is estimated to be 
£12,000, while that for a patient with non-rectal colon cancer is approximately £8,800[4].  Early 
diagnosis is a key aim in managing colorectal cancer and population based screening has been 
shown to reduce long term mortality from colorectal cancer when implemented[5]. 
1.2 Acquired risk factors 
Many studies have reported associations between dietary and lifestyle factors and the risk of 
developing colorectal cancer.  Others have gone further, with attempts to discover and describe 
potential, underlying biological processes and mechanisms that could influence genetic mutations 
and subsequent cancer formation. 
1.2.1 Diet 
The so-called western diet is characterised by higher proportions of processed foods and red meats, 
than other regional world diets, together with reduced dietary fibre and reduced protective 
phytochemicals found in fruits, vegetables, and whole grains compared to traditional diets[6].  With 
the latter having a potentially protective effect against colorectal cancer and the former being pro-
oncogenic[7]. 
1.2.2 Dietary fibre 
The hypothesis that dietary fibre was important in the development of colorectal cancer was born 
out of global observations in the areas of low incidence (Africa, Asia) the consumption of fibre is 
greater than in the western world where the incidence is high[8].  The view that dietary fibre is 
protective against colorectal cancer, gained more credence in 2011 when the World Cancer 
Research Fund / American Institute for Cancer Research Report upgraded the association between 
fibre and risk of colorectal cancer from “probable” to “convincing”[9].  
The presence of fibre in the diet leads to quicker colonic transit, dilution of colonic content and, 
most significantly, enhancement of bacterial fermentation, which leads to increased production of 
short-chain fatty acids (acetate, propionate, and butyrate), of which butyrate is  recognised to have a 
 3 
 
chemoprotective role by slowing growth and activating apoptosis in colon cancer cells[6,10].  Short 
chain fatty acids have been shown to interfere with numerous regulators of the cell cycle, 
proliferation, and apoptosis, such as β-catenin, p53, p21, Bax, and caspase 3 genes[11–13].  They 
have also been shown to have an anti-inflammatory effect decreasing the production of IL-6 and 
TNFα and also cycloxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) gene 
expression[14,15].  Research conducted by the European Prospective Investigation into Cancer and 
Nutrition (EPIC) analysed fibre intake and incidence of colorectal cancer in more than 500,000 
individuals. In doing so, they demonstrated a 40% reduction in the incidence of colorectal cancer 
when doubling fibre intake, with an even greater reduction in individuals who consume higher levels 
of fruit and vegetables[16].  
A meta-analysis conducted in 2011, looking at 25 prospective cohort and nested case-control studies 
of dietary fibre or whole grain intake and incidence of colorectal cancer, concluded that a high intake 
of dietary fibre, in particular cereal fibre and whole grains, was associated with a reduced risk of 
colorectal cancer.  The summary relative risk of developing colorectal cancer for 10 g daily of total 
dietary fibre (16 studies) was 0.90 (95% CI 0.86-0.94), for fruit fibre (n = 9) was 0.93 (95% CI 0.82-
1.05), for vegetable fibre (n = 9) was 0.98 (95% CI 0.91-1.06), for legume fibre (n = 4) was 0.62 (95% 
CI 0.27-1.42), and for cereal fibre (n = 8) was 0.90 (95% CI0.83-0.97). The summary relative risk for 
an increment of three servings daily of whole grains (n = 6) was 0.83[17].  However, a Cochrane 
review conducted in 2002 did not demonstrate similar results and  concluded that there was 
currently no evidence from RCTs to suggest that increased dietary fibre intake will reduce the 
incidence or recurrence of adenomatous polyps[18].   
1.2.3 B Vitamins- including folate (B9) 
Fibre rich foods are frequently also high in B vitamins, including Vitamin B9, folate.  Results from the 
EPIC study were initially questioned, due to the confounding presence of folate, however 
subsequent analysis showed this to be independent[19].  B vitamins have a key role in DNA 
synthesis, repair, and methylation[20].  They have recently been shown to reduce the invasiveness 
of colorectal cancer by the activation of the Hedgehog Shh signaling pathway through promoter 
hypomethylation and stimulation of the nuclear factor κB (NF-κB) pathway[21].  This benefit has not 
been demonstrated when pharmacologically supplemented folate is given and is only present when 
taken via the diet[19].  In fact, excessive supplementation of folate in humans has been shown to 
increase colorectal cancer and adenoma formation[22]. 
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Vitamin B6, or pyridoxal phosphate, has also been shown to be important.  A meta-analysis carried 
out in 2010 demonstrated the risk of colorectal cancer decreased by 49% for every 100-pmol/mL 
increase in blood Vitamin B6 (RR 0.51; 95% CI 0.38-0.69)[23]. 
1.2.4 Red and processed meat 
A meta-analysis from 2011 demonstrated further association between red and processed meat and 
colorectal cancer.  This is particularly pertinent since the World Cancer Research Fund/American 
Institute of Cancer Research Report of 2007 upgraded the evidence for this to “convincing”.  The 
summary relative risk of colorectal cancer for the highest versus the lowest intake was 1.22 (95% CI 
1.11-1.34) and the RR for every 100 g/day increase was 1.14 (95% CI 1.04-1.24). Non-linear dose-
response meta-analyses revealed that colorectal cancer risk increases, approximately linearly, with 
increasing intake of red and processed meats up to approximately 140 g/day, where it begins to 
plateau[24].  This becomes particularly significant when considering the average daily intake in the 
USA is 128 g[25]. 
Potential reasons for the association between high red and processed meat intake and colorectal 
cancer risk include the content of the meat (e.g. protein, haeme) and compounds generated by the 
cooking process (e.g. N-nitroso compounds, heterocyclic amines). These factors can affect the large 
intestine mucosa with genotoxicity and metabolic disturbances, including expression of numerous 
cytokines (e.g. IL-6, IL-8, TNFα, NF-κB), leading to increased cytotoxicity and stimulation of an 
inflammatory response[26].  Furthermore the processing of red meat, including frying or grilling at 
high temperatures causes degradation of muscle creatinine and amino acids, resulting in the 
formation of numerous carcinogenic heterocyclic amines[6].  
Increased bacterial fermentation (putrefaction) of undigested protein and production of bacterial 
metabolites derived from amino acids may affect colon epithelial homeostasis and renewal. This 
correlates with the fact that most colonic cancers are detected in the distal colon and rectum where 
protein fermentation occurs[27].  Animal models, with high protein diets, have demonstrated 
increased genetic damage in colon cells, as well as the level of faecal p-cresol (synonyms include 4-
methylphenol, m-cresol and 4-cresol) , compared to that of rats fed a normal-protein diet[28,29]. 
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Figure 1: Schematic view of the metabolism of undigested proteins in the large intestine. 
 
Alimentary and endogenous undigested proteins undergo metabolism by the microbiota leading to the release 
of amino acids and further metabolism resulting in the production of a complex mixture of metabolic end-
products that may enter into the colonocytes and exert deleterious effects when present in excess, adapted 
from Kim et al[27].  BCFAs= Branch chain fatty acids, SCFAs= short chain fatty acids.  
However, this does remains an area of contention, with a series of conflicting studies.  In a multi-
ethnic cohort, with 165,717 participants, it was concluded that there was no role for meat in the 
aetiology of colorectal cancer[30].  A further analysis of more than 35 prospective studies failed to 
find a clear dose-response relationship between red meat intake and colorectal cancer[31]. 
1.2.5 Smoking 
Unlike those factors arising from dietary exposures, there is little debate for the carcinogenic impact 
of smoking.  The EPIC study demonstrated the clear link between tobacco smoking and colorectal 
cancer, in both current and previous smokers (RR 1.21), with most cancers being right sided[6,16].  
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The main carcinogens found in tobacco smoke are aromatic amines, nitrosamines, heterocyclic 
amines, and polycyclic aromatic hydrocarbons[6].  These substances, via their metabolism through 
cytochrome p450 enzymes, result in aberrant DNA and specific oncogenic mutation e.g. KRAS[32].  
Nicotine also plays a key role through its activation of -adrenoreceptors, which in turn  trigger 
inflammatory and metastatic signalling through the COX-2, matrix metalloproteinase (MMP-2), and 
VEGF pathways[33]. 
1.2.6 Alcohol 
Excessive alcohol has been linked to a number of gastrointestinal (GI) malignancies.  Metabolism of 
alcohol via alcohol dehydrogenase, catalase and cytochrome p450, results in the production of 
acetaldehyde, which is a class 1 carcinogen and is responsible for chromosome damage[34].  Meta-
analysis of 9 cohort studies, from 2014, showed not only a clear link between alcohol and colorectal 
cancer, but also a dose response relationship.  Compared with non/occasional drinkers, the pooled 
RR was 1.03 (95% CI 0.93-1.15) for any, 0.97 (95% CI 0.86-1.10) for light (≤12.5 g/day of ethanol), 
1.04 (95% CI 0.94-1.16) for moderate (12.6-49.9 g/day of ethanol), and 1.21 (95% CI 1.01-1.46) for 
heavy drinkers (≥50 g/day of ethanol)[35].  This dose response has also been demonstrated in meta-
analysis considering intake below 50g/day[36].  This dose dependent relationship has been 
demonstrated on a cellular level, with an increase in DNA strand breaks in colonic mucosa cells with 
increasing ethanol levels[37]. 
A connection has also been described with adenomatous polyps, the precursor lesion to many 
colorectal cancers.  Analysis of 30 studies, with 26 145 incident colonic adenomas, demonstrated an 
increase of 25 g per day of alcohol consumption led to an increased risk of colonic adenoma 
(summary relative risk=1.27, 95% CI 1.17-1.37).  This association between alcohol consumption and 
adenoma formation applied equally to men and women, but did not apply to rectal adenomas[38]. 
In addition to the pro-oncogenic characteristics of alcohol, chronic exposure to alcohol results in 
deficiency of dietary B Vitamins, including folate.  This provides a second potential mechanism for its 
association with colorectal cancer. 
1.2.7 Obesity 
Obesity, defined as a BMI >25kg/m2, has been described as a contributing factor to many neoplasms, 
including colorectal cancer.  A systematic review in 2013 showed this association, both when 
considering general obesity (BMI) and central obesity (waist circumference, WC).  Approximately 9 
million participants from several countries were included in this analysis. 41 studies on general 
obesity and 13 studies on central obesity were included in the meta-analysis. The pooled RRs of 
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colorectal cancer for the obese vs. normal category of BMI were 1.334 (95% CI 1.253-1.420), and the 
highest vs. lowest category of WC were 1.455 (95% CI 1.327-1.596)[39].  Another systematic review 
assessing colorectal cancer and adenoma indicated their higher prevalence in obese individuals, 
particularly in men. Compared with BMI below 23.0 kg/m2, for BMI of 23.0–24.9, 25.0–27.4, and 
27.5–29.9 kg/m2 and BMI greater than 30 kg/m2, the risk of colorectal cancer was 14, 19, 24, and 
41 %, respectively[40]. 
Mechanisms that may account for the link between obesity and colorectal cancer risk include 
hyperinsulinemia, insulin resistance, inflammation, altered immune response, oxidative stress, as 
well as disturbances in insulin-like growth factors, adipokines, and sex steroids[41].  Adipose tissue is 
considered to be metabolically active and is responsible for the release of numerous cytokines, 
hormones and T-cell stimuli, all of which lead to chronic, low level inflammation, which leads to an 
increased risk of colorectal cancer[6].  Hormones specific to adipose tissue include leptin, 
adiponectin, and resistin are known to be carcinogenic.  Moreover, they have been demonstrated to 
be raised in the serum of obese patients with colorectal cancer and adenomas when compared to 
controls[42,43]. 
1.2.8 Exercise and physical activity 
The protective relationship of exercise and colorectal cancer has been demonstrated in a number of 
systematic reviews and meta-analyses some suggesting a 24% lower risk of colorectal cancer 
development in those undergoing regular exercise compared with those who have a sedentary 
lifestyle[44].  This benefit also extends to polyp development, with the same group showing 16% 
reduction in the incidence of colonic adenomas and 35% reduction in the incidence of large colonic 
polyps in the physically active group[45].  Other systematic reviews have suggested even greater 
impact.  Cross-sectional studies have shown that regular physical activity (7 hours of brisk walking 
per week) lowers the risk of colon carcinoma by 40%. Physical activity also improves the outcome of 
patients already diagnosed with colorectal carcinoma: for example, patients with advanced disease 
have been found to survive significantly longer if they perform 4 hours of brisk walking per week, or 
the equivalent degree of physical exercise[46].  Excessive exercise has been shown to be harmful, as 
it induces high levels of oxidative stress and subsequent DNA damage; this harmful effect is not 
demonstrated with moderate exercise[47]. 
There has also been a description of the effects of exercise on the site of colonic cancers.  Physical 
activity was related inversely to the risk of cancer at the proximal (RR 0.76, 95% CI 0.70-0.83) and 
distal colon (RR 0.77, 95% CI 0.71-0.83). Such a relationship could not be established for the rectum 
(RR 0.98, 95% CI 0.88-1.08)[48]. 
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The protective nature of physical activity is likely to arise from increased insulin sensitivity, lower 
insulin levels, decreased body mass, and decreased adipose tissue volume, leading to a reduction of 
chronic inflammation.  Physical activity causes the reduction of adipose tissue.  Adipose tissue is 
known to produce TNFα, which in turn results in chronic low-grade inflammation and colorectal 
cancer.  In people undertaking regular exercise, lower levels of TNFα and iNOS have been measured 
in the serum, with increased levels of IL-6, leading to enhanced immunity and also increased lipolysis 
in adipose tissue[49,50]. 
1.2.9 Circadian rhythm 
The circadian timing system (CTS) controls several critical molecular pathways for cancer processes 
and treatment effects over the 24 hours, including drug metabolism, cell cycle, apoptosis, and DNA 
damage repair mechanisms[51].  There is clear variation in the mechanisms of cell proliferation, 
differentiation, apoptosis, and DNA repair during the day and night[52].  In fact, Hrushesky et al, 
showed a 50% increased risk of developing colorectal cancer in night-time shift workers[52].  
Circadian clock genes have been described, these include PER1, PER2, PER3, and CLOCK[6].  These 
have been shown to up- and down-regulate oncogenes, such as p53, and to be key to cell signalling 













1.3 Pathogenesis of colorectal cancer  
Vogelstein first described a model of colorectal  carcinogenesis arising from an accumulation of 
genetic alteration, now widely accepted[55]. The development of molecular genetic understanding 
has demonstrated these critical mutations underlying the pathogenesis of the sporadic and inherited 
forms of colorectal cancer (Figure 2).  Recent genome wide studies have demonstrated up to 80 
individual mutations per colorectal cancer, there is certainly a subset within this larger number of so 
called “drivers”, of which there are fewer than 15[56,57].  These genes with a more prominent role 
include APC, KRAS and p53[58].  They have prominent roles in a number of inherited syndromes and 
also in the adenoma-carcinoma sequence. 
Figure 2: Adenoma-carcinoma sequence with associated genetic alterations leading to 
progression. 
 
Identifies the points at which specific genetic mutations and alteration occur, modified from Vogelstein[55].  
For tumour progression to occur multiple genetic events, as outlined above, need to take place: 
genetic instability being key to this process.  In colon cancer, at least 3 distinct pathways of genomic 
instability have been described, the chromosomal instability (CIN), microsatellite instability (MSI), 
and CpG island methylator phenotype (CIMP) pathways[57]. 
1.3.1 Chromosomal instability 
Chromosomal instability (CIN) is observed in 65%–70% of sporadic colorectal cancers[57].  The 
consequence of this instability is loss of genetic heterozygosity (LOH) and aneuploidy.  Chromosome 
segregation appears to be an important influence on CIN.    If this is faulty, there is impaired 
segregation of chromosomes leading to an abnormal number of chromosomes being distributed to 
daughter cells[57].  Another proposed mechanism is abnormal centrosome number and function.  
This is pivotal during mitosis and chromosome separation, if there are too many centrosomes 
present then there is an unequal distribution of chromosomes to daughter cells and the potential for 
carcinogenesis[59].  The abnormalities that occur during CIN result in an impaired ability to repair 
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damaged DNA and a set of characteristic mutations in specific tumour suppressor genes and 
oncogenes which are crucial to the progression through the adenoma-carcinoma pathway. 
 
 
Table 1: Overall prevalence of genetic mutations in chromosomal instability–positive colorectal 
cancers. 
Gene Prevalence of mutation % Function of gene product 
KRAS 30-50 Cell proliferation, survival and transformation 
CTNNB1 4-15 Regulation of tumour growth and invasion 
PIK3CA 20 Cell proliferation and survival 
APC 30-70 Inhibition of Wnt signalling 
TP53 40-50 Cell cycle arrest, apoptosis 
SMAD4 and 2 10-20 Intracellular mediator of TGF-Beta 
DCC 6 Cell surface receptor to netrin-1 
 
Another key component of CIN is telomere dysfunction.  Telomeres are DNA-protein complexes that 
have a protective role in preventing the fusion of chromosomal ends and disordered segregation.  
With each round of cell division a length of telomere is lost until they are unable to continue to 
function.  Ordinarily this shortened telomere length would lead to programmed cell death.  If this is 
incomplete and the cell manages to survive it will activate telomerase, in order to lengthen the 
remaining telomeres.  In doing so it enters the breakage-fusion-bridge cycle that can continue for 
multiple cell generations and lead to dramatic genome reorganization[57].  Shorter telomere length 
has been demonstrated in both high grade dysplasia and established colorectal cancer[60].  
Furthermore, an increase in telomerase activity has been shown to be associated with carcinoma.  
When comparing Dukes A to Dukes D carcinoma there is greater telomerase activity in Dukes D 
tumours[61]. 
1.3.2 Microsatellite instability (MSI) 
The term microsatellite instability is applied, by international consensus, when >30% of the 
microsatellite marker panel is mutated[62].  Cancers with MSI account for approximately 15% of all 
colorectal cancers and 90% of colorectal cancers in patients with Lynch syndrome[63].  DNA 
mismatches, either insertions or deletions, can occur during replication, MMR protein complexes 
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bind to these defective areas and correct them, thus repairing the DNA sequence.  If this MMR is 
defective then novel microsatellite fragments are created.  
When MSI occurs in DNA mismatch repair genes (MLH1, MSH2 MSH6 and PMS2) this gives rise to 
the Lynch Syndrome as described above.  MSI tumours are typically located in the proximal colon, 
are poorly differentiated and have a mucinous appearance[62].  The frequency with which MLH-1 is 
lost within colorectal cancer increases with age and by the age of 90 years, the gene is lost in 50% of 
tumours[64]. 
MSI can affect similar molecular pathways to those seen in CIN, but has interactions with different 
proteins.  For example, unlike in CIN, MSI tumours have a normal APC expression, instead having a 
mutation in β-catenin meaning it is unable to interact with APC[65]. 
1.3.3 CpG island methylator phenotype (CIMP) 
The CpG sites are regions of DNA where a cytosine nucleotide occurs next to a guaninenucleotide in 
the linear sequence of bases along its length.  Throughout human evolution most of these sites have 
been lost, but about 1% of human DNA consists of short areas where CpG sites have escaped 
depletion[66].  Half of all human genes have their promoter regions embedded with these islands.  
Methylation of these areas, by DNA methyltransferase will silence the genes and such methylation 
will persist to daughter cells[67]. 
Cancer cells often have been found to have a global loss of methylation and a gain of methylation at 
the promoters of selected CpG islands, resulting in suppression of many genes, including tumour 
suppressor genes[68].  It has also been surmised that hypomethylation could lead to under-
suppression on oncogenes.  Observations relating to abnormal methylation, secondary to viruses, 
smoking and radiation have been described, but direct causality is unproven [67,69]. 
A subset of colorectal cancers are characterised by CIMP and they have a number of unique 
features.  They are more common in the proximal colon, compared to the distal colon, and tend to 
occur in women[67].  Typically there are high levels of typical genetic abnormalities, namely of p53 
mutations and particularly of KRAS, such that nearly every CIMP-positive tumour has evidence of 
activation of the RAS oncogenic pathway[67,70]. 
1.3.4 The APC gene and colorectal cancer 
 The adenomatous polyposis coli (APC) gene is a key tumour suppressor gene in colorectal cancer.  
The APC gene product is a 312kDa protein that acts on various other proteins, including β-catenin.  
Through some of these interactions APC suppresses canonical Wnt signalling, which is essential for 
tumourigenesis.  Further work demonstrates that APC plays roles in several other fundamental 
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cellular processes. These include cell adhesion and migration, organization of the actin and 
microtubule networks, spindle formation and chromosome segregation. Deregulation of these 
processes caused by mutations in APC is implicated in the initiation and expansion of colon 
cancer[71]. 
The Wnt signalling pathway is dependent upon β-catenin. APC protein is  a major binding partner 
and regulator of the β-catenin protein[72].  In the absence of the APC gene, the regulation and 
destruction of β-catenin is lacking and so it accumulates.  As a result, cytoplasmic β-catenin 
complexes with DNA-binding proteins of the TCF/LEF (T cell factor/lymphoid enhancer family) family, 
and translocates to the nucleus[71,72].  Dysregulation of a number of genes results, including up 
regulation of a number of oncogenes.  Ultimately, this leads to the development of colorectal 
cancer.  This pathway has been shown to be fundamental in inherited and, more so in, sporadic 
colorectal cancer.  It is thought that the APC mutation is the initiating step in the adenoma-
carcinoma pathway, and perhaps the initiating step in up to 80% of all sporadic carcinomas[58]. 
1.3.5 The KRAS gene and colorectal cancer 
KRAS is mutated in 30%–50% of colorectal cancers[73].  Under normal conditions growth factors, 
binding to their cell surface receptors, activate guanine exchange factors (GEF), such as SOS (son of 
sevenless) that are attached by the adaptor protein GRB2 (growth-factor-receptor bound protein 2). 
SOS stimulates the release of bound guanosine diphosphate (GDP) from RAS, and it is exchanged for 
guanosine triphosphate (GTP), leading to the active RAS-GTP conformation[57].  This in turn 
activates downstream signalling.  As a result of the mutation in the KRAS gene, the usual conversion 
back to RAS and GDP does not occur, meaning there is continual downstream activation by RAS-GTP, 
with sustained proliferation signalling in the cell. 
KRAS mutations are present in hyperplastic lesions with little or no malignant potential[74].  
However they have also been shown to increase in frequency in enlarging adenomatous polyps: up 
to 50% of adenomas >1cm showing KRAS mutations, whilst <10% of adenomas smaller than 1cm 
have them[55]. 
The presence of KRAS mutation and its association with prognosis has been described with 
conflicting comments.  Confusion arises from the conflicting genetic factors associated with KRAS 
mutations.  Principally, KRAS-mutated colorectal cancer is less likely to exhibit MSI and is almost 
never BRAF-mutated[75].  Tumours with high levels of MSI have been shown to have a better 
prognosis, whilst BRAF-mutated cancers have a poorer prognosis[76,77].  A study did show a poorer 
prognosis for those with KRAS mutation, but only in those with Dukes C and only in those with the 
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KRAS p.G12V mutation[78].  The presence of KRAS has also been shown to be a negative predictor in 
response to therapy with anti-epidermal growth factor receptor antibodies, such as cetuximab[79]. 
1.3.6 The p53 gene and colorectal cancer 
The p53 tumour suppressor gene encodes a nuclear phosphoprotein with the ability to bind directly 
to DNA and act as a transcriptional activator[80].  In most tumours, the two TP53 alleles are 
inactivated, usually by a combination of a missense mutation that inactivates the transcriptional 
activity of p53 and a 17p chromosomal deletion that eliminates the second TP53 allele[81].  The role 
of the p53 gene is to arrest the cell cycle in response to the damage in order the facilitate repair or 
the initiation of apoptosis[82].  In colorectal cancer, p53 mutations play a pivotal role in the 
transformation of large adenomas into invasive carcinoma, as they promote continued growth, 
survival against various stresses and invasive properties[58,83]. 
1.3.7 Growth factor pathways 
The activation of growth factor pathways is common in colorectal cancer, some of these are 
described in this section. 
1.3.7.1 Aberrant regulation of prostaglandin signalling 
Adenoma development relies on the critical step of activation of prostaglandin signalling[81].  Up-
regulation of COX-2 leads to overproduction of prostaglandin E2, this is strongly associated with 
colorectal cancer[84].  Increased levels of prostaglandin E2 can also result from the loss of 15-
prostaglandin dehydrogenase (15-PGDH), the rate-limiting enzyme in catalysing degradation of 
prostaglandin[81].  This specific change is seen in up to 80% of adenomas and cancers[84].  There 
have been a number of clinical trials that have demonstrated a reduction in development of new 
adenomas and regression of existing adenomas in the presence of COX-2 inhibitors[81,85,86]. 
1.3.7.2 Epidermal growth factor receptor 
Epidermal growth factor (EGF) is a soluble protein that has trophic effects on intestinal cells. Clinical 
studies have supported an important role of signalling through the EGF receptor (EGFR) in a 
subgroup of colorectal cancers[81].  As previously described, advanced colorectal cancers with 
tumour-promoting mutations of these pathways, including activating mutations in KRAS and BRAF,  
do not respond to anti-EGFR therapy[79,81]. 
1.3.7.3 Vascular endothelial growth factor 
Vascular Endothelial Growth Factor (VEGF) is produced both as a result of injury and normal growth 
in order to promote angiogenesis.  These angiogenic pathways have been shown to be key to the 
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growth and maintenance of colonic tumours and provides new potential targets for therapy, for 
example bevacizumab in metastatic colorectal cancer. 
1.4 Health screening and colorectal cancer 
Often described as Wilson’s criteria, the principles of screening were defined in 1968 by the World 
Health Organisation[87].  These criteria are still applicable today and form the basis of modern 
health screening.  They consist of 10 key points: 
1. The condition should be an important health problem. 
2. There should be a treatment for the condition. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a latent stage of the disease. 
5. There should be a test or examination for the condition. 
6. The test should be acceptable to the population. 
7. The natural history of the disease should be adequately understood. 
8. There should be an agreed policy on whom to treat. 
9. The total cost of finding a case should be economically balanced in relation to medical 
expenditure as a whole. 
10. Case-finding should be a continuous process, not just a "once and for all" project. 
Clinical screening strategies are essentially of two types: those that involve direct investigation of 
the patient, often with an invasive procedure such as colonoscopy or smear testing, and those based 
on laboratory analysis of patient specimens, such as urine, faeces or peripheral blood[88].  As above, 
Wilson’s criteria have been used to define health screening, however to be truly utilised, a screening 
tool must satisfy 4 key points; 
1) it must have acceptable performance in terms of positive and negative predictive value for 
the target population;  
2) a reduction in mortality from the disease;  
3) acceptable levels of patient compliance;  
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4) and low enough cost to be affordable within the context of the specific health-care 
system[88].   
It is unrealistic to expect a completely ideal screening tool, but around the world a combination of 
non-invasive faecal occult blood testing (FOBt) followed by colonoscopy in those with an initial 
positive FOBt is an example for colorectal cancer.  
The progression of normal mucosa to adenomatous polyp and then to colorectal cancer make 
colonic cancer a suitable screening target. 
Figure 3: Simplified colorectal cancer natural history progression model 
 
Adapted from Tappenden et al[89]. 
It has been stated that over 95% of colorectal cancer cases would benefit from surgical treatment, a 
potential cure, if diagnosed early or at the stage of the premalignant polyp[88].  It is estimated that 
in developed countries 40-50% of the population will have at least one colonic polyp.  
A report by the European Commission in 2008 revealed that only 12 of its then, 22 member states, 
had organized population-based colorectal cancer screening programs in place or due to be 
activated.  Following this report member states were urged to ensure fair access to preventive 
services and cancer screening programs for all citizens[90].  In 2010, new guidelines were published 
by the EU relating to colorectal cancer screening and diagnosis quality levels[91]. Not only did this 
include guidance on implementing and maintaining a screening programme but also included 
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encouragement of member states to seek improved primary prevention, such has improving dietary 
and environmental factors that lead to the development of colorectal cancer.  The colorectal cancer 
screening method envisaged by European Council directives is based on a faecal occult blood test 
(FOBt) offered to 50–74 year olds, but different strategies are adopted in different countries.  The 
UK completed its roll out in 2010. 
European-wide guidance for bowel cancer screening suggests a faecal occult blood test (FOBt) 
between the ages of 50-74, followed by a colonoscopy if FOBt is positive, as the gold 
standard[90,92].  Two forms of FOBt (immunological e.g. OC-Sensor and guaiac e.g. Hemoccult-II) 
are currently available and used for screening purposes worldwide[93].   
1.4.1 Faecal occult blood testing  
A guaiac-based Faecal Occult Blood Test (gFOBt) uses the chemical alpha-guaiaconic acid (reagent 
derived from wood resin of Guajacum trees) to detect haem in stool.  After stool is smeared on to 
the device hydrogen peroxide is added.  As haem contains pseudoperoxidase there is a reaction 
which converts guaiac to the colour blue, giving an indication there may be blood in the stool.  Foods 
which can give a false positive result include red meat, carrots, potatoes and figs.  The guaiac-based 
faecal occult blood test usually picks up a daily blood loss of approximately 10 ml.  The gFOBt 
currently used in the England Bowel Cancer Screening Programme (BCSP) has a sensitivity of 36% 
and a specificity of 94% for the detection of colorectal cancer when colonoscopy is used as the gold 
standard for cancer detection[94–96]. 
Immunological FOBt is an instant and objective test which utilizes immuno-chromatography to 
detect occult blood loss in stool. It is specific to human haemoglobin and only reacts with the intact 
haemoglobin molecule. It therefore requires no dietary restriction and it only identifies pathology 
limited to the colon.  With all this in mind it has a lower false positive rate, thus reducing 
unnecessary colonoscopy[97].  The detection “cut-off” can be adjusted with iFOBt thus allowing it to 
be more adaptive to the needs of an individual population of programme[98]. In addition, testing 
may be performed on a single stool sample and integrated into the clinical examination providing an 
instant result which can be used as an adjunct to clinical assessment[99]. 
Faecal DNA testing is a promising development for point of care testing and thus screening, in 
conjunction with the gold standard colonoscopy.  This essentially revolves around the analysis of 
DNA alterations present in tumour cells exfoliated into faeces[100].  The normal colonic epithelium 
renews itself daily, thus resulting in large numbers of exfoliated cells being present in faeces.  It has 
been shown that epithelial exfoliation is more pronounced in the presence of colorectal cancer, with 
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colon cancers accounting for <1% of the total epithelial surface area but between 14-25% of the DNA 
retrieved from faecal analysis[101].  This may be because cancer cells are able to survive much 
longer due to the inhibition of apoptotic and cell death processes 
1.4.2 Adherence and compliance with colorectal cancer screening 
Greater levels of population participation in colorectal cancer screening programs are associated 
with reduced mortality and greater cost-effectiveness[102].  The European Commission has  
previously set 45% as  an acceptable uptake level[91], but greater than this is certainly desirable; 
similar American guidance sets the level at 75%.  Across Europe, within countries and within areas 
covered by the same UK BCSP, uptake varies greatly.  When assessed in boroughs of London, (UK), 
gFOBt return rate varied from 32 and 49%[103]. 
Uptake rates between men and women have been extensively studied, with contrasting results.  
Male participation appears to be greater, but this does vary between countries.  Others have 
suggested that female participation, particularly in Europe and Australia is greatest[90].  In the UK 
female uptake is 4.8% greater than males, with the greatest difference being seen in London[5].  
However, overall there is probably little significant difference between the two sexes[102]. 
Socio-economic status (low income, unemployment, low education and area of residence) appears 
to have the most significant impact on uptake to colorectal cancer screening programmes [90,103].  
Von Wagner et al showed a direct correlation between socio-economic groupings and uptake to the 
colorectal cancer screening in London, with those living in areas of social deprivation having lower 




Figure 4: FOBt return by quintile of area-based socio-economic deprivation 
 
Taken from von Wanger et al (n=401 197)[103]. (Reproduced with permission from British Journal of Cancer). 
Married people are more likely to participate than those who are single, whilst smokers are less 
likely to participate than non-smokers[90]. 
Given the low participation in colorectal cancer screening programs, despite the clear medical 
benefit, it is important to understand the barriers to screening to develop successful alternative 
approaches.  A series of studies have described such barriers, these include factors specific to the 
tests themselves, such as embarrassment, reluctance to handle stool, fear of the procedure, or 
inconvenience, as well as broader factors such as lack of access to care, limited knowledge of 
screening and a lack of physician recommendation[104].  A study from Germany showed that patient 
choice can be key to improving compliance: they offered a stool or blood test prior to colonoscopy 
and found well in excess of 80% preferred blood testing[105]. 
Patient knowledge is a key feature when considering compliance with bowel cancer screening.  This 
includes knowledge of the procedure and intended benefits.  Studies have posed questions including 
those about risk factors for developing colorectal cancer, incidence, prognosis, age-related risk, 
warning signs or symptoms, and knowledge about recommended colorectal cancer screening tests.  
There is huge international variation in patient knowledge, which may account for the variation in 
uptake.  In the USA some studies have reported knowledge of colorectal cancer and screening was in 
excess of 80%, whilst in the UK it has been reported to be as low as 30%[104,106]. 
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The Health Belief Model (HBM) can be used to understand patient participation in screening 
programmes.  This model theorizes on people's beliefs regarding the risk for a disease or health 
problem, and according to their perceptions on the benefits of taking actions to avoid it and analyzes 
their readiness to take action.  Considering this, people with negative attitudes such as 
embarrassment, anxiety, disinterest, fear of cancer or screening, lack of time, feeling healthy, 
apprehensions about the bowel preparation, handling stool for FOBt, laxatives or insertion of a tube, 
and discomfort are more reluctant to participate in screening programmes[107–109].  A Spanish 
study, from 2009, showed that embarrassment was the leading barrier to participation in the bowel 
cancer screening programme, this included stigma of handling stool[110]. 
1.4.3 Impact of bowel cancer screening 
Randomised trials have shown that screening for bowel cancer using guaiac-based faecal occult 
blood tests (gFOBts) can reduce mortality by 16% in people offered screening and 25% in those 
accepting it[111,112].  Other studies have shown that gFOBt screening followed by colonoscopy in 
gFOBt-positive patients produced a 33% reduction in colorectal cancer mortality with gFOBt 
performed yearly and a 21% reduction with gFOBt performed at 2-year intervals; incidence rates fell 
by 20% and 17%, respectively[113,114].  Zorzi et al demonstrated a superior reduction in mortality 
when faecal immunochemical test FIT based screening is adopted compared to gFOBt[115].  Analysis 
of the economics has shown it to be beneficial, with a cost per quality-adjusted life-year gained of < 
£3000 for gFOBt screening[89]. 
Earlier lesion detection is a recognised effect of colorectal cancer screening, both in terms of 
established cancers and polyps.  A Cochrane review by Hewitson et al showed a significant reduction 
in Dukes D and increased Dukes A detection[112].  Other such studies report an increased diagnosis 
of Dukes A lesions with colonoscopy and a corresponding reduction of Dukes C lesions in subsequent 
screening rounds[116,117].  Polyps are also detected at an earlier stage, when they can be 
considered lower risk.  This becomes a significant feature when considering the subsequent risk of 
colorectal cancer and associated death after removal of a high risk polyp.  Loberg et al assessed 
40,826 people following polypectomy over a median follow-up of 7.7 years (maximum, 19.0): a total 
of 398 deaths from colorectal cancer were expected and 383 were observed, for an SMR of 0.96 
(95% CI 0.87-1.06) among patients who had had adenomas removed. Colorectal-cancer mortality 
was increased among patients with high-risk adenomas (expected deaths, 209; observed deaths, 
242; SMR, 1.16; 95% CI 1.02 to 1.31), but it was reduced among patients with low-risk adenomas 
(expected deaths, 189; observed deaths, 141; 95% CI 0.63 to 0.88)[118].   
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On the whole the literature suggests an overall reduction in mortality from colorectal cancer as a 
result of bowel cancer screening programmes, however some studies have not shown a reduction in 
all-cause mortality and there is active debate as to whether disease-specific or direct cancer death is 
the most appropriate endpoint[112]. 
1.4.4 Bowel cancer screening programme in the UK 
In the UK screening takes place on a biennial basis using non-rehydrated guaiac-based faecal occult 
blood tests, followed by colonoscopy with participants being aged 60-69 years.  Whilst in place, this 
programme has been shown to reduce mortality from colorectal cancer, increase adenoma 
detection rates and be cost effective[119,120].  For the UK, the proportion of subjects returning kits 
with positive test results was 2.0% and was higher in men (2.5%)[5].  From its initiation until 2008, 
17518 positive FOBts have been resulted in investigation, 83% of the total positive tests.  Of this 
17518, 98.1% had a colonoscopy.  1772 subjects were recorded as having a colorectal cancer 
(10.1%), together with 4,777 having either intermediate or high risk polyps requiring further 
intervention.  A total of 71.3% of the cancers were polyp cancers or Dukes A or B and so potentially 
curable.  28.7% of the cancers were found in the rectum or recto-sigmoid colon and, overall, 77.3% 
were recorded as being left-sided colorectal cancers while only 14.3% were recorded as being in the 
right colon. As expected right-sided cancer was more commonly found in women (19.2%) than in 
men (12.2%) and conversely rectal cancer was less common in women (20.3%) than men (28.5%)[5]. 
A one-off flexible sigmoidoscopy, known as bowel scope screening, is a new part of the UK BCSP.  It 
began its nationwide roll out in 2013.  It involves a once-only flexible sigmoidoscopy in men and 
women once they turn 55 years of age.  Atkin et al demonstrated that such a programme could 
reduce the incidence of colorectal cancer by 33% and mortality by 43%, over an 11-year follow-up.  
Moreover the incidence of distal cancers was reduced by 50%[121].   
These early results indicate that the BCSP in England is on track to match the 16% reduction in 
colorectal cancer mortality found in the randomised trials of gFOBt screening[5,112].  Replacing the 
gFOBt with another method, such as FIT, DNA analysis or novel technique currently in development 
may improve this further. 
By identifying colorectal cancer at an earlier stage and advanced pre-malignant neoplasia, it is clear 
that bowel cancer screening improves long term outcomes from colorectal cancer.  Limiting 





1.5 Hepatocellular carcinoma 
Primary liver cancer (hepatocellular cancer, HCC) is the third largest contributor to cancer mortality 
in the world, with more than half a million people worldwide diagnosed each year[122].  Liver cancer 
is the fifth most common cancer in men and the seventh in women. Most of the burden of disease 
(85%) is borne in developing countries, with the highest incidence in regions where infection with 
hepatitis B virus (HBV) is endemic[123].  Over the last 3 decades the incidence of HCC has been 
steadily increasing, this has been mirrored by an increasing mortality rate.  Age-standardized rates 
are particularly high in eastern and south-eastern Asia (over 20/100,000 men and over 10/100,000 
women) and middle and western Africa (15-20/100,000 men and about 8-19/100,000 women); in 
most high-income countries, including the Americas, Australia, western and northern Europe, rates 
are below 7.5/100,000 men and below 2.5/100,000 women, while intermediate rates (around 
10/100,000 men and 3/100,000 women) are observed in southern Europe[124]. 
Mortality and 5-year survival from HCC is variable worldwide, but generally would be considered to 
be poor.  This may stem from the variation of underlying aetiology, surveillance programmes, 
economics factors and mortality reporting, along with a long list of other potential factors.  In 
Europe, 5-year survival is reported to be approximately 12%, but there is significant variation 
between its member states[125].  The highest overall mortality rates from primary liver cancer in 
men were in France (6.2/100,000), Spain (4.9), Austria (4.3), and Italy (4.0), while the lowest ones 
were in Sweden (1.1), the Netherlands (1.2), the UK (1.8), and Denmark (1.9)[124].  However, in 
recent years, there has been a rising trend in mortality in the UK and Germany, whilst rates are 
beginning to fall in France and Italy.  Consequently, mortality rates are becoming more uniform 
across Europe.  In lower income countries, around the world, the 5-year survival has been reported 
to be as low as 5%, interpretation needs to be with some caution due to the questionale reliability of 
diagnosis and death certification. 
HCC typically occurs on a background of liver cirrhosis (80-90%) and most commonly in the presence 
of viral hepatitis, namely hepatitis B  and C (HCV).  After viral aetiologies, alcoholic liver disease and 
non-alcoholic fatty liver disease are the most common underlying causes, with less common causes 
such as hereditary haemochromatosis, alpha1-antitrypsin deficiency, autoimmune hepatitis, some 
porphyrias, and Wilson's disease being described[123]. 
 Worldwide, chronic HBV infection accounts for approximately 50% of all cases of hepatocellular 
carcinoma and virtually all childhood cases[123].  Infection with HBV can lead to the development of 
HCC in the absence of cirrhosis, but this only occurs in approximately 20% of patients with HBV-
related HCC.  The risk of developing HCC in the presence of HBV is further increased if there is co-
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infection with HCV, alcohol consumption, increasing age and high circulating HBV DNA 
levels[123,126]. 
HCCs develop as small nodules. The majority of their growth takes place in an asymptomatic phase 
which may be years in length, the median time of size doubling being six months.  The major factors 
contributing to survival are the degree of the underlying liver disease and the size of the tumour at 
diagnosis[127].  According to specific clinical parameters the Childs Pugh score can be calculated in 
order to define the severity of cirrhosis.  Childs Pugh A cirrhosis has an 85% 2-year survival rate, 
compared to an 80% 2-year mortality for Childs Pugh C.  Similarly, as size increases so does mortality 
if cases are left untreated.  This all suggests that early diagnosis and treatment will have an impact 
upon mortality rates, thus implying the need for screening of at-risk groups as a potential measure.  
Moreover, cirrhosis is a progressive disease that affects patient survival. The presence of cirrhosis 
then influences the chances of receiving an effective treatment, thus making an early diagnosis of 
HCC even more crucial. 
Decision analysis and cost–effectiveness models suggest that an intervention is considered cost-
effective if it provides gains of life expectancy of at least 3 months with a cost lower than 
approximately US$ 50,000 per year of life saved[128,129].  This cost effectiveness can be further 
improved by identifying those at low risk and those whose liver disease is too advanced.  Such a 
strategy has led to the recommendations by the European Association for the Study of Liver (EASL), 
stating that the following patients should be offered HCC surveillance: 
-Cirrhotic patients, Childs-Pugh A and B 
-Cirrhotic patients, Childs-Pugh C awaiting transplant 
-Non-cirrhotic HBV carrier with active hepatitis or family history of HCC 
-Non-cirrhotic patients with chronic hepatitis C and advanced liver fibrosis 
1.5.1 Screening and HCC 
In order to effectively define the role of screening in HCC, an ideal randomized, controlled study 
would compare a group of at-risk subjects undergoing surveillance to a group that does not undergo 
surveillance.  In order to increase efficiency, only the patients with the highest risk of HCC should be 
included. Those in the arm undergoing surveillance should receive ultrasound every six months[130].  
Disease stage at diagnosis, treatment efficacy and mortality outcomes could then be accurately 
compared, in order to ascertain whether surveillance reduces the mortality from HCC.  Another 
strategy to assess the impact of surveillance is to study cohorts of screened patients who develop 
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HCC compared to unscreened patients who develop HCC, however this process is open to lead-time 
bias making the results difficult to interpret and generalise[130] 
The results from one of the first randomised HCC surveillance studies, conducted in China, were 
published in 2003.  It compared surveillance with alpha-fetoprotein (AFP) to no surveillance.  In the 
study, an AFP cut-off of >200g/ml was used.  Subjects with such a result were then subjected to 
ultrasound assessment.  As one may expect, there were a greater number of tumours diagnosed in 
the surveillance arm, together with more tumours being diagnosed at an earlier stage.  Despite this 
the study failed to demonstrate a survival benefit[131].  This study was widely criticised as the 
treatment given following a diagnosis of HCC was inconsistent and in many cases not completed, 
thus making comparison of outcomes difficult.  Other such earlier studies, also conducted in China, 
showed a reduction in mortality with combined AFP and ultrasound screening, in one instance up to 
a 37% reduction[132]. 
It is very unlikely that such an ideal study, to compare surveillance to no surveillance in high risk 
groups, will be conducted.  Not only would it be unethical but research into this matter showed 
categorically that patients will not consent to such a study [133]. 
In the absence of this “ideal” study there is some evidence to suggest a benefit of screening for 
HCC[134].  In 2014, Yeh et al, from Taiwan, undertook a study in a population selected by 
establishing a risk score. The risk score was constructed from a panel of blood tests, and a history of 
diabetes or chronic viral hepatitis. Those with a risk score above a cut-off were invited to participate 
in a one-off screening protocol. The mortality in this group was then compared to the mortality of a 
similar group who did not respond to the invitation to be screened, and to the general population 
not invited to participate in the programme.  This study did demonstrate a reduction in mortality 
from HCC for the surveillance group[134].  The high prevalence of viral hepatitis in this area could 
make it difficult to generalise these results to the UK population.  A number of studies have shown 
that screening results in a greater detection of earlier stage tumours.  These are potentially curative 
by resection or transplant, but have failed to show a significant difference in survival[135,136]. 
As described above, cost effectiveness is another way to analyse the impact of screening for HCC.  
There are a number of studies that look at this aspect but there is little homogeneity between them, 
with different surveillance techniques and intervals, different intervention after diagnosis and 
different costs.  The diversity in the underlying aetiology of cirrhosis and subsequent disease course 
greatly affect any cost effectiveness analysis.  What they do have in common is that they show that 
the cost effectiveness of surveillance is critically dependent on the incidence of HCC, but  virtually all 
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show surveillance is cost effective[130]. On balance,  surveillance appears to be cost effective if the 
incidence of HCC exceeds 1.5-2%/year[137,138] which is consistent with AASLD recommendations. 
Andersson et al, in 2008, demonstrated the cost effectiveness of ultrasound.  They also showed that 
the use of CT and MRI for screening is not cost effective, with an incremental cost effectiveness ratio 
of more than $100,000 to $300,000, respectively[139]. 
1.5.2 Evidence for surveillance modalities and intervals in HCC 
Until relatively recently screening has involved the use of AFP, either alone or in combination with 
another modality such as ultrasound.  Much of the data suggest that AFP contributes little to the 
detection of HCC when it is used in combination, with a sensitivity for small HCCs of approximately 
60-65%[140,141].  It also carries a significant false-negative rate, with approximately 40-50% of 
people with a diagnosis of small HCC having a normal AFP[130,142].  AFP has an unacceptable false-
positive rate as it is elevated in patients with active hepatitis and cirrhosis without HCC.  There is also 
clear evidence that shows a higher AFP is more likely to be associated with advanced size, thus 
limiting its role as a screening tool for early cancer [143]. 
The application and the sensitivity of ultrasound for the detection of HCC is highly operator 
dependent: it may be 80% in expert hands, however, when a more generalised approach is assessed, 
the sensitivity for early HCCs is 65% i.e. similar to AFP and other biomarkers.  A recent meta-analysis 
including 19 studies showed that US surveillance detected the majority of HCC tumours before they 
presented clinically, with a pooled sensitivity of 94%.  However when further analysis looked at early 
lesion detection the sensitivity fell to 63%[144].  Operator dependence was clearly highlighted by a 
Japanese study of 1432 patients: careful US surveillance performed by highly skilled operators 
resulted in an average size of the detected tumours of 1.6 ± 0.6 cm, with less than 2% of the cases 
exceeding 3 cm[145].  Ultrasound is a very appealing screening modality because of the absence of 
risks, non-invasiveness, good acceptance by patients and relatively moderate cost.  There was hope 
that contrast assisted ultrasound would improve the detection of early HCC by reducing the inter-
operative dependency, but this was shown not to be the case[146]. 
The performance of CT and MRI as surveillance tools for HCC has not been evaluated and so no data 
exist [129,130].  There are significant issues related to using CT and MRI for HCC screening.  Cost and 
accessibility are two such issues, there needs to be a much greater infrastructure in place to use 
these modalities, which significantly increases cost and reduces accessibility.  There is also a 
significant false positive rate with CT and MRI scanning for surveillance, due to intra-hepatic shunts, 
dysplastic nodules and cirrhotic nodules.  EASL guidelines suggest that these techniques should be 
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also considered when obesity, intestinal gas, and chest wall deformity prevent an adequate US 
assessment. Even in these circumstances, radiation risk due to repeated exposure to CT scan and 
high cost of MRI make debatable their use in long-term surveillance[129]. 
1.5.3 Screening schedule 
The ideal interval of surveillance for HCC should be dictated by two main features: rate of tumour 
growth up to the limit of its detectability, and tumour incidence in the target population.  The 
doubling time of HCC suggests the screening interval time should be 6 months.  Some studies have 
shown variation of this, in relation to the differing underlying aetiologies, others show 6 months to 
be appropriate.  Han et al compared 6-monthly to 12-monthly and demonstrated that survival was 
better with 6-monthly surveillance than with 12-monthly surveillance[147,148].    Six-monthly 
surveillance has been compared to 3-monthly: it did not reduce mortality, but did lead to a higher 
number of false-positives and a greater number of investigations to evaluate these[149].  Meta-
analysis of prospective studies has shown that the pooled sensitivity of US-based surveillance 
decreases from 70% with the 6-month program to 50% with the annual program[144].  Cost-
effectiveness studies have shown that 6-monthly ultrasound based surveillance improves quality-
adjusted life expectancy at a reasonable cost, further supporting the use of ultrasound as the 
preferred imaging modality in HCC surveillance[139].  
1.5.4 Current recommendations 
There is still controversy around the benefit and recommendation of HCC surveillance.  A recent 
systematic review concluded that there was insufficient evidence to recommend HCC 
surveillance[150].  However the majority of the literature concludes that, despite relatively poor 
evidence, it should take place[129,130,151].  All surveillance programmes bring with them the 
possibility of harm to the patient. This may be psychological, related to anxiety waiting for results 
every time surveillance is done, or it may be harm resulting from investigation of false-positives. In 
the case of HCC the potential harms are those mentioned above, plus the possibility of treating a 
cancer that might never have caused any clinical symptoms, plus the harm related to complications 
of treatment.  Indolent HCCs are very rare and in fact malignant nodules detected on ultrasound that 
are not treated grow and become obviously malignant within the space of a few years[130].   
Current EASL guidelines are: 
 Patients at high risk for developing HCC should be entered into surveillance programmes 
(High risk groups seen in figure 6) 
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 Surveillance should be performed by experienced personnel in all at-risk populations using 
abdominal ultrasound every 6 months.  A shorter period of 3-4 months should be employed 
where a nodule of less than 1 cm has been detected or in surveillance after local resection. 
 Patients on the waiting list for liver transplantation should be screened for HCC in order to 
detect and manage tumour progression and to help define priority policies for 
transplantation. 
 
Such an approach is generally supported by the majority of the available literature and is routine 
practice in the UK.  Screening will, ideally, identify HCC at an earlier stage, when curative 
intervention can be offered.  This has been defined by the Barcelona Clinic Liver Cancer staging 
(BCLC)[129,152].  This staging system scores disease as 0, A, B, C or D according to lesion size, 
number of lesions and underlying composite liver disease.  It then defines 0 and A as potentially 
curative, whilst B-D are non-curative and should receive treatments such as radiofrequency ablation 
(RFA) or transarterial chemoembolisation (TACE).  Therefore an ideal screening tool would identify 
those classified as 0 or A in order to offer potentially curative treatment.  
1.6 Pathogenesis of HCC according to aetiology 
The variety of the underlying aetiologies of HCC means that the disease is heterogenous, both from a 
molecular and a clinical standpoint.  This is mirrored on a global scale with HBV being prominent in 
eastern countries, whilst alcohol, non-alcoholic steatohepatitis and HCV are dominant in the 
west[123].  In >90% of cases HCC will develop on a background of cirrhosis, therefore the severity of 
the underlying cirrhosis will influence molecular and clinical factors.  These changes drastically alter 
the matrix and microenvironment of the liver[153,154].  The risk of HCC in patients with liver 
cirrhosis depends on the activity, duration and the aetiology of the underlying liver disease. 
Coexistence of aetiologies, e.g., HBV and HCV infection, HBV infection and aflatoxin B1, HCV 
infection and alcohol, or HCV infection and liver steatosis, increases the relative risk of HCC 
development[155].  Moreover, the aetiology of the non-cirrhotic HCC will be different as this altered 
matrix and microenvironment is not present.    
The main causative agents—HBV, HCV and aflatoxin B1 (AFB)—which together are responsible for 
about 80% of all HCCs in humans, leave ‘molecular marks’ on hepatocytes that enable the causes of 
individual HCCs to be determined accurately in many instances[156].  HCC, like other cancers, is a 
disease of the genome and is defined by malignant hepatocytes accumulating somatic genetic 
alterations that combine mutations in both pro-oncogenes and tumour suppressor genes[157].  This 
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process can take place over a long period, up to 30 years, after chronic HBV or HCV have been 
diagnosed.  Pre-neoplastic cells may take between 10-30 years to develop, this is followed by 
dysplasia and ultimately carcinoma[156]. 
1.6.1 Pathogenesis of HCC related to HBV 
An estimated 300–400 million individuals worldwide are chronically infected with HBV. Prevalence 
rates range from 0.1 to 1% of the general population in North America and western Europe, to up to 
20% in southeast Asia and parts of Africa[155].  Studies have shown that areas with a high 
prevalence of HBV carriage also have a high incidence of HCC[158].  It is the leading aetiology in 
Asian and African countries.  Compared to those not infected with HBV the life time risk of HCC is 
100-fold greater in those infected, with approximately 40% of males infected with HBV developing 
HCC[155].  Unlike many of the other causes of HCC, HBV infection can result in HCC development in 
the absence of cirrhosis[159], but in the majority of cases there is the underlying chronic 
inflammation, fibrosis and cirrhosis . 
One specific pathogenic feature of HBV infection is the integration of viral DNA into human DNA.  
Integration of HBV DNA is not part of the viral life cycle, but rather occurs as an epiphenomenon of 
HBV replication[155].  Overall, at least 70-80% of HCC due to HBV infection show clonal integration 
of the viral genome[160,161].  It would appear that the site of HBV DNA insertion is somewhat 
random, potentially explaining why the majority of people with chronic HBV infection do not 
develop HCC.  However, several recurrent sites of insertion in key genes associated with 
carcinogenesis have been described, these include TERT (telomerase reverse transcriptase), MLL4 
( mixed-lineage leukaemia 4), CCNE1 (cyclin E1) , CCNA2 (cyclin A2)and RARB (Retinoic Acid Receptor 
Beta)[160,162].  The insertion of HBV DNA frequently occurs at promoter regions and results in 
overexpression, as has been demonstrated in TERT and CCNE1[160].  Chromosomal instability may 
also result from viral DNA integration.  Wang et al described another integration site of viral DNA 
that resulted in the identification of the human cyclin A gene[163].  This integration resulted in an 
HBV pre-S2/S-cyclin A fusion protein with increased stability. Constitutive expression of this 
stabilized cyclin A protein may have led, or contributed, to increased cell proliferation.  This effect 
was to cause HCC in the absence of underlying cirrhosis, further supporting the direct carcinogenic 
effect of HBV. 
Another carcinogenic effect arises from the oncogenic viral proteins, e.g. HBx or the pre S2/S 
protein.  The impact of these proteins has been suggested to be a key mechanism promoting 
carcinogenesis in humans through activation of several signalling pathways, control of apoptosis and 
DNA repair.  In addition, frequent truncated HBx proteins are produced, and this protein could 
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increase metastasis or cell invasiveness in vitro models[164,165].  Other studies have suggested a 
link between the HBx protein and regulation of the mitotic spindle, resulting in chromosomal 
instability[166]. 
1.6.2 Pathogenesis of HCC relating to HCV 
Hepatitis C is a single-stranded RNA virus belonging to the flaviridae virus family[155].  Unlike HBV, 
HCV cannot integrate into the host DNA, with the majority of its cell cycle occurring in the 
cytoplasm.  Consequently, the development of HCC in the context of HCV results from the 
underlying cirrhosis, with a similar pathogenesis to alcohol and NASH.  Experimental evidence 
suggests that HCV might operate through specific pathways that promote the malignant 
transformation of hepatocytes.  These have included descriptions of modifications of signalling 
pathways like Wnt/B-catenine, TGF Beta, NFKappaB and P53, with these pathways having also been 
recognised as abberant in colorectal cancers[167,168].  Viral proteins, like those in HBV, have also 
been shown to have a carcinogenic role, namely HCV protein core or NS3, NS4B and NS5A[155,157].  
Interpretation of these finding is difficult as the models used may not be transferrable to humans, 
particularly as most of these studies were performed in heterologous overexpression systems.  With 
new and highly effective treatments for HCV answering this question may no longer be relevant. 
1.6.3 Pathogenesis of HCC in alcoholic liver disease 
Alcohol is a carcinogen and increases the risk of a number of cancers, including oesophageal, gastric, 
breast and colonic.  Alcohol alone is likely to cause an increase in HCC, however, the vast majority of 
HCCs that occur in the context of excessive alcohol arise on a background of cirrhosis.  Little is 
known about alcohol and non-cirrhotic HCC formation.  In patients with HBV, HCV, NASH and 
haemochromatosis, excessive alcohol is known to significantly increase the risk of HCC when 
compared to a single factor[169,170].  Interestingly, patients with alcohol-related cirrhosis who stop 
drinking have a higher risk of HCC development than patients with persistent consumption[171].  
This is likely to result from premature death in those who continue to drink, before the HCC has 
developed. 
In the context, it is very difficult to separate alcohol consumption itself and underlying cirrhosis as 
two independent risk factors for HCC.  When rodents have been given ethanol there is an increase in 
tumours, however this finding is inconsistent and often found in the presence of other known 
carcinogens[157,172].   Acetaldehyde is an ethanol metabolite that has carcinogenic properties 
through DNA binding.  In addition, CYP2E1, a cytochrome induced by ethanol consumption, converts 
ethanol into acetaldehyde, but also into reactive oxygen species (like superoxide anion and 
hydrogen peroxide).  Chronic oxidative stress induced by alcohol intake and cytokine production in 
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the context of chronic inflammation is a well-known phenomenon leading to cirrhosis and HCC 
development[157,173,174].  A further impact of excessive alcohol is an iron overloaded state, this is 
most noticeable in people with haemochromatosis who drink excessively, with a massive increased 
of HCC.   Additional mechanisms of alcohol-mediated carcinogenesis exist, including down-regulation 
of levels of retinoic acid and modulation of methylation by down-regulation of S-adenosyl L 
methionine (SAMe)[175–177]. 
1.6.4 Pathogenesis of HCC in non alcoholic fatty liver disease and non alcoholic steatohepatitis 
Obesity and diabetes are also direct risk factors for the development of HCC.  Again the majority 
arise from a background of NASH and the subsequent chronic inflammation and cirrhosis, however a 
number of groups have described the occurrence of HCC in NASH without underlying 
cirrhosis[178,179].  This suggests a specific carcinogenic pathway outside the classic 
inflammation/cirrhosis pathways, but much like HCC in alcohol these are difficult to separate.  The 
association between obesity and HCC appears to be derived from alteration in levels of cytokines 
and other inflammatory mediators, these include IL-6 TNF-alpha, leptin, adipokine and adiponectin. 
An abnormal balance between leptin and adipokine characterizes NAFLD and predisposes to HCC 
development. A decreased level of adiponectin, an anti-inflammatory, anti-proliferative cytokine 
exclusively produced by adipocytes, and a parallel increase in leptin, a pro-inflammatory, angiogenic 
and profibrogenic cytokine predominantly produced by adipocytes, are cardinal features of NAFLD 
and appear to increase the risk of HCC[157,180,181]. 
NASH is associated with lipotoxicity, secondary to lipid droplet deposition in the liver, which has 
been shown to directly contribute to HCC formation.  In addition, there is also insulin resistance, 
resulting in hyperinsulinaemia and excessive production of IGF1, along with other growth factors 
such as insulin-like growth factor II, insulin receptor substrate 1, transforming growth factor-a and b 
as well as hepatocyte growth factor (HGF)[155,182].  These abnormal levels of growth factors alter 
signalling pathways that result in promotion of cell proliferation and inhibition of apoptosis. 
From the various animal models described it would appear there are specific carcinogenic pathways 
separate from those associated with cirrhosis, but these require validation in human studies before 





1.7 Genetic alteration associated with HCC formation 
1.7.1 Oncogenes and tumour suppressor genes 
Activation of pro-oncogenes, particularly of the ras family have been described in spontaneous and 
chemically induced rodent hepatocarcinogenic models[155].  In human HCC studies high levels of 
cyclin-D have been described, thus promoting cellular proliferation via ras signalling, this however, 
has only been described in up to 20% of cases, making its significance questionable[183].   
The somatic genetic alterations first identified in HCC were activating mutations of beta-catenin 
(CTNNB1) and inactivating mutations of p53, in 20-40% and 20-50% of cases, respectively.  The 
alteration in p53 is significantly overexpressed in HCC associated with HBV[184,185].  Aflatoxin B1 is 
a well-recognised carcinogen for the formation of HCC.  It is a contaminant of foods that are 
commonly consumed in Asia and Africa, for example chilli peppers, corn, cotton 
seed, millet, peanuts, rice, sorghum, sunflower seeds, tree nuts, wheat, and a variety of spices, with 
a linear relationship between levels of ingestion and incidence of HCC.  Aflatoxin has been shown to 
cause specific mutations in the p53 gene (R249S), as a result of its specificity this mutation can be 
used a biomarker of aflatoxin B1 exposure in patients with HCC[155,185].  In areas were aflotoxin 
levels are high this mutation is seen in up to 70% of HCCs, whilst being present in <5% were aflatoxin 
levels are low[186].  
Activation of telomerase, preventing the shortening of telomeres, is frequently found in HCC. Recent 
evidence suggests that telomere dysfunction, leading to telomere based chromosomal instability, 
may be operative during the early stages of carcinogenesis while telomerase activation occurs during 
HCC progression[155,187].  
Chronic inflammation and hepatic fibrosis underlie the carcinogenesis of hepatocytes.  This results 
from increased cell turnover, oxidative DNA damage, activation of cellular oncogenes, the 
inactivation of tumour suppressor genes DNA mismatch repair defects and impaired chromosomal 
segregation, over expression of growth and angiogenic factors, and telomerase activation.  Despite 
this, there are clear aetiology-specific processes that contribute to the formation of HCC and modify 
the disease course. 
1.8 Biomarkers for colorectal cancer and HCC 
In 1998, the National Institutes of Health Biomarkers Definitions Working Group defined a biomarker 
as “a characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic response to a therapeutic intervention[188].”  
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The World Health Organisation (WHO) has sought to define biomarkers further as “any substance, 
structure, or process that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease[189]”.  Using this board definition of a biomarker, clinical signs such 
as height and weight could be considered as biomarkers, however, the term is now typically 
shorthand for “molecular biomarker.” Molecular biomarkers can themselves take many forms, and 
as a consequence there are many strategies available for their discovery and validation. When 
considering malignancy any measurable specific molecular alteration of a cancer cell either at the 
DNA, RNA, protein, or metabolite level can be referred to as a cancer biomarker.  An ideal biomarker 
for cancer would have applications in determining predisposition, early detection/screening, 
assessment of prognosis, and predicting drug response or amenability to therapy.  No one single 
biomarker could meet all these needs and so combinations of specific applications of  biomarkers 
are often performed. 
There has been a great deal of work recently to find and define the role for non-invasive biomarkers, 
particularly for cancer.  In order to prevent disorganized and uncoordinated biomarker research, 
Cancer Research UK’s Biomarker Discovery and Development Committee has suggested 
‘roadmaps’(figure 6), which define a succinct research pathway. These are broadly divided into four 
chronological sections[190]. 
1) Rationale: does the envisioned biomarker address an unmet clinical need? 
2) Biomarker assay development: the assay must be accurate and reproducible. The assay should be 
simple and cost effective, and performed to good clinical laboratory practice standards (as laid out 
by the British Association of Research Quality Assurance). 
3) Biomarker discovery: the distribution of the biomarker in an appropriate sample population 
should be defined, and a retrospective analysis of the relationship between the biomarker and 
clinical outcome should be performed. 
4) Biomarker clinical qualification: the relationship between the biomarker and clinical outcome 
should initially be assessed in a large retrospective analysis. Then, a large, prospective randomized 
study should be performed to assess the impact of the biomarker on clinical outcome. 
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Figure 5: Screening biomarker roadmap.  
 
Adapted from Newton et al[190] 
A key feature of biomarkers, particularly those used in colorectal cancer, is the ability to detect early 
stages of the disease or a pre-cancerous stage e.g. adenomatous polyps.  This in turn allows the 
biomarker to have applications in screening.  Colonoscopy is a key part of colorectal cancer 
screening, as it allows for confirmation of diagnosis, definition of morphology, site and histological 
analysis.  As discussed, FOBt is the most widely used test, but this has low sensitivity and specificity, 
leading to a high normal colonoscopy rate.    Ideally the biomarker used to indicate the need for 
colonoscopy, should have high sensitivity and specificity, while producing a low number of false-
negative and false-positive results, to prevent subjecting healthy individuals to unnecessary 
colonoscopies.  In addition to such detection biomarkers, prognostic markers which can predict the 
probable course of the cancer, stratification markers which can predict the response to drugs prior 
to beginning treatment, and efficacy markers which can monitor the efficacy of drugs treatment may 
also reduce the mortality rate of colorectal cancer[191].  Biomarkers can also be defined by the site 




1.8.1 Colorectal cancer biomarkers  
FOBt has been discussed earlier in this chapter. 
1.8.1.1 Faecal DNA and genetic markers 
Colonocytes are continuously shed from the mucosa into the faecal stream, cellular shedding from 
colorectal cancers occurs at an even greater rate[101].   The apoptotic resistance of cancerous cells 
means there is greater potential to detect the intact genomic DNA (L-DNA) for analysis, along with 
MSI detection.  These cells found within stool can then be analysed for known genetic targets, such 
as, K-ras, p53, and adenomatous polyposis coli (APC)[191]. 
A systematic review conducted in 2014 considered seven studies investigating faecal DNA markers, 
looking at DNA hypermethylation of a single gene, or of a panel of genes.  Overall sensitivities for 
colorectal cancer detection by faecal DNA markers ranged from 53% to 87% with varying specificities 
all of which are greater than 76%. Adenoma detection sensitivity ranged from 17% to 61%[192].  
Boynton et al amplified six genomic fragments of different length from each of four different genetic 
loci (APC, p53, BRCA1, and BRCA2) using faecal specimens collected from 25 colorectal cancer 
patients and 77 controls.  The specificity for colorectal cancer detection was 97% and the sensitivity 
was 57%[193]. 
Other studies that have directly compared faecal DNA markers to FOBt have shown that the DNA 
analysis has greater sensitivity than the FOBt without reduced specificity.  The same studies show 
improved detection, by the DNA marker system, of invasive colorectal cancer and adenomatous 
polyps with high grade dysplasia, when compared to FOBt, 40.8% versus 14% [94].  When a 
combination of faecal DNA analysis and FOBt is performed the highest sensitivities and specificities 
can be achieved[191]. 
1.8.1.2 Pyruvate kinase isoenzyme type M2 (M2PK) 
M2-PK is an isoenzyme of pyruvate kinase, a key enzyme within glycolysis which catalyzes the ATP-
producing conversion of phosphoenolpyruvate (PEP) to pyruvate. Depending upon the metabolic 
functions of the tissues, different isoenzymes of pyruvate kinase are expressed[194].  During 
tumourigenesis other isoenzymes of pyruvate kinase are lost and there is increased expression of 
the M2 subtype[195].  M2 pyruvate kinase can exist in two distinct forms, these are a nearly inactive 
dimeric form and a highly active tetrameric form. In tumour cells, M2-PK is mainly found to be in the 
dimeric form and has therefore been termed “Tumour M2-PK”.  This dimerisation is induced by 
interaction with a number of oncoproteins, making it specific to cancerous states[194].  M2-PK is 
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released by tumour cells into blood and specifically by colorectal cancers into the faecal stream.  
Quantification of M2-PK in stool can, therefore act as a biomarker for colorectal cancer. 
A meta-analysis, in 2012, concluded the use of M2-PK in screening would “close a clinical gap”, due 
to its high sensitivity and specificity.  704 patients with colorectal cancer and 11,412 healthy 
subjects, from seventeen independent studies, were included in this meta-analysis. The mean faecal 
M2-PK sensitivity was 80.3%; the specificity was 95.2%. Four studies compared faecal M2-PK head-
to-head with guaiac-based faecal occult blood test (gFOBt). Faecal M2-PK demonstrated a sensitivity 
of 81.1%, whereas the gFOBt detected only 36.9% of the colorectal cancers[194].  A further meta-
analysis in 2014 looked at six papers relating to faecal biomarkers which assessed the same enzyme 
M2-PK as a potential biomarker in colorectal cancer detection. These studies used a sandwich ELISA 
to measure M2-PK activity and reported overall sensitivities ranging from 68% to 91%[192].   
M2-PK has also been shown to have superiority in detecting adenomatous polyps, including non-
bleeding lesions. Koss and colleagues showed the tumour M2-PK assay could be utilized to detect 
adenomas with a sensitivity of 60%[196].  Eight studies were described in the meta-analysis from 
2012, this included 554 patients, with the following sensitivities: adenoma < 1 cm in diameter: 25%; 
adenoma > 1 cm: 44%; adenoma of unspecified diameter: 51%. In a direct comparison with gFOBt of 
adenoma > 1 cm in diameter, 47% tested positive with the faecal M2-PK test, whereas the gFOBt 
detected only 27%[194]. 
1.8.2 Serum Markers 
1.8.2.1 Carcinoembryonic antigen (CEA) 
Carcinoembryonic antigen (CEA) is a high molecular weight glycoprotein belonging to the 
immunoglobulin superfamily.  It is involved in cell adhesion, being produced during normal foetal 
development, however after birth its production ceases[190,191].  CEA is one of the most widely 
studied biomarkers in colorectal cancer[197].   It has been shown to be elevated not only in 
colorectal cancer but also in a number of other cancers including pancreatic, gastric, lung and breast, 
as well as several non-cancerous conditions including diabetes mellitus, ulcerative colitis, 
pancreatitis and heavy smokers.[190].  A number of recent meta-analyses have concluded that CEA 
has no role as a screening or diagnostic tool, particularly in an asymptomatic patient,  and are in line 
with the American Society of Clinical Oncology (ASCO) and European Group on Tumour Markers 
(EGTM) recommendations[190,191,197].  This conclusion stems from the lack of sensitivity and 
specificity provided by CEA.  The summary estimates from the meta-analysis performed by Liu et al 
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found the sensitivity and specificity for CEA in colorectal cancer to be 46.1% (95% CI: 44.8–47.4%) 
and 89.2% (95% CI: 88.2–90.2%), respectively. 
The role for CEA lies in prognostics, directing treatment and detecting recurrence.  A number of 
studies have demonstrated the use of CEA as a prognostic indicator, both as an independent factor 
and in combination with other factors[198–200].  Colorectal cancer patients with higher CEA levels 
have poorer prognosis[191].  Baseline CEA levels have been shown to be an independent predictor 
of treatment response, to bevacizumab-based treatment in metastatic disease.  Baseline CEA serum 
levels inversely correlated with therapeutic response in patients receiving bevacizumab-based 
treatment (disease control rate, 84% vs 60%)[201].  Elevated CEA in patients undergoing 
hepatectomy with curative intent has been shown to indicate recurrence with high accuracy.  Hara 
et al showed the post-test probabilities of recurrence in post-hepatectomy colorectal cancer 
patients with positive and negative serum CEA were approximately 70-90% and 10%, 
respectively[202]. 
1.8.2.2 Carbohydrate antigen (CA19-9) 
Carbohydrate antigen (CA) 19-9 is the second most investigated tumour marker relating to colorectal 
cancer, after CEA.  CA 19-9 was originally defined by a monoclonal antibody produced by hybridoma 
prepared from the spleen cells of mice immunized with the human colorectal cancer cell line, SW 
1116[191].  It is the most widely used biomarker for adenocarcinoma of the pancreas.  However, this 
does not translate into use for colorectal cancer, due to its inferior sensitivity when compared to 
CEA, with both ASCO and EGTM not recommending its use in colorectal cancer[197,203]. 
1.8.2.3 Tissue inhibitor of metalloproteinase type (TIMP)-1     
Tissue inhibitor of metalloproteinase type (TIMP)-1 is a multifunctional glycoprotein which inhibits 
most matrix metalloproteinases (MMPs)[191].  Studies have shown TIMP-1 to be elevated in the 
serum of patients with colorectal cancer when compared to healthy volunteers[204].  It has also 
been shown  not to be significantly elevated in patients with colonic adenomas and IBD[205].  The 
use of TIMP-1 appears to be limited to predicting prognosis, as it appears elevation of TIMP-1 is 
restricted to advanced colorectal cancer.  Holten-Andersen et al demonstrated this relationship, 
their study showed a highly significant association between pre-operative plasma TIMP-1 levels and 
survival in colorectal cancer patients, with higher plasma TIMP-1 levels being associated with a poor 
outcome. Independent of clinical parameters including Dukes’ stage, plasma TIMP-1 levels were 




1.8.2.4 Five-Serum-Marker panel (Spondin-2, DcR3, Trail-R2, Reg IV, MIC 1) 
A study looking at the serum of 600 patients taken from patients with colorectal cancer, normal 
controls and benign disease evaluated four serum biomarkers, spondin- 2, tumour necrosis factor 
receptor superfamily member 6B (DcR3), TRAIL receptor 2 (TRAIL-R2) and Reg IV.  All four markers, 
as well as a fifth marker, macrophage inhibitory cytokine 1 (MIC1), were found to be elevated in 
patients with colorectal cancer when compared to normal controls and patients with benign disease.  
The study also demonstrated a better sensitivity and specificity than CEA, suggesting a potential to 
improve early diagnosis[191,207]. 
1.8.2.5 Collapsin response mediator protein-2 (CRMP-2) 
Wu et al identified collapsin response mediator protein-2 (CRMP-2) and evaluated it as a potential 
colorectal cancer biomarker in the serums of 201 colorectal cancer patients and 210 healthy controls 
(48). The use of CRMP-2 alone showed better sensitivity but poorer specificity than CEA. 
However, combined detection using CEA and CRMP-2 produced better sensitivity (77%) and 
specificity (95%) than detection using either of these markers alone.  CRMP-2 may therefore, be a 
valuable serum marker when used in combination with CEA[191,207,208].  
1.8.2.6 MicroRNAs as biomarkers 
The Tenth Annual MicroRNA (miRNA) as Biomarkers and Diagnostics Conference, 2014, was 
primarily focused on recent advancements in the field of miRNA in the early detection of disease, 
monitoring tumour growth/progression and its potential for precision medicine.  The predominant 
outcomes from this meeting were that miRNAs are now well-established as regulators of 
tumourigenesis and can be utilized not only as potential biomarkers for the diagnosis and prognosis 
of a disease but also are useful in patient stratification and treatment response[209]. 
A number of miRNAs have been identified in colorectal cancers, both with up and down regulation, 
for example miR-34a[191].  These have been shown to interact with key oncogenes and tumour 
suppressor genes, such as APC and p53[210].  The significance of miRNAs in predicting treatment 
response with 5-fluorouracil based chemotherapy was described by Ju et al in 2013.  Several miRNAs 
(miR-192, miR-215, miR-140, miR-129, let-7, miR-181b, miR-200 s) were found to be associated with 
chemoresistance by regulating key cell death pathways such as apoptosis and autophagy[211].  
Other such important miRNAs have also recently been described, for example miRNA-215. miR-215 
was identified to suppress the expression of both thymidylate synthase and dihydrofolate reductase. 
In addition, the expression of miR-215 was directly regulated by p53. The expression of miR-215 was 
significantly associated with colorectal cancer patient survival[209,212].  Other miRNAs that have 
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been shown to influence prognosis are hsa-miR-21 and hsa-miR-106a[213,214], with hsa defining 
the human origin of the miRNA. 
 
It can be concluded therefore, that miRNAs appear to have a role in predicting survival and response 
to potential chemotherapy treatments. 
 
1.8.3 Genetic and DNA markers in tissue 
Detection of genetic alteration in tissue either acquired from biopsy or following resection has a 
potential as a biomarker.  These markers have a role in predicting response or appropriateness of 
treatment and prognosis. 
1.8.3.1 KRAS/B-RAF and anti-EGFR therapy 
Cetuximab and panitumumab are monoclonal antibodies that target EGFR, they have a role in the 
treatment of metastatic colorectal cancer.  The abundance of EGFR in tumours has been shown to  
correlate poorly with response and is, therefore, an inadequate biomarker[215].  These drugs are 
effective in approximately 10% of unselected chemotherapy treatments.  It has been shown, by 
many studies, that in chemotherapy-refractory metastatic colorectal cancer, a KRAS mutation 
predicts a complete lack of response to anti-EGFR therapy[79,190].  The phase III randomised trial of 
panitumumab showed almost a 2 fold increase in survival when the KRAS mutation was absent.  
Similar results have been noted in phase III trials of cetuximab[216,217].  Measurement of KRAS 
before commencing such treatment is recommended as routine practice by both the FDA and 
European Medicines Agency. 
B-RAF is a mutant KRAS gene accounts for only 30–40% of the 90% of patients who do not respond 
to anti-EGFR therapy[190].  Nicolantino et al examined the effects of the KRAS/B-RAF mutation on 
treatment success with the anti-EGFR drugs.  As fully expected those with the mutant KRAS gene all 
failed therapy.  They also found that all those with the B-RAF mutation did not respond, whilst all the 
responders were free of the B-RAF mutation.  Being positive for this mutation also conveyed a 
negative outcome for both progression free survival and overall mortality[218].  The evidence would 
appear to suggest that B-RAF testing should take place alongside the current practice of KRAS 
assessment. 
1.8.4 Hepatocellular carcinoma biomarkers  
The development of biomarkers in HCC has been thwarted by insufficient accuracy, making 
translation into routine clinical use difficult.  Recently, advances in technology and an increased 
understanding of HCC biology have led to the discovery of novel biomarkers, which are currently in a 
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variety of development stages (Table 2 and 3).  There are a number of serological markers for HCC, 
these include alpha-fetoprotein (AFP), MAGE-4 protein, des-gamma-carboxy prothrombin (DCP), the 
ratio of glycosylated AFP (L3 fraction) to total AFP, alpha-fucosidase, and glypican 3, transforming 
growth factor-beta (TGF-Beta) and most recently microRNAs (MiRNA).  The application of a 
biomarker in HCC may be influenced by the underlying aetiology i.e. viral hepatitis, as they can be 
associated with specific genetic alterations and oncogenic protein formation.  Despite this relatively 
large number of potential biomarkers very few are routinely used in clinical practice and, of those 
that are, their use is becoming more limited as knowledge and experience of their use grows.  
 
 
Table 2: Biomarkers for the early detection of HCC and their stage of development. 
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Table 3: Phases of biomarker development for early detection[218]. 
Phase of development Study design Description 
1 Pre-clinical Identification of potential candidates 
2 Case control studies Characterisation of diagnostic 
performance 
3 Retrospective longitudinal Ability to detect pre-clinical disease 
4 Prospective screening Define sensitivity and specificity 
5 Randomised controlled Determine ability to reduce mortality 
 
1.8.4.1 Alpha-fetoprotein 
AFP is the biomarker that has been most prominent over recent years but most recently has fallen 
out of favour due to its low sensitivity, particularly at a lower cut-off value[141].  It is a glycoprotein 
produced by the foetal liver and yolk sac during pregnancy.  A systematic review evaluating AFP in 
cirrhotic patients, using a cut-off level of 20ng/mL, showed sensitivities and specificities of 41-65% 
and 80-94% respectively HCC at any stage[219].  Although 20ng/mL is the most commonly used cut-
off in clinical practice, this value was derived from a study in which only one-third of patients had 
early HCC (70 HCC and 170 chronic liver disease)[220].  The detection of HCC based on a significant 
rise of AFP in the absence of a positive US is considered to be exceptional[140].  Furthermore, only a 
small proportion of early HCCs are associated with a rise in AFP serum levels, with studies clearly 
demonstrating the correlation between tumour size and serum AFP levels[143].  Approximately 40% 
of patients with early HCC and 15-20% of patients with advanced HCC show normal AFP levels. In 
China, where HCC is extensively studied, around 30-40% of HCC patients are AFP negative[142].  
Tumours that are associated with increased AFP,  should be considered to have a greater malignant 
potential and a poorer prognosis[142].  The role of AFP is now for prognostic estimation and 
treatment monitoring, rather than surveillance.  Of the other potential biomarkers, most have been 
described in a diagnostic setting rather than surveillance.  Some, namely, DCP and glycosylated AFP-
total ratio, have been shown to be associated with advanced disease, including local invasion, thus 
making them redundant as a screening tool[221].  None has  been shown to be superior to AFP 
alone, therefore they  are not currently recommended for clinical use[129]. 
Recent studies have shown the variation of AFP when considering different aetiologies and levels of 
hepatic inflammation.  These studies have suggested the accuracy of AFP may be improved by 
adjusting for degree of hepatic inflammation and/or aetiology of liver disease[222].  It would appear 
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that AFP tends to correlate with ALT levels in patients with chronic viral hepatitis in the absence of 
HCC, whereas AFP often increases disproportionately to ALT levels in those with HCC[223].  Also, 
recently described is the impaired accuracy and specificity of AFP in HCV-positive patients compared 
to negative patients, specificity 0.89 vs. 0.83, p = 0.007[224]. 
1.8.4.2 AFP-L3 
Lens culinaris agglutin-reactive AFP (AFP-L3) is the glycosylated isoform of AFP.  It has been 
proposed as a biomarker for the early detection of HCC as it has a superior specificity compared with 
AFP.  During its early development it was found to have a specificity approaching 90%[225].  Further 
assessment of AFP-L3 in large cohort studies, including the Early Detection Research Network (EDRN) 
multi-centre phase II study, support this finding with specificities above 90%.  However, sensitivity 
across all these studies was low, ranging from 37-60%[226,227].  AFP-L3 is reported as the 
proportion of AFP-L3 to total AFP, with a cut-off of 10% traditionally used for HCC detection.  The 
development of a highly sensitive assay for AFP-L3 (hs-AFP-L3) has improved sensitivity.  It means 
that APF-L3 can be measured in those with lower AFP levels, in fact hs-AFP-L3 can be measured in 
patients with AFP as low as 2 ng/mL[222].  The sensitivity of hs-AFP-L3 for early stage HCC appears 
to be significantly higher than that of conventional AFP-L3 (49% vs 17%)[228].  Phase III biomarker 
studies are currently in progress to assess the utility of AFP-L3. 
1.8.4.3 Des-Gamma-Carboxy Prothrombin (DCP) 
DCP is produced by malignant hepatocytes. It is an abnormal prothrombin protein that is generated 
as a result of an acquired defect in post-translational carboxylation[222].  DCP production is 
independent of vitamin K deficiency, although pharmacological doses of vitamin K can transiently 
suppress DCP production in some tumours[229].  Normalization of DCP levels correlates with 
successful tumour resection and appears to be a marker of tumour activity.  Plasma DCP does not 
correlate with AFP levels.  However, they do show similar traits in terms of the correlation with 
increasing tumour size.  In tumours of less than 3 cm, DCP levels are increased in only 20% of 
patients[229,230].  An earlier phase II biomarker study reported DCP had a sensitivity and specificity 
of 89% and 95% for differentiating patients with HCC from those with cirrhosis and chronic 
hepatitis[231].  Further phase II studies and several prospective cohort studies failed to demonstrate 
this high level of sensitivity, with sensitivities ranging from 23 to 57% when DCP was used alone 
[232,233].  Secondary analysis from the HALT-C trial showed a significant improvement in the 
sensitivity for tumour detection from 58% to 87% three months prior to HCC presentation, 
suggesting that there is a role for DCP in early detection of HCC[234].  Phase III biomarker studies are 




Glypican-3 (GPC3), a membrane-anchored heparin sulfate proteoglycan, has been demonstrated to 
interact with growth factors and modulate their activities and, as such, it plays an important role in 
cell proliferation and survival regulation. It binds to the cell membrane through the 
glycosylphosphatidylinositol anchors. GPC3 mRNA was up-regulated significantly in tumour tissues of 
HCC compared to liver tissues of healthy adults, and liver tissues of patients with non-malignant liver 
disease.  It can be detected in 40–53% of HCC patients and 33% of HCC patients seronegative for 
both AFP and DCP[229,235,236].  GPC3 demonstrated 100% specificity among 50 patients with 
chronic hepatitis and 50 with intrahepatic cholangiocarcinoma and 98% specificity among 50 
patients with cirrhosis[237].  Much like DCP, the good specificity is associated with an insufficient 
sensitivity, with a number of studies showing it to be consistently around 50%, but this has been 
shown to been independent of tumour size, allowing early tumour detection[222]. GPC3 positivity 
has also been shown to be an independent negative prognostic indicator in patients with HCC[238]. 
1.8.4.5 Osteopontin 
Osteopontin is an integrin-binding phosphoprotein that is over-expressed in several cancers 
including lung, breast and colon cancer[222].  One of the first descriptions of osteopontin was in 
2006, when 62 patients with HCC were compared to 60 with cirrhosis only and 60 healthy controls.  
This study demonstrated a sensitivity and specificity of 87% and 82%[239].  Further assessment of 
osteopontin, in a Thai cohort, demonstrated a 93% sensitivity and 61% specificity.  Attempts have 
been to improve this by combining measurement with AFP levels.  In a US this cohort:  the 
combination of  AFP and osteopontin had a sensitivity of 83% and specificity of 63% for early 
HCC[240].  Assessment of osteopontin, either alone or in combination with other biomarkers, is 
currently underway in phase III biomarker trials.  
1.8.4.6 Alpha-l-fucosidase (AFU) 
Alpha-l-fucosidase (AFU) is a lysosomal enzyme found in all mammalian cells with a function to 
hydrolyze fucose glycosidic linkages of glycoprotein and glycolipids, its activity increasing in the 
serum of HCC patients[229].  There have been reports that a raised AFU level could act as a 
precursor to HCC development, with 85% of patients in a study having an elevated AFU at least 6 
months before the detection of HCC by ultrasonography[241].  Sensitivity and specificity levels of 
81% and 70%, respectively, have been reported with a cut-off of 870nmol/mL/h.  This could 
potentially be improved further with the combined measurement of AFP and AFU[229]. 
 42 
 
1.8.4.7 Golgi protein-73 
Golgi Protein-73 (GP73) is a trans-membrane glycoprotein that is normally expressed in epithelial 
cells but whose biologic function is unknown[222].  Golgi-apparatus-associated protein has been 
shown to have a higher sensitivity than AFP in the detection of HCC[242].  This study found GP73 to 
have a sensitivity and specificity of 69% and 86% respectively; of note, GP73 levels were elevated in 
32 of 52 HCC patients with an AFP < 20ng/mL.  A study looking at serial ELISA measurements of 
GP73, in patients with HCV, appears to demonstrate that it is a promising complimentary serum 
marker in the surveillance of HCC[243].  Elevated GP73 levels have been shown to be independent of 
cirrhosis aetiology, liver function, and tumour size.  When used in combination with AFP, sensitivity 
and specificity have been shown to improve to 98% and 85%, respectively.  Systematic reviews of 
the literature associated with GP73 have drawn different conclusions about its clinical application: 
those that have criticised it have suggested that the studies have been of poor quality and 
conducted in non-representative cohorts, while others have suggested that GP73 is superior to AFP 
for the detection of early HCC, but concluded that further phase III biomarker studies are required. 
1.8.4.8 Transforming growth factor-beta (TGF-Beta) 
Belonging to a superfamily of polypeptide signalling molecules involved in regulating cell growth, 
differentiation, angiogenesis, invasion, and immune function, TGF-beta is a predominant form of the 
growth factor family in humans[229].  TGF-Beta has been shown to be elevated in the serum of 
patients with HCC when compared to healthy controls and cirrhotic patients without HCC, along with 
the over-expression of  mRNA[244,245]. 
1.8.4.9 Squamous cellular carcinoma antigen (SCCA) 
Squamous cellular carcinoma antigen (SCCA) is a serine protease inhibitor that is physiologically 
present in squamous epithelium[222].  Evaluation of SCCA, in 2005, assessed 210 patients with HCC 
and 90 with cirrhosis and found that it had a sensitivity of 84% but a specificity of 49%[246].  Further 
assessment by the same group looking specifically at early lesion detection (<3cm) demonstrated a 
sensitivity of 56%, and specificity of 75%[247].  Systematic reviews have concluded that SCCA is 
inferior to AFP and so it is unlikely to find a place in clinical practice. 
1.8.4.10 Micro RNA 
MicroRNAs (miRNAs) are a family of endogenous, small (21–23 nucleotides), non-coding but 
functional RNAs, which have been found in worms, flies, and mammals including human beings.  
MicroRNAs regulate gene expression by binding to specific messenger RNAs and prevent their 
translation into protein.  They can act to down regulate a large number of genes at any one time, 
which in turn can have profound effects on cellular programmes, including repair and death[248].  
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As a result, some miRNAs are involved in direct HCC carcinogenesis by promoting cancer stem cells 
and by controlling cell proliferation and apoptosis. Others are associated with HCC progression by 
influencing cell migration and invasion[229].  miR-124 and miR-224 are greatly up-regulated in 
human HCC when compared to both paired pre-cancerous cirrhotic tissues and cirrhotic livers 
without HCC, and play a role in cell proliferation, migration, invasion and anti-apoptosis[249].  miR-
101 is a tumour-suppressive miRNA. It is significantly under-expressed in multiple types of cancers 
including HCC[250].  The role of miRNAs as biomarkers for HCC has yet to be clearly defined but they 
appear to have a place in diagnosis and prognosis.  
Because of the large number of potential biomarkers that have been described in this condition, 
selecting a single agent or combination that will provide suitable clinical applications is difficult.   
 
1.9 Human gut microbiome, colorectal cancer and volatile organic compounds 
1.9.1 The human gut microbiome 
The human body consists of far more than just human cells, it plays host to a vast number of 
microbial cells, including bacteria, viruses, eukaryotes and fungi.  Collectively, the microbial 
organisms that reside in and on the human body constitute our microbiota, and the genes they 
encode are known as the microbiome.  Advancements in culture-independent high-throughput 
sequencing has increased our knowledge of the microbiota species diversity[251,252].  In doing so it 
is said that the human gut contains some 1013 different  bacteria[253], only a small minority of these 
can be cultured.  With an individual human colon containing approximately 160 species[254]. 
Following birth, as we develop from infancy into adulthood, so too does our microbiota.  It was 
originally thought that the foetal gut was sterile and free of microbes, therefore was essentially a 
blank canvas upon delivery.  However, recent work has provided evidence that there are bacteria 
present in the amniotic fluid in utero in healthy foetuses and in neonates. although, the number and 
diversity is very low[255].  The first stool passed by an infant is known as the meconium, it has been 
shown to be free of viral matter but contains a small number of bacterial species, again suggesting 
the foetal gut may not be sterile as previously thought[256].  However, there is also clear evidence 
that the mode of delivery impacts on the bacteria that can be identified within the infant gut.  Those 
born vaginally have been shown to have a gut microbiota that resembles that found in the vaginal 
microbiota of their mothers.  Whilst those delivered via caesarean section demonstrate a microbiota 
characteristic of skin and dominated by taxa such as Staphylococcus and Propionibacterium 
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spp[257].  This suggests any bacteria detected in the meconium actually colonise the gut after 
exposure during the delivery process, rather than in utero. 
This initially minimally diverse microbiota quickly increases shortly after birth, with both bacteria and 
viruses increasing in cell and species number[256,258].  Early colonizers are generally aerotolerant, 
as the gut initially contains oxygen, and then are replaced by anaerobes that are typical of the adult 
gut microbiota.  These initial colonizers are replaced by species, that by 11 months, are specific to 
the infant and different from those found in the mother[251,258].  As time passes and the infant 
develops the composition and diversity of the microbiota changes (Figure 6).  This change has been 
shown to be gradual process, but can be punctuated by significant changes associated with life 
events such as infections, use of antibiotics, environmental exposures and the introduction of solid 
foods.  The bacterial composition begins to converge towards an adult-like microbiota by the end of 
the first year of life and fully resembles the adult microbiota by 2.5 years of age[256,259]. 
Figure 6: Development of the human microbiota from foetal to childhood, then through to 
adulthood 
 
Dominant bacterial species shown, along with regulation of functionality[251]. 
 
Functional genetic analysis of the infant microbiome demonstrates a functionality found in mothers, 
despite having a different taxonomic composition, with some specific differences such as, an 
enrichment in genes to facilitate lactate utilization when the infant’s diet is breast or formula milk.  
Other analyses have shown that the ability the utilise plant-derived glycans is present before the 
introduction of solid foods, suggesting that the infant gut is ready to switch to a diet not exclusively 
based on milk before the actual change in diet takes place[256,258]. 
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Once the microbiota has reached maturity it remains mostly stable until old age[251].  The 
composition of the intestinal microbiota in older people (>65 years) is extremely variable between 
individuals, and differs from the core microbiota and diversity levels of younger adults[260].  A 
feature of the ageing process is immunosenescence, this term describes the negative impact that the 
ageing process has on the immune system, including its development and its ability to function.  
Alterations to the innate and adaptive immune systems are recognised as a feature of 
immunosenescence, the interaction of both the innate and adaptive immune systems is key for the 
gut microbiota health and function[261,262].  Whether the alteration in an ageing immune system 
results in alteration in the composition of the gut microbiota, or the host’s ability to interact with an 
already altering diversity is not clear.  Deterioration in dentition, salivary function, digestion, 
intestinal transit time and changes in diet may affect the intestinal microbiota upon ageing.  
Exposure to antibiotics and other medications that may occur through a person’s life also affects the 
composition[251,263].  Antibiotics have a profound effect on the microbiota, with good evidence to 
suggest major alterations of the microbiota following treatment with antibiotics.  As the established 
gut bacterial community reshapes after treatment with antibiotics, there is a reduced resistance to 
colonization, allowing foreign microbes that can outgrow commensal bacteria to cause permanent 
changes in the structure of the microbiota and varying states of disease[251,264]. 
1.9.2 Gut microbiota and colorectal cancer 
As the understanding of the composition of the gut microbiota has developed, so too has the 
knowledge of its diverse function and influence of health, including in the development of colorectal 
cancer.  The intestinal bacteria are essential in digestion and absorption of non-digestible 
carbohydrates (fibre), production of vitamins B and K, metabolism of endogenous and exogenous 
compounds, immune potentiation, are actively involved in innate and cell mediated immunity, help 
to maintain intestinal barrier function, help to maintain intestinal barrier function and assist with an 
appropriate immune response against pathogenic microbes[265].  This symbiotic relationship, 
normobiosis, is essential for maintaining overall gut and human health.  When there is a shift in this 
delicate balance, dysbiosis, there can be detrimental effects for the host, including the development 
of colonic polyps and colorectal cancers[251,253,266,267]. 
The relatively long duration over which colorectal cancer develops and the multi-factorial nature of 
its aetiology have made it difficult to accurately define the exact role of microbiota.  However, 




 Inflammation: it is becoming increasing clear that the microbiota has a major influence on 
immune response and induction of chronic inflammation[268]. 
 Altered metabolic profiles: either through reduction production or increased consumption of 
protective metabolites.  Together with production of toxic/harmful metabolic by-products 
from dietary carbohydrates, protein, bile and mutagenic precursors e.g. phenol 
compounds[265,269] 
 Cell wall antigens and bacterial colicins: Streptococcus gallolyticus (formally knonw as 
Streptococcus bovi)s antigens have been shown to promote premalignant lesions through 
aberrant crypt formation.  E.coli strains have been shown to induce DNA double strand 
breaks in intestinal cells and trigger chromosomal instability, gene mutations and cell 
transformations[270,271]. 
Studies of immigrants show that cancer rates quickly match those of the current country of 
residence, even when they originate from a country with a lower incidence.  Genes do not change 
over such a short period of time, therefore dietary changes and environmental changes that lead to 
dysbiosis are thought to be important contributors to the development of colorectal cancer[272].  A 
summary of recent human studies of gut bacteria associated with adenoma and colorectal cancer 
formation, is seen in Table 4: 





Disease Summary of findings 
Nugent et al. 
2014 
Colonic tissue Adenoma Bacterial dysbiosis, with alterations specific 
to adenomatous tissue when compared to 
non adenomatous 
Brim et al, 2013 Faeces Adenoma Altered microbiome to subgenus level, 
overall genome existed unaltered 
Chen et al. 2013 Faeces Adenoma Lower SCFA production in adenoma group, 
specifically reduced butyrate producing 
bacteria than in healthy controls 
Shen et al. 2010 Colonic tissue Adenoma Higher relative abundance of Proteobacteria 
and lower abundance of Bacteroides 
Zackular et al 
2014 
Faeces Adenoma and 
colorectal 
cancer 
Higher relative abundance of Fusobacterium, 
Porphyromonas and Enterobacteriaceae, 




Ohigashi et al 
2013 
Faeces Adenoma and 
colorectal 
cancer 
Decreased SCFAs and increased pH in 
colorectal cancer 
Marchesi et al. 
2011 
Colonic tissue Colorectal 
cancer 
High abudance of Fusobacterium in 
colorectal cancers compared to normal 
tissue 
 
Adapted from [272]. 
1.9.3 The microbiota and inflammation 
As the colonic mucosa is constantly exposed to the gut microbiota and its metabolites, bacterial 
stimulation of immune responses has the potential to cause continuous low-grade inflammation.  
The innate and adaptive immune systems work to maintain a homeostatic state in the context of this 
low-grade inflammation.  This homeostasis creates a balance between the pro-inflammatory 
mediators (e.g. IL-1B, IFNү, IL-8, TNF-, IL-23, IL-12 IL-17 and IL-6) and the anti-inflammatory 
mediators (e.g. IL-10 and TGF-Beta).  Disruption of this pro and anti-inflammatory state can lead to 
uncontrolled chronic inflammation and subsequently colorectal cancer.  The ratio of the harmful and 
protective commensal bacteria is key to maintaining homeostasis and gut health.  Variation in 
numbers and diversity contributes to increased mucosal permeability, bacterial translocation and 
increased activation of components of the innate and adaptive immune system to promote chronic 
inflammation[265,273]. 
Assessment of the microenvironment of colorectal tumours demonstrates several different immune 
cells types, the origin of which is felt to arise from alteration in the microbiota.  The most numerous 
of these is tissue-associated macrophages (TAMs)[268].  TAMs have been shown to promote tumour 
growth, with high numbers of TAMs correlating with progression[274].  The next most abundant 
immune cells in the microenvironment are T cells, they have been shown to exert both a suppressing 
and promoting effect.  TH1 cells have a direct lytic impact on cancer cells and secrete cytotoxic 
cytokines that limit cancer progression, whilst IFN-γ producing T cells are associated with 
tumourigenesis.  Inflammation in the absence of microbiota or its products seems to be insufficient 
to induce colorectal cancer[270].  This interaction is not only seen with sporadic cases but also in 
inherited conditions.  Germ free mice with the APC gene have been shown to exhibit a two-fold 
reduction in the number of intestinal adenomas, when compared to APC mice with a conventional 
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microbiota[275].  Mouse models using chemically induced colorectal cancer models have also shown 
the importance of the microbiota.  In this model antibiotics were used to “knock out” the 
microbiota, those mice that received antibiotics had significantly fewer tumours in the colon than 
untreated mice (p=<0.001)[266]. 
Another major consequence of the chronic inflammation induced by the dysbiosis of the microbiota 
is the activation of key pro-survival and pro-proliferative signalling pathways by transcription factors 
such as NF-κB and STAT3 in epithelial cells well as generation of reactive oxygen or nitrogen species 
that leads to oxidative stress, DNA damage, aberrant proliferation and, ultimately, development of 
colorectal adenomas and cancer[265,276]. 
1.9.4 The microbiota, metabolites and diet 
The principal elements of the human diet, namely carbohydrates, protein and fat, that are 
undigested and reach the colon undergo bacterial digestion and fermentation by the anaerobic 
microbial community.  This produces a widely diverse set of metabolites with both protective and 
potentially toxic effects.  As such, the link between diet and colorectal cancer may be explained, in 
part, by the activities of the intestinal microbiota.  The major fermentation products in healthy 
adults are gases and organic acids, particularly the three short-chain fatty acids (SCFAs) acetate, 
propionate and butanoate typically in a 3/1/1 ratio[268]. 
1.9.4.1 Impact of SCFA 
The production of SCFAs is influenced by diet, specifically the ingestion of non-digestable 
carbohydrates, such as resistant starches, pectins, gums, and cellulose.  Higher levels of ingestion 
lead to increased colonic fermentation, increased gut transit, increased stool output and a decrease 
in the luminal pH.  Different groups of enteric bacteria appear to favour the production of specific 
SCFAs.  Acetate, propionate and butyrate are rapidly absorbed from the gut lumen, but their 
subsequent distribution, fate and effects on host cell metabolism differ. Butyrate (aka butanoate) is 
preferentially used as an energy source by gut epithelial cells, and its concentration in the systemic 
circulation is low. Propionate is mostly metabolized in the liver, and only acetate achieves relatively 
high concentrations in peripheral blood[268].  Approximately 95% of the butyrate produced by 
colonic bacteria is transported across the epithelium, but concentrations in portal blood are usually 
undetectable as a result of rapid utilisation as the preferential energy source of colonocytes[277].  
There is an inverse relationship between butyrate concentrations and pH.  More acidic conditions 
favour further fermentation and  reduce the absorption of potential carcinogenic substrates.  There 
is also an increased excretion of ammonia[278]. 
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The luminal concentration of SCFAs, specifically butyrate, appears to be the key factor when 
considering their impact on colorectal cancer.  In higher concentrations butyrate appears to exhibit a 
protective effect.  Butyrate influences gene expression through its non-competitive inhibition of 
histone deacetylases (HDACs), leading to hyperacetylation of chromatin[279].  This has multiple 
consequences for gene expression and cellular differentiation, including the down-regulation of pro-
inflammatory cytokines, such as IL-6 and IL-12, and inhibition of activation of the transcription factor 
NF-kappa B[268,280].  A further mode by which butyrate affects inflammation is via the induction of 
differentiation of regulatory  T cells that express the transcription factor FOXP3[281]. 
In normal cells butyrate acts as a survival factor by acting as a major source of energy, but it is an 
inducer of apoptosis in human colonic carcinoma cells[282].  Studies have shown that the influence 
of butyrate over apoptosis is lost when the early DNA damage of the adenoma –carcinoma pathway 
has occurred[283].  This impact appears to be concentration dependent, as low amounts of butyrate 
enhance cell proliferation while high amounts inhibit it.  Butyrate also conveys influence over 
metastasis once the carcinoma has developed.  It has been shown to alter the expression of both 
pro- and anti-metastatic genes, with a net suppression of pro-metastatic and up-regulation of anti-
metastatic genes[284].  It has also been suggested that butyrate inhibits tumour induced 
angiogenesis through interaction with two angiogenesis-related proteins, vascular endothelial 
growth factor (VEGF) and hypoxia-inducible factor (HIF)-1a[285]. 
Butyrate also shows a protective effect against oxidative damage by modulation of genes associated 
with oxidative stress.  The expression of human catalase, human cyclo-oxygenase 2 and human 
metallothionein 2A is enhanced, whereas that of glutathione reductase, PG-endoperoxide synthase 
2 and superoxide dismutase 2 is lowered[283].   Other effects of butyrate studied in multiple colonic 













Adapted from Guilloteau et al[283]. 
Weir et al demonstrated how butyrate-producing species were under-represented in the analysis of 
stool from patients with colorectal cancer when compared to healthy controls, such as 
Ruminococcus spp. and Pseudobutyrivibrio ruminis,    While a mucin-degrading species, Akkermansia 
muciniphila, was about 4-fold higher in colorectal cancer (p=0.01). Proportionately higher amounts 
of butyrate were seen in stool of healthy individuals while relative concentrations of acetate were 
higher in stools of colorectal cancer patients[286]. 
1.9.4.2 Harmful metabolites 
The metabolites that potentiate a harmful effect are derived primarily from protein fermentation in 
the colon.  With increased protein ingestion, the colonic residue contains more sulphur, nitrates, 
ammonia, amines, branched chain amino acids, and hydrogen sulphide[265].  Some bacteria ferment 
aromatic amino acids to produce potentially bioactive compounds, including phenylacetic aicd, 
phenols, indoles and p-cresol.  These compounds have been shown to exhibit carcinogenic effects 




















Figure 7: Multiple intestinal effects of butyrate. 
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the distal colon where tumour development in most common[287].  These and nitrogen containing 
compounds, particularly N-nitroso, were shown to positively correlate with colorectal cancer in the 
European population.  Ammonia, which is another product of protein fermentation, is also a poten-
tially carcinogenic agent at relatively low concentrations, as shown by the increase in mucosal 
damage and colonic adenocarcinoma in a rat model[288,289]. 
Amine production, predominately in the form of putrescine, spermidine and spermine, are produced 
from arginine, both by human cells and gut bacteria. Certain bacteria are known to increase 
production by up-regulating synthesis by host cells e.g. Bacteroides fragilis.   At physiological levels 
they serve an essential purposes, such as the maintenance of the structural integrity of membranes 
and nucleic acids, gene regulation and translation[290,291].  However, at high levels they have been 
shown to be toxic, inducing oxidative stress and potentially colorectal cancer[290]. 
Hydrogen sulphide is produced in the gut via the reduction of diet derived sulphate and through the 
metabolism of other compounds, e.g. sulphur amino acids[292].  Within the microbiota specific 
bacteria have been identified as specialist sulphate reducing organisms, for example Desulfovibrio 
spp. are present in most individuals, but have yet to be shown to be more numerous in patients with 
colorectal cancer[268,293].  Hydrogen sulphide exhibits a toxic effect through the inhibition of 
butyrate oxidation resulting in colonocyte barrier breakdown and DNA damage. 
Diets that are high in fat are associated with increased bile secretion and thus increased 
concentration of bile acids in the colon.  Increased faecal bile acid concentrations have been linked 
to colorectal cancer[294,295].  Animal models fed a high fat diet have been shown to have 
significant alteration in their microbiota and a fall in the production of SCFAs.  Bile acids such as 
deoxycholic acid contribute to increased reactive oxygen species, DNA damage, genomic instability 
and tumour growth.  Bacteria such as Clostridium spp. have been implicated in these processes, 
particularly reactive oxygen species and the subsequent chronic inflammation[268,296].   
Consumers of a “western” diet have low fibre, high protein and high fat.  Thus, they will have lower 
concentrations of SCFAs, higher levels of amino acid derived products and higher concentrations of 
bile acids.  The interaction of these dietary compounds with the microbiota and the subsequent 
metabolism of the by-products can produce volatile organic compounds detectable in the faeces. 
1.9.5 Carcinogenic impact of the microbiota 
As previously described chronic inflammation of the colonic mucosa predisposes to the development 
of colorectal cancer.  One example is the Bacteroides fragilis-mediated pathogenesis model of 
colorectal cancer[297].  In this model there are two types of Bacteroides fragilis, classified according 
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to their ability to secrete B. fragilis toxin.  They are termed enterotoxigenic B. fragilis (ETBF) and 
nontoxigenic B. fragilis (NTBF).  When mice are inoculated with ETBF they have been shown to 
develop colitis and colorectal cancer whilst those inoculated with NTBF develop neither[298]. 
Fusobacterium species, in particular Fusobacterium nucleatum have been implicated as having a 
direct carcinogenic effect in the development of colorectal cancer, with a significant over-
representation in colorectal cancer tissue.  F. Nucleatum is an invasive, adherent and pro-
inflammatory anaerobic bacterium[299].  They have been shown to be more numerous in colonic 
tumour tissue when compared to normal colonic tissue[300].  This effect has been shown to be 
derived from the FadA adhesion protein complex (FadAc).  Studies have demonstrated its interaction 
with E-cadherin and the Wnt signalling pathway, subsequently promoting invasion of the tumour 
cells and cell proliferation[301].  Castellarin et al also demonstrated a positive correlation with 
lymph node metastasis. 
E.coli species have been demonstrated to have a carcinogenic role in colorectal cancer.  Mice treated 
with azoxymethane, that subsequently develop colorectal cancer, have been shown to have an 
increased number of the NC101 strain of E.coli, that is known to promote highly malignant colonic 
tumours[270]. 
Transplantation of faeces from tumour bearing mice into germ free mice has been shown to result in 
an increase in inflammation and colorectal cancers in the recipient when compared to those not 
receiving transplanted stool.  The same has been demonstrated with the transplantation of human 
stool from colorectal cancer patient into germ free mice[302,303]. 
Alterations in the gut microbiota that occur with age have also been linked to the development of 
colorectal cancer.  As the host ages the total number of bacteria reduce and the composition 
changes with lower numbers of Firmicutes and increased proportion of Bacteroidetes[304]: a 
composition that has previously been shown to increase colorectal cancer.  Others have also 
reported an increase in Escherichia coli and Enterococci spp. with increasing age, but this has failed 
to be consistently shown in similar studies[305]. 
1.9.6 Volatile organic compounds and colorectal cancer 
Volatile organic compounds (VOCs) are a diverse group of carbon-based chemicals that are volatile 
at ambient temperature. They may be odorous and may be emitted from bodily fluids and, as a 
result, VOCs emitted from faeces and urine may include biomarkers of use in the assessment of GI 
and liver disease[306].  Their place as diagnostic tools can be traced back to Hippocrates who 
instructed his students to smell the breath of their patients, as well as pour human sputum on hot 
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coals, in order to produce a smell as a potential indicator of human diseases.  The understanding of 
VOCs and their role in human disease has risen dramatically in the last two decades, with the 
introduction of solid phase microextraction (SPME) in 1989.  This was combined with traditional 
techniques using a separation step with gas chromatography and analysis with mass spectrometry, 
electron capture detection or flame ionization detector.  Gas chromatography and mass 
spectrometry in combination with SPME, is now a widely accepted method of VOC identification 
with published SOPs relating to the topic[307].  There have also been studies that have identified the 
canine ability to identify disease from the associated scent[308].  Analysis of human VOCs can be 
performed on exhaled breath, urine, sweat, skin, vaginal secretions, and faeces.  The number of 
VOCs varies significant depending upon the source, with breath producing the most and blood the 
lowest[309].     
There is strong anecdotal evidence that faeces from patients with GI disease have an abnormal 
smell, moreover, that different malodours are indicative of particular conditions.  VOCs are the 
product of the microbiota and thus the specific changes that occur within it, in the presence of GI 
and other disease can be associated with changes in VOC profiles.  Studies have demonstrated 
significant shifts in the gut microbiota in patients with colorectal cancer when compared to healthy 
controls, e.g. overrepresentation of the genera Coriobacteriaceae, Roseburia, Fusobacterium and 
Faecalibacterium.  Interestingly, the genera Roseburia, Fusobacterium and Faecalibacterium, which 
are moderately enriched in tumours, belong to the major butyrate producing intestinal bacteria.  
Further supporting the theory that the protective nature of butyrate is only pertinent in the early 
phases of carcinogenesis[253]. 
Using faeces, breath and urine a number of studies have examined VOCs as potential biomarkers for 
colorectal cancer and pre-malignant lesions.  They also used a number of different detection 
techniques including GCMS, canine sensing, nanosensors and “eNoses”.  Peng et al used 
nanosensors linked to GCMS and examined breath in a number of cancer patients, including lung, 
breast and colorectal cancer.  The exhaled breath of patients with colorectal cancer contained 
significantly higher levels of a number of VOCs, these were, 1, 10-(1-butenylidene) bis benzene, 1, 3-
dimethyl benzene, 1-iodononane, 1, 1-dimethylethylthio acetic acid, 4-(4-propylcyclohexyl)-40-cyano 
[1, 10-biphenyl]-4-yl ester benzoic acid and 2-amino-5-isopropyl-8-methyl-1-azulene 
carbonitrile[310].  Altomare et al compared a pattern of 15 compounds in the breath of colorectal 
cancer patients and healthy people with a sensitivity of 86%, a specificity of 83 % and an accuracy of 
85 % (area under the receiver operating characteristic (ROC) curve 0·852)[311].  
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Urine has been examined by Arasaradnam et al and Silva et al.  Arasaradnam et al used Field 
Asymmetric Ion Mobility Spectrometer (FAIMS) to identify the VOCs.  FAIMS analyses demonstrated 
that the VOC profiles of colorectal cancer patients were tightly clustered and could be distinguished 
from healthy controls. Sensitivity and specificity for colorectal cancer detection with FAIMS were 
88% and 60% respectively[312].  Silva et al used SPME and GCMS to report 5 significantly elevated 
VOCs in the urine of patients with colorectal cancer.  These were 4-methyl-2-heptane, hexanal, 3-
heptanone and 1, 4, 5- trimethyl-naphthalene.  The validity of which was questioned as they were 
thought to be environmental in origin, from petroleum products or lab contaminants[313,314].  
Sonoda et al demonstrated the utility of VOC assessment by canine sensing.  The dogs were able to 
identify the faeces from patients with colorectal cancer with a sensitivity of 97% and a specificity of 
99%[308]. 
A study using a pattern recognition–based detection technique (eNose) looked at faecal VOCs for the 
identification of colorectal cancer and pre-cancerous adenomatous lesions.  Faecal VOC profiles of 
patients with colorectal cancer differed significantly from controls.  Receiver operating characteristic 
area under curve, 0.92; sensitivity, 0.85; and specificity, 0.87. Patients with advanced adenomas 
could also be distinguished from controls, with a receiver operating characteristic area under the 
curve of 0.79; sensitivity, 0.62; and specificity, 0.86[315].    
The evidence suggests that VOC analysis for the detection of both colorectal cancer and pre-
malignant colonic polyps could be utilised as a future screening tool.  In isolation the evidence would 
suggest VOC superiority when compared to current methods, such as gFOBt.  If used in combination 
with other methods of screening e.g. FIT, the accuracy of colorectal cancer-adenoma screening may 
be greatly improved.  Improved sensitivities and specificities will lead to a higher yield of the 
screening programm, improved cost effectiveness and a reduction in unnecessary colonoscopies.  If 
a suitable VOC based screening test could be identified using urine or breath then patient 
acceptability would be further improved in the absence of handling faeces.   
Finally, when sensor technology progresses over the years, desktop or even consumer “eNoses” may 
become available to analyze VOCs, allowing for general practice based assessment or the study of 
changes in individual VOCs at home.  This may be of specific importance when VOCs will be used in 
monitoring therapeutic response in treatment of colorectal cancer or to determine colonoscopic 
surveillance intervals[316].    
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1.10 Hypothesis, aims and objectives 
The studies included will investigate the hypothesis that volatile organic compounds emitted from 
stool and urine differ in those with gastrointestinal malignancy, when compared to those without 
malignancy;  allowing for the identification of VOC based biomarkers, paying particular attention to 
colorectal cancer and hepatocellular carcinoma.  This difference will be categorised using HS-SPME-
GC-MS. 
The aim is to identify biomarkers that can be used for the screening and/or surveillance of colorectal 
cancer and hepatocellular carcinoma.  It will also explore the utility of other biomarkers, namely 
faecal tM2-PK for the diagnosis of colorectal neoplasia. 
 
The objectives are: 
1) to further develop current methods for the analysis of urine using GCMS 
2) to analyse urine samples from patients with hepatocellular carcinoma in order to identify 
potential biomarkers for screening and/or surveillance 
3) to analyse urine samples from patients with colonic neoplasia in order to identify potential 
biomarkers for screening and/or surveillance 
4) to analyse faecal samples from patients with colonic neoplasia in order to identify potential 
biomarkers for screening and/or surveillance 
5) to determine whether the faecal tM-PK assay has a role in diverse settings or as an adjunct to 
existing FOBt based screening 
6) to explore the potential carcinogenic role of the microbiome in colorectal cancer by examining the 
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This chapter describes the development of standard operating procedures for the analysis of VOCs 
emitted from the headspace of human urine, paying particular attention to urine volume 
optimisation and preparation with freeze drying. In addition, laboratory methods for faecal and 
urine headspace SPME GCMS analysis, tM2-PK ELISA testing, headspace SPME GCMS analysis of 
Fusobacterium nucleatum and Campylobacter showae cultures are described.  Finally, compound 
identification methods and statistical methods used in this thesis are also detailed. 
2.1 Urine volume optimisation: 
There is no generally accepted, standardised approach to optimise VOC yield from human urine.  
Many potential strategies, including using unadulterated urine, adding NaOH, HCl and freeze drying 
have been employed[317,318].  Within our laboratory, previous work had taken place looking at 
optimisation using 4ml of urine, in 10ml headspace vials, analysed by GCMS.  It found that freeze 
drying was the method that yielded the most VOCs, whilst preserving the integrity of the GC column, 
together with a diverse range of VOCs[317]. The addition of acids or bases often results in an 
increase VOC yield but in favour of their respective chemical derivatives, however freeze srying does 
not appear to favour one chemical group giving a wider spread of compound class.  
For the urine volume optimisation work, the HS-SPME-GCMS method used is fully described in 
section 2.3. 
The urine samples provided by collaborators was supplied as volumes between 0.5ml and 1.5ml per 
patent, therefore experimental work was conducted in order to assess on optimal sample volume 
based upon the smaller volumes provided.  
2.1.1 Experiment 1  
Less than 4ml of urine was available for the present study.  As a result, further work to optimise 
freeze drying of smaller urine volumes was performed.  Freeze drying removes water from the urine 
samples and, therefore, concentrates the residual compounds. 
2.1.2 Aim 
To identify the optimal volume of urine for VOC analysis when using a freeze drying technique and 
2ml headspace vials for GCMS. 
2.1.3 Hypothesis 
There will be a significant difference in the VOC yield from the different volumes of urine. 
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2.1.4 Experiment 1-Method: 
First pass urine was collected from a healthy volunteer.  The sample was collected in a 500 ml 
universal glass bottle from within the laboratory.  This was then aliquoted as 100ul, 200ul and 400ul 
volumes into 2ml headspace vials (Agilent Technologies).  Five replicates were made of each volume.  
These were then stored frozen at -20°C for 24 hours.  Freeze drying was then conducted for a further 
24 hours (-30°C and 8 mbar pressure), followed by storage at -20°C until analysis. GCMS, compound 
identification and statistical analysis methods described in section 2.2.1 were used to complete 
analysis. 
2.1.4.1 Results 
100ul volumes of urine gave the fewest VOCs, mean= 25.4 (range 18-32).  The 400ul samples gave 
the most VOCs, mean = 40.2 (range 34-45).  Falling between these two were the 200ul samples, 
mean=35 (range 28-42). 
 
Figure 8: Scatter plot showing number of compounds identified for each sample and volume of 
urine. 
 




400ul appears to give the highest prevalence of VOCs, particularly when compared to the 100ul 
samples.  There is no statistically significant difference between 200 and 400ul, despite this the 
mean VOC prevalence in the 400ul samples is larger than the 200ul. Based on this information, a 
further experiment was performed to compare the VOC yield from 400ul of urine freeze dried in a 
2ml headspace vial to 4ml of urine freeze dried in a 10ml headspace vial.  
 
2.1.5 Experiment 2 
Experiment 1 had identified 400ul as the optimal volume of urine to use in a 2ml headspace vial 
when using the freeze dry technique.  Previous work in our laboratory looking at urinary VOCs 
related to prostate cancer had used 750ul of urine in a 10ml headspace vial with NaOH added to the 
urine before GCMS analysis[318].  Later work had demonstrated the superiority of freeze drying and 
the use of 4ml of urine[317], with a high number of VOCs whilst maintaining a wide diversity of 
chemical class.  In future larger volumes of urine will be available to allow the use of 4ml in a 10ml 
headspace vial.  Identification of the difference, if any, between the 400ul and 4ml volumes was an 
important outcome of this experiment. 
2.1.5.1 Aim 
To compare the number of VOCs identified from 400ul of freeze dried urine in 2ml headspace vial 
and 4ml of freeze dried urine in a 10ml headspace vial. 
2.1.5.2 Hypothesis 
4ml of urine in a 10ml headspace vial will provide a greater number of VOCs than the 400ul in the 
2ml headspace vials. 
2.1.5.3 Method 
First pass urine was collected from the same volunteer.  400ul was then aliquoted in to five 2ml 
headspace vials (Agilent Technologies) and frozen at -20°C.  Similarly 4ml was aliquoted into 10ml 
headspace vials.  There were 5 replicates of each vial volume.  After freezing at -80°C they were 
placed into the freeze dryer at -30°C and 8 mbar of pressure for 24 hours.  Following this the 
samples were placed at -20°C for storage.  GCMS, compound identification and statistical analysis 
methods are described elsewhere (sections 2.3 and 2.3.2). 
2.1.5.4 Results 
There were significantly more VOCs identified in the 4ml samples, p=0.01. 
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Figure 9: Scatter plot demonstrating the number of compounds identified in 400ul and 4ml urine 
samples. 
 
The standard error of mean bar and mean bar are shown, p=0.01. 
2.1.5.5 Conclusion: 
4ml of urine in 10ml headspace vial gives a better yield than smaller volumes in the 2ml headspace 
vial.  However, if smaller volumes of urine are available analysis of 400ul in a 2ml headspace vials, 
that has been freeze dried, can be an option that yields a suitable number of VOCs.  There was a 
difference in the mean number of compounds identified from the 400ul samples between 
experiment 1 and 2.  Experiment 1 had a mean of 40 VOCs, whilst experiment 2 produced a mean of 
24.  The same GCMS method was used in both experiments, together with the same 2ml headspace 
vial.  The urine utilised was different between the two experiments, it was from the same donor but 
acquired from two separate donation 1 week apart.  The difference in the means is likely to originate 
from the variation in diet, microbiome and metabolic activity of the two donations. 
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2.2 Sample acquisition and handling 
2.2.1 Urine acquisition and sample preparation for VOC analysis in hepatocellular carcinoma study 
Acquisition of urine occurred in different locations for the small and larger pilot studies.  Those 
forming the small pilot study were supplied by collaborators having been provided by a third party.  
This was permitted in line with existing ethical approval.  Patient recruitment and sample acquisition 
for patient in Liverpool was in line with full ethical permission, ref 15/LO/0836.  
As part of the small pilot study urine was collected from patients attending the hepatology service, 
at Queen Elizabeth Hospital Birmingham; they were initially collected in standard universal (hard 
plastic) containers.  As soon as possible (in Birmingham) up to 1.5ml of the urine was aliquoted into 
an Eppendorf tube and stored at -20°C until use.  All patients had a confirmed diagnosis of liver 
cirrhosis, based on a combination of clinical, biochemical and radiological markers; this included 
those with a diagnosis of hepatocellular carcinoma (HCC).  Samples were then transferred, frozen, to 
Liverpool and stored at -20°C once again.  Prior to preparation for analysis, there were no other 
freeze-thaw cycles.  In Birmingham, the sex and age of the patient were recorded, along with the 
aetiology of the cirrhosis.   
Before analysis, the samples were re-aliquoted, in batches of 10 to reduce the time out of the 
freezer;   400ul of urine was added to 2ml headspace vials (Agilent Technologies) and then refrozen 
before the next batch of 10 were removed from the freezer to be aliquoted.  Once all 60 samples 
had been aliquoted they were stored at -20°C for a further 24 hours.  All 60 samples were then 
subjected to freeze drying as a complete batch for 24 hours.  Freeze drying was performed at -30°C 
and 8 mbar of pressure.  Freeze drying was completed and the vials were sealed with magnetic caps 
of 2 ml (Agilent Technologies) and then stored at -20°C until processing[317]. 
Urine collection for the pilot study occurred at two clinical sites within the city of Liverpool.  A 
random pass urine sample was provided by patients attending outpatient clinics at both sites and 
collected in standard universal containers.  Clinical data was recorded and correlated.  These 
samples were then returned to the laboratory and frozen at -20°C.  Subsequently they were thawed 
and aliquoted as 4ml into a 10ml glass headspace vial and sealed with magnetic caps (Supelco, UK).  
Freeze drying was performed at -30°C and 8 mbar of pressure for 24 hours,  the samples then being 
returned to -20°C storage until further steps were performed[317].  
2.2.2 Stool acquisition and sample preparation for VOC analysis in colorectal cancer study 
Patients undergoing colonoscopy, following a positive FOBt, as part of the Merseyside and Wirral 
Bowel Cancer Screening Programme (BCSP) were recruited.  Additional symptomatic patients were 
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recruited from those undergoing colonoscopy for polyp surveillance, planned polypectomy, 
colonoscopy for the investigation of iron deficiency anaemia (IDA), change in bowel habit or 
abnormal radiological imaging; the FOBt of these controls was unknown.  These patients were 
identified on the basis of the referral sent to the Endoscopy Department at the Royal Liverpool 
University Hospital.  Patients with a confirmed diagnosis of colorectal cancer awaiting surgical 
resection or other management, at the Royal Liverpool University Hospital, were also included in the 
recruitment.  These patients had not received any prior therapy for the cancer, including 
chemotherapy or radiotherapy.  If these patients were identified via the BCSP then the FOBt status 
was noted as positive.  Sample acquisition took place with full written consent, with BCSP committee 
and research ethics committee approval (14/SW/1162).  Ethically approval was provided as 
amendments to existing local ethical approval in both Sheffield and Plymouth for the use of their 
samples.  
BCSP patients were recruited when they attended their routine pre-procedural interview.  Patient 
information sheets, consent forms and collection kits were distributed during this interview.  Those 
undergoing colonoscopy for other indications were sent these items in the post with the other 
procedural items.  Patients with a known diagnosis of colorectal cancer were recruited at their clinic 
appointments, during which time they were given the patient information sheet, consent form and 
collection kit. 
Two other stool acquisition streams provided samples.  The first was derived from all-comers to 
colonoscopy in Sheffield.  Samples were provided by the patients and the results of their 
colonoscopy were retrospectively collected.  The second stream, from patients in Plymouth, was 
obtained from patients undergoing colonoscopy investigating iron deficiency anaemia (IDA).  Again 
the outcome of the respective colonoscopy was retrospectively recorded.  The FOBt status of these 
patients was unknown. 
During the recruitment, screening suitability and demographic questions were asked.  This included 
smoking status and exposure to antibiotics in the last 6 months.  Sample collection kits were 
provided to each patient (OdoReader Sampler, University of the West of England).  This contained a 
hard plastic spoon to aliquot the sample into a dedicated glass vial.  Patients were instructed to 
place at least 3 spoonfuls of faeces into the glass vial before sealing. Patients produced the sample 
within 48 hours of attending their colonoscopy and before commencing the required bowel 
preparation.  They were asked to keep the sample in a cold environment prior to their attendance.  




Following transfer of the sample to the laboratory, 450mg of unadulterated faeces was then 
aliquoted into 10ml headspace vials and sealed with magnetic caps (Supelco, UK)[307].  Both the 
sample intended for analysis and the residual faeces were then stored at -20°C until GCMS analysis 
was performed. 
2.2.3 Urine acquisition and sample preparation for VOC analysis in colorectal cancer study 
Patients providing stool samples were also asked to provide urine samples.  Therefore, the method 
of identification and patient recruitment was the same as that used in Section 2.2.2.  A 10ml hard 
plastic universal container was provided to patients for collection of the urine, they were asked to fill 
the container with their sample.  Patients produced the sample within 48 hours of attending their 
colonoscopy and before commencing the required bowel preparation.  They were asked to keep the 
sample in a cold environment prior to their attendance.  The sample was then collected from the 
endoscopy department upon the patient’s presentation. 
Following transfer to the lab 4ml of unadulterated urine was then aliquoted into 10ml headspace 
vials (Supelco, UK).  This was subsequently frozen at -20° C, in batches of 20, because of the capacity 
of the equipment, the samples were then freeze dried at -30°C and 8 bar pressure for 24 hours.  The 
vials were then sealed with magnetic caps and placed at -20°C until GCMS processing[317]. 
2.2.4 Fusobacterium nucleatum and Campylobacter showae culture 
This was performed by Dr Georgina Hold, a collaborator in Boston, USA.  It was performed as part of 
a larger piece of work between Harvard University and University of Aberdeen.  Prior to the VOC 
analysis the Fusobacterium nucleatum and Campylobacter showae were maintained on Columbia 
blood plates (Columbia base agar + 10% sheep blood and with further supplementation of sodium 
formate (0.2% w/v) and sodium fumarate (0.3% w/v), under strict anaerobic conditions at 37°C.  For 
the VOC experiments the bacteria were cultured in Columbia base broth + 10% foetal bovine serum 
and with further supplementation of sodium formate (0.2% w/v) and sodium fumarate (0.3% w/v), 
under strict anaerobic conditions at 37°C.  To generate liquid cultures bacteria were transferred to 
liquid media and grown over night in mono-cultures.  This occurred in 15 ml culture tubes.  In the 
morning, cultures were measured to calculate OD (600nm) and diluted to an OD of 0.15 to generate 
equivalent cfu for both Fusobacterium nucleatum and Campylobacter showae. Previous work had 
confirmed using plate counts that an equivalent cfu was obtained from both organisms with an OD 
of 0.15 being equivalent to a cfu of 107cfu/ml. Further confirmation was obtained by using qPCR 
analysis of 16S rRNA gene copies equivalents using universal and genus specific primers to allow 
comparisons of Fusobacterium nucleatum and Campylobacter showae levels within mixed cultures.    
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2.2.5 Faecal tM2-PK quantification  
Stool samples provided by patients according to the method described in Section 2.2.2 were used, 
storage of the stool samples was as described in Section 2.2.2.  ScheBo® Tumor M2PK™ stool ELISA 
kits, in conjunction with ScheBo® Master Quick-Prep™ for extraction (Biotech, Germany) were used 
for stool analysis.  An M2PK cut-off of 4u/ml was used.  Four training events/sessions were made 
using ready-to-use standards ensuring operator technique prior to analysis of samples.  No more 
than 18 samples were analysed on a single ELISA plate in order to minimise incubation time between 
the first and last sample.  Duplicates were carried out for all samples (Figure 10). 
 
Figure 10: ELISA plate layout for M2PK analysis. 
 1 2 3 4 5 6 
A Blank Blank Sample XX Sample XX Sample XX Sample XX 
B Standard 1 Standard 1 Sample XX Sample XX Sample XX Sample XX 
C Standard 2 Standard 2 Sample XX Sample XX Sample XX Sample XX 
D Standard 3 Standard 3 Sample XX Sample XX Sample XX Sample XX 
E Standard 4 Standard 4 Sample XX Sample XX Sample XX Sample XX 
F Control Control Sample XX Sample XX Sample XX Sample XX 
G Sample XX Sample XX Sample XX Sample XX Sample XX Sample XX 
H Sample XX Sample XX Sample XX Sample XX Sample XX Sample XX 
Optimisation of operator technique used columns 1 and 2, together with row A-F.  Plates 1-5 
contained 18 samples, the sixth plate contained 10 samples. 
 
A maximum of 18 samples were randomly removed from frozen storage and left to thaw at room 
temperature for one hour.  The ScheBo® Master Quick-Prep™ extraction kits, with their dosing tip, 
allowed for a reproducible extraction process, with a previously documented coefficient of variance 
of 2.7%.  Each extraction tube was vortexing and left to stand allowing the sediment to settle.  This 
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process took an average of 20 minutes.  During this time the investigator was blind to the diagnosis 
of each sample.  The diagnosis was only correlated to the samples when the analysis was complete. 
A ready to use substrate solution was used for the colour reaction followed by the included stop 
solution.  Optical density was read at 450nm using an automated plate reader, 5 minutes after the 
stop solution had been applied.  A standard curve was generated for each plate using the optical 
densities of the internal standards, plotted on log-log axes.  This analytical performance of each 
plate was assessed by interpolated control calculation using a sample of known tM2-PK abundance. 
If a deviation >15 % from expected concentration was identified assay failed QC and was repeated. 
Figure 11: Standard curve generated from one M2PK ELISA plate. 
 
2.3 Headspace extraction and gas chromatography mass spectrometry method 
The same method was applied to urine and stool and includes samples analysed for colorectal 
cancer and hepatocellular carcinoma.  As described all samples were placed in 10ml headspace vials 
(Supelco, UK). 
A Perkin Elmer Clarus 500 GC/MS quadruple bench top system (Beaconsfield, UK) was used in 
combination with a Combi PAL autosampler (CTC Analytics, Switzerland) for the analysis of all 
samples.  SPME-GC-MS method was used.  The GC column used was a Zebron ZB-624 with inner 
diameter 0.25 mm, length 60 m, film thickness 1.4 μm (Phenomenex, Macclesfield, UK). The carrier 
y = 0.1036x - 0.0457 









gas used was helium of 99.996% purity (BOC, Sheffield, UK). The SPME fibres used were CAR-PDMS 
85 μm (Sigma-Aldrich, Dorset, UK). 
Samples were placed on the autosampler tray in batches of five, each batch being preceded and 
followed by lab air assessment to monitor for contaminates.  During all processing the tray was kept 
at a constant 1°C.  This was performed as a continuous process in order to maximise efficiency.  
Once 10 samples were available following recruitment they were processed through the GCMS in 
order to minimise time frozen at -20°C.  Specifically, this minimised the time difference between 
freezing the first sample obtained and processing the last. 
The fibre desorption conditions were 5 minutes at 220°C. The initial temperature of the GC oven was 
set at 40°C and held for 1 minute before increasing to 220°C at a rate of 5°C/min and held for 4 min 
with a total run time of 41 min. A solvent delay was set for the first 6 min and the MS was operated 
in electron impact ionization EI+ mode, scanning from ion mass fragments 10 to 300 m/z with an 
interscan delay of 0.1 sec and a resolution of 1000 at FWHM (Full Width at Half Maximum). The 
helium gas flow rate was set at 1 ml/min. The sensitivity of the instrument was determined with 2-
pentanone only and will vary for other compounds[307,318,319]. 
 
2.3.1 Headspace extraction and gas chromatography mass spectrometry method relating to F. 
nucleatum and C. showae 
A manual injection technique was used for this element of the work.  Specific manual SPME fibres 
were used DVB/CAR-PDMS (Sigma-Aldrich, Dorset, UK) which underwent  a 10 minute exposure to 
the headspace gas of the culture vials in Boston, USA.  The fibres were shipped to Liverpool within 
48 hours at ambient temperature.  They were transported with a septum covering the inlet of the 
fibre.  They were then placed at -20°C until processing.  The Perkin Elmer Clarus 500 GC/MS 
quadruple bench top system (Beaconsfield, UK) was used with injection via the manual port.  There 
were 35 samples in total which were processed as a continuous batch, with every third fibre being 
followed by a blank fibre, that had been stored in Liverpool only.  The GCMS settings, were as above, 
Section 2.3.    
2.3.2 Identification of volatiles 
Mass spectral data were analysed using Automated Mass Spectral Deconvolution and Identification 
System (AMDIS) (AMDIS-version 2.71, 2012) and the National Institute of Standards and Technology 
(NIST) (version 2.0, 2011).  Data bridge was used to covert raw data files into CDF files that could 
then be analysed in AMDIS.  Three components were used within NIST to identify the compounds, 
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applying percentage probability, a forward and reverse matching of 800/1000 as above, allowing for 
compound identifications (Figure 12).  A compound was considered to be present when it satisfied 
these 3 criteria.  This process provides a relative ion abundance, therefore no units of ion abundance 
are available.  Further processing and alignment of data was performed using the Metab package in 
R[320].  A dedicated library for analysis of these samples was built using at least 50% of the samples 
in each cohort.  During this library building the investigator was blind to the sample diagnosis or 
cultured bacterium.  Log transformation was used to normalise data. 
Figure 12: Screenshot of the NIST VOC library used to identify compounds. 
 
The image includes the “match” process, probability assessment and head-to-tail fragment analysis.  
This is the screen used to identify all compounds and in this case butanoic acid. 
 
2.4 Data handling and statistical analysis 
2.4.1 GCMS data handling and statistical analysis 
All GC-MS data was processed using the AMDIS (version 2.71, 2012) in conjunction with the NIST 
mass spectral library (version 2.0, 2011) and the R package Metab[320]. VOCs were identified using 
an in-house library built from a combination of previous work on urine GCMS and at least 50% of the 
samples in each study.  AMDIS in combination with the NIST library was utilised for this element. All 
statistics were performed using R version 3.0.2[90,321,322]. Fisher’s exact test, Student’s t test, chi-
squared testing and a one-way analysis of variance (ANOVA) followed by HSD Tukey testing was 
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applied.    Principal component analysis (PCA) was used to show similarities within data classes.  P-
values <0.05 were considered significant (unless specified otherwise).  Finally, partial least squares 
discriminant analysis (PLS-DA) was used to look for separation within the samples followed by ROC 
analysis testing of potential biomarker candidates, using Metaboanalyst(3.0)[323,324].  Within 
Metaboanalyst relative abundances were normalised by log transformation and auto-scaling, an 
example of this can be been in the Appendix 4.  This consists of a data output report of the samples 
used in the studies detailed within.   
2.4.2 Biomarker analysis of VOCs 
Analysis of potential biomarkers was conducted using Metaboanalyst[324]. Following the 
assessment of fold change and Student’s t test, potential VOCs were taken forward for biomarker 
analysis.  This was performed in Metaboanalyst and was performed on quantitative data.  The VOC 
abundance was normalised by median, log transformed and scaled using the auto-scaling function 
built into Metaboanalyst.  Initially univariate ROC analysis was performed.  Combination testing was 
based upon previous p values and FDR values.  Calculating ratios of all possible metabolite pairs and 
then choosing top ranked ratios, based on p values, allowed for further biomarker assessment.  
Logistic regression and a 10-fold cross validation modelling was used to generate AUROC, sensitivity 
and specificity[324].  An example of the Metaboanalyst data handling process can reviewed in 
Appendix 4.  
2.4.3 tM2-PK data handling and statistical analysis 
The optical reader was programmed to read three separate optical densities for each plate, this was 
performed at 8 second intervals.  A mean optical density from these three runs could then be 
calculated.  Standards provided with each ELISA kit were used to generate the standard curve and R2 
value for each plate.  These were correlated with the 4.5u/ml control, +/- 15%.  Once optical 
densities had been produced each sample was then cross referenced to the colonoscopy findings 
cancer, adenoma or normal.  Using a pre-defined cut off of 4u/ml, each M2PK result was defined as 
true positive (TP), false positive (FP), true negative (TN) and false negative (FN), according to the 
colonoscopy findings.  All analysis was performed by an investigator blinded to the patients’ 
diagnoses, under standardised conditions. Graphpad Prism 6 was used to compare pathological 
groups by two tailed t test and Kruskal-Wallis and Dunn’s post-hoc analyses (p value significant 
<0.05), and to determine the area under ROC curves, sensitivity, specificity, positive predictive value 
and negative predictive values. Further testing was performed using a binomial method McNemar’s 
test.  
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Primary liver cancer/hepatocellular carcinoma ( HCC) is the third largest contributor to cancer 
mortality in the world[122].  Mortality and 5-year survival from HCC is variable worldwide, but is 
considered to be poor.  HCC typically occurs on a background of cirrhosis, developing as small 
asymptomatic nodules.  It has an average doubling time of 6 months.  The size of the HCC and 
severity of liver disease at the point of diagnosis have a significant impact on survival, therefore early 
diagnosis and screening should be beneficial.  Current European guidelines recommend 6-monthly 
liver ultrasound scanning of patients with cirrhosis to screen for HCC.  Detection of early lesions by 
ultrasonography has been reported to be as low as 63%, therefore the addition of other screening 
modalities has the potential to improve this[144].  
3.1.1 Aim 
The study was performed as two parts, a small pilot study followed by a larger scale replication 
study.   
1) The aim of the small (Birmingham) pilot study was to assess a recently published departmental 
standard operating procedure to a real life cohort and then to assess if differences in VOCs emitted 
from urine could be detected between those with and without HCC[317]. 
2) The aim of the larger (Liverpool) replication study was to assess the utility of these differences in 
urinary based VOCs as a biomarker for the diagnosis and/or monitoring of HCC. 
3.1.2 Method 
For the small pilot study, samples were obtained from Prof Philip Johnson, who had recruited 
patients from University Hospitals Birmingham NHS Trust. SPME headspace extraction followed by 
GCMS was used to assess VOCs emitted from freeze dried urine of cirrhotic patients with and 
without HCC.  Four hundred microlitres of urine was freeze dried in 2ml headspace vials for the small 
pilot study.  After further method development, the larger pilot used 4ml of freeze dried urine to 
perform SPME GCMS in the larger pilot these were supplied by patients from Liverpool, UK: the full 
method is described in Chapter 2.  Data analysis was performed in R[320] and Metaboanalyst[324], 
utilising Student’s t test, Fisher’s exact test, false discovery rate correction, PLS-DA and  ROC 






3.2.1 Small pilot study  
In total 62 samples were included in this study collected from 29 patients with HCC and 33 without 
HCC.  Patients were HCC were older than those without (p= 0.02).  There was no significant 
difference with regard to gender (p= 0.1) (Table 5). 
Table 5: Demographic details of patients included in the small pilot study. 
 Male (%) Female (%) Mean age, years (range) 
No HCC 19 (58%) 14 (42%) 61 (35-82) 
HCC 20 (74%) 7 (26%) 68 (46-78) 
 
A total of 118 VOCs were identified across all samples.  The mean number of VOCs in all samples was 
25.1.  There were significantly more VOCs identified in the cirrhotics without HCC compared with 
those with HCC, p=0.034 (Table 6, Figure 13). 
Table 6: Mean number of VOCs identified in each group, with standard deviation and error of 
mean. 
 Cirrhosis without HCC Cirrhosis with HCC 
Mean number of VOCS 26.5 23.7 
Standard deviation 5.2 4.9 




Figure 13: Box plot to show the distribution of the number of VOCs identified in the patients 
without and those with HCC 
 
*p=<0.05 
Categorical comparison for the prevalence of VOCs was performed and found one VOC to be 
signficantly different: methanethiol, whichwas found in 19/33 (57.6%) cirrhotics without HCC and 
6/27(22.2%) with HCC (p=0.0083).  Semi-quantitative analysis demonstrated 4 VOCs, including 
methanethiol, the abundance of which was significantly greater in those without HCC (p=<0.05), 
Table 3.  However, when false discovery rate correction was applied in order to correct for multiple 
comparisons, none of the 4 VOCs achieved a significant q value (≤0.05).   
PLS-DA comparing those with and without HCC showed separation suggesting a potential 








Table 7: VOCs shown to be different following assessment of abundance using Metaboanalyst.   
VOC p value False discovery rate q value 
Methanethiol 0.005 0.6 
Dimethyltrisulphide 0.01 0.6 
2,2-dimethylbutanoic acid 0.02 0.6 
2,2,2-trifluoroethanol 0.02 0.6 











3.2.2 Diagnostic model and validation 
 
The 4 VOCs identified in the smaller pilot study were then entered into a logistic regression model 
and 10 fold cross validation used to perform ROC analysis.  The optimal AUROC achieved was 0.75 
(95% CI 0.61-0.85), sensitivity 85% (95% CI 0.8-0.89) and specificity 58% (0.52-0.63).  Validation of 
this model failed when applied to the Liverpool cohort from the pilot study.  When the Birmingham 
VOCs were applied to the Liverpool samples the AUROC fell from 0.75 to 0.47. 
 
PLS-DA examining all samples from both the small pilot and larger pilot study suggested a significant 
intra and inter cohort difference (Figure 15). 
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Figure 15: PLS-DA containing all samples from both pilot studies.   
 










3.3 Larger scale pilot Study 
 
3.3.1 Patient demographics 
One hundred and three patients were recruited: 59 with HCC and 44 without.  There was a male 
predominance in both the HCC and no HCC group.  The mean age of the entire cohort was 64 years: 
patients with HCC were significantly older than those without, p=<0.0001, (Table 8).  All patients had 
previously been diagnosed with cirrhosis as part of their clinical assessment and management.  The 
diagnosis of cirrhosis was based upon clinical, biochemical and radiological parameters and was 
made by the managing clinicians, prior to recruitment. 
Table 8: Patient demographic details and clinical parameters for those included in the Liverpool 
pilot study analysis. 
 No HCC HCC Total p value 
Number 44 59 103 - 








Male 35 48 83  
Female 9 11 20 
Childs Pugh score 0.6 
A 33 44 77  
B 10 15 35 
C 1 0 1 







Underlying aetiology 0.4 
ALD 16 27 43  
Viral 12 9 21 
Metabolic disease 14 20 34 
Autoimmune 2 3 5 
 
All patients included in the HCC group had had their diagnosis confirmed via the standard clinical 
methods and multi-disciplinary assessment.  Of the 59 patients, 39 had received treatment: 38 in the 
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form of radiofrequency ablation (RFA) or trans-arterial chemoembolisation (TACE), these treated 
patients still had radiological evidence of active disease (Table 9). 
 
Table 9: Clinical parameters for those in the HCC cohort, stratified by treated and treatment naive. 
 Treatment naive Treated Total p value 
Number 20 39 59  
BCLC stage 0.3 
A 15 34 49 
B 4 3 7 
C 1 1 2 
D 0 1 1 
Mode of treatment NA 
TACE NA 26 26  
RFA NA 10 10 
TACE and RFA NA 2 2 
Resection NA 1 1 
Sorafenib NA 0 0 
Multifocal lesions 0.02 
Yes 6 24 30 
No 14 15 29 
Lesion > 3 cm 11 20 31 0.5 
AFP positive 0.7 
Yes 8 14 22 
No 12 25 37 
 
BCLC= Barcelona clinic liver cancer staging. 







3.3.2 VOC profile of larger scale Liverpool cohort 
 
Across all 103 samples, 216 VOCs were identified.  There was no significant difference in the number 
of VOCs identified between the two groups, p=0.4 (Figure 16).  The mean number of VOCs was 
greater in the larger pilot cohort (Table 10). 
Figure 16: Box plot to show the number of VOCs identified in the patients without and those with 
HCC from the larger pilot study cohort. 
 
 
Table 10: Mean number of VOCs identified in each group, with standard deviation and error of 
mean. 
 No HCC HCC 
Mean number 33.5 35 
Standard deviation 9 7.6 







3.4 Comparisons to assess and model biomarker utility 
For all modelling and ROC analysis a logistic regression with 10-fold cross validation was used.  Only 
significantly different VOCs with a p value of ≤0.01 were considered for candidate testing.  All 
analysis in this section was conducted in Metaboanalyst and is quantitative[324]. 
3.4.1 Comparison of VOCs in patients with cirrhosis and those complicated by HCC 
All 103 samples were assessed with 3 VOCs demonstrating a p value ≤0.01 (Table 9).  PLS-DA based 
on all samples demonstrated separation, with particular clustering of the HCC cohort (Figure 6).  ROC 
analysis based upon the 3 VOCs in Table 9 demonstrated an AUROC 0.76 (95% CI 0.65-0.83), 
sensitivity 65% (95% CI 0.61-0.69) and specificity 74% (95% CI 0.69-0.78). 
 
Table 11: VOCs found to be significantly different (p= ≤0.01), when assessing VOC abundance in 
those with and without HCC.  
VOC p value False discovery rate 
Styrene <0.0001 0.03 
Pyrazine-2-5-dimethyl-3 0.003 0.1 
D-limonene 0.004 0.1 




Figure 17: PLS-DA based upon all VOC in all samples from the larger Liverpool pilot study 
comparing those with and without HCC. 
 
 
3.4.2 Comparison of VOCs of HCC patients who are treatment naive and who have received 
treatment 
 
The 59 HCC patients were then stratified according to their treatment status.  Two VOCs were found 
to be significantly different (Table 12).  PLS-DA demonstrated separation of the cohorts with no 
overlap of samples (Figure 22).  ROC analysis combining the two VOCs in Table 12 demonstrated an 
AUROC 0.75 (95% CI 0.51-0.89), sensitivity 73% (95% CI 0.67-0.79) and specificity 76% (95% CI 0.72-
0.81). 
 
Table 12: VOCs found to be significantly different (p ≤0.01), when assessing VOC abundance in HCC 
patients who had received treatment and were treatment naive.   
VOC p value False discovery rate 
Phenol <0.0001 0.04 
3-methyl-2-butanone 0.001 0.1 
  False discovery rate applied in order to correct for multiple comparisons (q=≤0.05 for significance). 
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Figure 18: PLS-DA based upon all VOC in all samples when assessing VOC abundance in HCC 
patients who had received treatment and were treatment naive. 
 
 
3.4.3 Comparison of VOCs in cirrhotic patients without HCC and treatment naive HCC 
 
All 44 patients without HCC and the 20 treatment naive HCC patients were entered into this analysis.  
Five VOCs were found to be significantly different, with three -  styrene, phenol and D-limonene 
being identified as significant in the earlier analysis (Table 13).  Combining these VOCs as a 
biomarker panel for treatment naive HCC produced an AUROC of 0.81 (95% CI 0.66-0.93), sensitivity 
77% (95% CI 0.71-0.83) and specificity 75% (95% CI 0.71-0.79) (Figure 19). 
Table 13: VOCs found to be significantly different (p= ≤0.01), when assessing VOC abundance in 
those without HCC and HCC patients who were treatment naive.   
VOC p value False discovery rate 
Phenol 0.005 0.3 
Styrene 0.006 0.3 
D-limonene 0.01 0.3 
Benzene-1-1-dimethylethoxy- 0.01 0.3 
o-cymene 0.01 0.3 




Figure 19: ROC curve produced with logistic regression and 10-fold cross validation modelling, 
based upon the 5 VOC found to be significantly different for no HCC against treatment naive HCC. 
 
 
3.4.4 Comparisons of VOCs in HCC patients according to their Alpha-Fetaprotein status at diagnosis 
Thirty percent of HCCs will not produce alpha feto-protein (AFP), therefore this 30% will be missed if 
AFP is used as a biomarker.  This absence of production also suggests a difference in underlying 
metabolic pathways within the HCC. 
3.4.4.1 AFP negative versus AFP positive HCC 
Thirty seven (62%) of the HCC patients in our cohort were AFP negative.  When compared to those 
HCC patients who were AFP positive three VOCs were identified as being significantly different, p= 
≤0.01, (Table 142).  PLS-DA using all samples and all VOCs demonstrated separation. 
Table 14: VOCs found to be significantly different (p= ≤0.01), when assessing VOC abundance in 
those AFP negative and positive HCC.   
VOC p value False discovery rate 
Ethylalcohol 0.001 0.1 
3-methyl-2-hexanone 0.007 0.4 
3-methylene-2-pentanone 0.01 0.4 
False discovery rate applied in order to correct for multiple comparisons (q=≤0.05 for significance). 
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3.4.4.2 Comparison of VOCs in those cirrhotics without HCC and those HCC patients with a 
negative AFP 
Comparison of all those without HCC and the 62% of our cohort with HCC and a negative AFP was 
then conducted, thus exploring the ability of VOCs to identify those HCCs that would not be 
identified by AFP.  Five compounds were found to be significantly different, with styrene and D-
limonene again being identified (Table 15).  These compounds were entered into logistic regression 
and 10 fold cross validation ROC analysis in order to assess diagnostic utility, AUROC 0.82 (95% CI 
0.69-0.89), sensitivity 84% (95% CI 0.8-0.88) and specificity 66% (95% CI 0.61-0.71) (Figure 20). 
Table 15: VOCs found to be significantly different (p= ≤0.01), when assessing VOC abundance in 
those with no HCC and AFP negative HCC.   
VOC p value False discovery rate 
Styrene <0.0001 0.06 
Ethylalcohol 0.001 0.06 
D-limonene 0.001 0.07 
2-3-butanedione 0.006 0.1 
Pyrazine-2-5-dimethyl-3 0.01 0.3 
False discovery rate applied in order to correct for multiple comparisons (q=≤0.05 for significance). 
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Figure 20: ROC curve produced with logistic regression and 10 fold cross validation modelling, 
based upon the 5 VOC found to be significantly different for no HCC against AFP negative HCC. 
 
 
3.4.5 VOC comparisons stratified by Barcelona Clinic Liver Cancer stage 
 
The Barcelona Clinic Liver Cancer (BCLC) staging tool is commonly used as a decision aid in UK 
practice.  The staging tool separates disease into early (potentially curative) disease and later (non-
curative disease)[152]. 
Comparisons demonstrated significant differences in VOCs between those deemed to have curative 
(n=16) and non curative disease (n=43) according to the BCLC staging.  Further sub-analysis was then 
performed to assess the ability of VOCs to identify those with early and therefore potentially 




3.4.5.1 Comparison of VOCs in cirrhotic patients without HCC and those whose HCC is classified 
curative by BCLC 
 
This comparison showed five VOCs to be significantly different, with styrene, D-limonene, 3-methyl-
2-butanone and phenol again being significant (Table 16).  Separation seen with PLS-DA supported 
further assessment of diagnostic utility (Figure 21).  Diagnostic utility assessed with ROC analysis 
demonstrated an AUROC of 0.82 (95% CI 0.69-0.96), sensitivity 67% (95% CI 0.67-0.91) and 
specificity 93% (95% CI 0.86-1.0) (Figure 22). 
Table 16: VOCs found to be significantly different (p= ≤0.01), when assessing VOC abundance in 
those with no HCC and BCLC curative (early) HCC.   
VOC p value False discovery rate 
3-methyl-2-butanone 0.001 0.07 
o-cymene 0.001 0.07 
D-limonene 0.001 0.07 
Phenol 0.004 0.1 
Styrene 0.01 0.2 




Figure 21: PLS-DA based upon all VOC in all samples when assessing VOC abundance in those with 





Figure 22: ROC curve produced with logistic regression and 10 fold cross validation modelling, 















This chapter reports the results of two pilot studies (smaller and larger) examining the utility of 
urinary VOCs as a biomarker for HCC.  The smaller pilot study demonstrated differences according to 
the absences and presences of HCC.  This significance did not persist after correction for false 
discovery and was not validated by the larger, Liverpool pilot study.  The larger pilot study allowed 
for further stratification and modelling of VOC profiles, providing an accurate diagnosis of HCC and in 
particular for those who are treatment naive and staged earlier according to the BCLC stage.  This 
has the potential to improve outcomes as early diagnosis has been shown to improve survival from 
HCC[127,129]. 
Currently in the UK, HCC surveillance is recommended for patients with underlying cirrhosis, EASL 
specifically recommend it for those who are Childs-Pugh A and B, Childs-Pugh C awaiting 
transplantation, non-cirrhotic HBV carrier with active hepatitis or family history of HCC and non-
cirrhotic patients with chronic hepatitis C and advanced liver fibrosis[129].  For patients with 
preserved hepatic function, no evidence of portal hypertension and early HCC (a single lesion <5cm 
in diameter) resection has been shown to provide 5 year survival rates of 70%, with transplantation 
in such cases having five year survival rates up to 74%[325,326].  For those with early disease who 
are not deemed suitable for resection or transplantation, RFA with curative intent, has been shown 
to have a 5-year survival of approximately 37%[144].  The survival of those with later staged HCC is 
stark in comparison with the median survival of patients reported to be between 6 and 13.5 months 
depending on treatment mode[327].  Unfortunately less than 30% of patients are diagnosed at an 
early enough stage to make them eligible for resection or transplantation[328].  A meta-analysis 
form 2009 looked specifically at studies examining the impact of ultrasound based screening on 
detection of early HCC.  Ultrasonography was demonstrated to be highly accurate for HCC at any 
stage, with pooled sensitivity of 94% and specificity of 94%.  However, this was significantly lower 
when analysis was modified for the detection of early HCC, with the pooled sensitivity falling to 64%.  
Meta-regression analysis demonstrated a significantly higher sensitivity for the early HCC with an 
ultrasound scan every 6 months rather than with annual surveillance[144].  Results from the larger 
pilot study for the diagnosis of all treatment naive HCC was AUROC of 0.81 (95% CI 0.66-0.93), 
sensitivity 77% (95% CI 0.71-0.83) and specificity 75% (95% CI 0.71-0.79), with those defined as BCLC 
early HCC having an AUROC of 0.82 (95% CI 0.69-0.96), sensitivity 67% (95% CI 0.67-0.91) and 
specificity 93% (95% CI 0.86-1.0).  Despite its limitations ultrasonography is currently the best 
screening tool for HCC.  Our results suggest that urinary VOC analysis is superior to ultrasound 
scanning, particularly for the pertinent question of early HCC.  Certainly, data from this meta-
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analysis supports the use of 6 monthly screening, with a significant improvement in detection of 
early lesions when compared to 12 monthly (p= 0.001).  We would therefore suggest urinary VOCs 
be assessed on a 6 monthly basis.  
There may be a place for a two modality screening method combining both ultrasound scanning and 
VOC analysis.  In previous clinical practice combined testing with AFP and ultrasonography was 
employed.  The same meta-analysis demonstrated a non-statistically significant increase in 
sensitivity when AFP was used in addition to ultrasound scans[144].  This finding is consistent with 
current American Association of Liver Disease guidance which suggests that AFP is not an adequate 
screening tool, but has a role in the diagnosis of HCC when >200 ng/ml in the setting of a mass 
detected on imaging[329].  Moreover, normal AFP levels are present in as many as 30% of patients 
at time of diagnosis and usually remain low, even with advanced HCC[330].  This was even greater in 
our study, with 37/59 (62%) of those with HCC being AFP positive at diagnosis.  We have 
demonstrated that VOCs are able to distinguish between HCC that is AFP negative and positive, 
along with those without HCC and AFP negative HCC.           
Other potential surrogates to ultrasound screening are AFP-L3% and Des-gamma-carboxy 
prothrombin (DCP), neither of these reported biomarkers has been shown to be consistently 
superior to the demonstrated ability of urinary VOCs[228,232,233].  Dedicated trials examining the 
addition of urinary VOCs to ultrasound screening would need to be conducted and would need to 
include longer term survival data. 
Four compounds were recurrently highlighted to be important for the identification of HCC, with all 
four being significant for the detection of early HCC.  These were 3-methyl-2-butanone, styrene, 
phenol and D-limonene.  3-methyl-2-butanone was most abundant in those without HCC, with the 
remaining three compounds being most abundant in those with early HCC.  Styrene is metabolised in 
the liver by the cytochrome P450-mediated monooxygenase system.   A number of genetic studies 
have suggested that individual susceptibility to cancer may be determined by an inherited genetic 
predisposition associated with the polymorphisms of genes encoding the enzymes involved in such 
metabolism, such polymorphism as CYP1A1 MspI[331].  The products of metabolism are excreted in 
the urine.  The National Toxicology Programme in the USA report that styrene is reasonably 
anticipated to be a human carcinogen based on limited evidence of carcinogenicity from studies in 
humans, sufficient evidence of carcinogenicity from studies in experimental animals, and supporting 
data on mechanisms of carcinogenesis[332].  An accumulation of styrene as a result of impaired liver 
function may be one reason for the increase seen in our cohort.  Most of the genetic damage 
associated with styrene exposure is thought to be due to styrene-7,8-oxide, a by-product of its 
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metabolism[333].  D-limonene, although at high doses have been shown to cause renal cancer in 
male rats, is considered by most researchers to be a potential chemo-preventive agent and has been 
declared via international consensus to have no carcinogenic potential.  In fact it has been suggested 
as having an efficacious chemotherapeutic agent for human malignancies[334].  Its greater 
abundance in those with HCC may therefore be related to altered metabolism and accumulation, 
rather than a direct causative effect.  Phenol in contrast to this, is recognised as being carcinogenic 
to humans, namely in colorectal cancer as part of bacterial fermentation[287].  Despite this, the 
International Agency for Research on Cancer (IARC) classified phenol as a category 3 carcinogen, i.e. 
not classifiable for its carcinogenicity to humans[335].  It is mostly metabolised in the liver and 
excreted in the urine.  In the liver phenol is metabolised by sulfotransferases, specifically phenol 
sulfotransferase 1[336].  This has been shown to be down-regulated in HCC and this potentially 
explains the accumulation of phenol in the urine of HCC patients[331].  Once again the increased 
phenol may be accumulation due to altered metabolism rather than a direct causative effect. 
Qin et al assessed VOCs emitted in the breath of 30 HCC patients who were infected with HBV and 
cirrhosis and from 27 cirrhotic patients without HCC, together with 36 healthy persons, both taken 
as controls.  3-hydroxy-2- butanone, styrene, and decane were identified as having the most 
potential as biomarkers for HCC.  Only 3-hydroxy-2- butanone (AUROC 0.75 [0.61-0.87], sensitivity 
70% and specificity 70.4%) and styrene (AUROC 0.69 [0.544-0.829], sensitivity 66.7% and specificity 
70.4%) were able to distinguish between HCC and cirrhotics without HCC.  They did not find any 
difference in those that were deemed to be AFP positive or negative[337].  In our pilot study styrene 
performed strongly in the diagnosis of all HCC, treatment naive and early stage HCC.  Mochalski et al 
performed VOC analysis of HCC cell culture in an attempt to assess the metabolites of the cells.  They 
characterised 9 VOCs that were categorised as HCC uptake and 12 that were released by the HCC 
cells[338].  None of these 21 VOCs was identified as being significant in our analysis.  A further study 
compared VOCs emitted from 31 HCC tissue and corresponding non-tumour liver tissue from the 
same liver.  HCC was characterized by approximately two-fold depletion of glucose, glycerol 3- and 
2-phosphate, malate, alanine, myo-inositol and linoleic acid[339].  Once again these compounds 
were not found to be significant in our study.  
Using the larger pilot study data, validation of the differences seen in the smaller pilot samples was 
attempted and failed.  There are a number of potential reasons why this may have occurred.  Firstly, 
the volumes of urine and the headspace vials used were different between the two groups.  The 
smaller pilot study used 400 ul of urine in a 2ml headspace vial, whilst the pilot study used 4 ml of 
urine in a 10 ml headspace vial.  Previous work, together with the increased mean VOC yield in the 
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pilot study, had demonstrated that 4 ml was the optimal volume to use[317].  VOCs may therefore 
not have been identified by the sub-optimal methodology employed in the smaller pilot study.  In 
some instances, samples from the smaller pilot study were more than 3 years old, whilst the 
maximum age of the pilot study samples was 6 months.  Therefore, there is likely to have been a 
greater degree of VOC loss and sample degradation owing to the difference in storage duration.  
Before taking custody of the smaller pilot samples they had been stored in soft plastic vials, such 
plasticizers are recognised contaminators of GCMS results.  The pilot study samples were not 
exposed to such plasticizers.  A further point of note is the geographical location of recruitment and 
thus the potential for large variation in the ethnicity of each cohort.  The smaller pilot cohort were 
all recruited from the Queen Elizabeth Hospital, Birmingham UK, whilst the larger pilot study 
patients were recruited from Liverpool, UK.  This point is demonstrated in by results from the 2011 
census (Table 17).  Dietary differences will be seen between geographical location and ethnicity, 
therefore making the range of VOCs identified in urine different.  Any future studies assessing 
urinary VOCs should aim to recruit patients in multiple geographic locations to correct for this factor.  
Table 17: Results from 2011 UK census showing the difference in population size and ethnic 
composition of Liverpool and Birmingham[340]. 
  White Asian or Asian British Black or Black British 
  White British & 
Irish 
Indian Pakistani Black African Black 
Caribbean 
City Population n= %  n= %  n= %  n= %  n= %  
Liverpool 466,415 402,399 86.3 4,915 1.1 1,999 0.4 8,490 1.8 1,467 0.3 
Birmingham 1,073,045 592,646 55.2 64,621 6.0 144,627 13.5 29,991 2.8 47,641 4.4 
 
False discovery rate testing was performed in Metaboanalyst.  The numerical figure generated 
represents a percentage, indicating the expected false positives among all features predicted to be 
significant.  The significance of the VOCs that were initially identified by the smaller Birmingham 
pilot study did not persist after a false discovery rate correction was applied.  This is likely to be 
because  the smaller numbers made the study under-powered.  It may also explain why these 
differences were not seen in the larger, adequately powered, Liverpool study.  Across the different 
sub-group analyses performed for the Liverpool pilot study a number of compounds achieved, or 
were close to, a significant false discovery rate correction.  These were styrene, D-limonene, phenol 
and 3-methyl-2-butanone.  Again some of this variation may be related to smaller numbers of 
patients in elements of the sub-group analysis.  These compounds featured in the biomarker 
modelling that assessed diagnostic utility.  Combining inclusion of VOCs with significant false 
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discovery rate (q=≤0.05) and performing logisitic regression together with 10 fold cross validation 
can limit overfitting, a common problem when identifying biomarkers[341].      
3.6 Conclusion 
 
Analysis of VOCs emitted from urine has the potential to discriminate those cirrhotic patients who 
have developed HCC.  Moreover, it can most accurately identify those who are treatment naive and 
who have early stage HCC.  This has the potential to improve long term survival as curative 
treatment is more likely if HCC is diagnosed at an earlier stage.  It appears that 4ml of urine and the 
use of a 10 ml headspace vial is superior to lower volumes and a 2ml headspace vial and that 
geographic differences may exist in the VOCs emitted from urine.   




















An investigation of volatile organic 
compounds found in the headspace gas 
of cultured Fusobacterium nucleatum 










The human intestinal microbiota contains a plethora of diverse microbial species, wherein certain 
bacteria, considered to be driver bacteria with carcinogenic features, contribute directly toward 
colonic epithelial cell damage and genetic mutations to initiate colorectal carcinogenesis: 
Campylobacter spp are such bacteria. However, some bacteria, in particular, Fusobacterium 
nucleatum, which is otherwise a normal resident of the oral microflora and a relatively poor 
colonizer of the healthy gut, have also been considered to play a role in the development of 
colorectal cancer.  The two species have been implicated in the driver-passenger model of colorectal 
cancer [342,343]. 
4.1.1 Aim 
 To characterise the VOCs emitted from a culture medium containing Fusobacterium 
nucleatum. 
 To characterise the VOCs emitted from a culture of Campylobacter showae 
 To assess the changes in VOCs emitted from co-cultures of Fusobacterium nucleatum and 
Campylobacter showae. 
4.1.2 Method 
Bacterial cultures were grown by a collaborator, Dr G Hold, in the School of Public Health, Harvard 
University, Boston, USA.  They consisted of F. nucleatum alone, C. showae alone, 30 min co-culture 
and a 24 hour co-culture.  The F. nucleatum and C. showae alone samples were cultured for 24 
hours.  A SPME fibre was then exposed to the headspace of the culture vials.  The fibres were then 
shipped to our laboratory in Liverpool, UK.  GCMS analysis was subsequently performed and AMDIS 
used for VOC identification and quantification.  Statistical analysis used the programme R and a 
dedicated in-house pipeline. 
 
4.2 Results 
35 fibres were exposed to the headspace gas and shipped from USA to Liverpool.  One fibre that was 
exposed to the C. showae culture failed to capture any volatiles and so was not included in the 





Table 18: Description of the headspace vial contents and the number of fibres exposed to the 
headspace gas. 
Headspace vial content Number of fibres exposed 
Media alone 4 
F. nucleatum and media 6 
C. showae (strain MSG) and media 9 
Overnight co-culture of F. nucleatum and C. 
showae (24 hours) 
8 
30 minute co-culture of F. nucleatum and C. 
showae 
8 
4.2.1 Normalisation against media 
4.2.2 F. nucleatum normalised against media 
Using the statistical package R, volatiles identified in the F. nucleatum cultures were normalised 
against media.  This enabled the VOCs to be classified as “produced” if there was a positive fold 
change and “utilised”, if the fold change was negative (Figure 23). 
Figure 23: Bar chart showing those compounds with the largest fold changes when F. nucleatum 




A negative value suggests utilisation of the compound by F. nucleatum, whilst a positive value is suggestive of 
production.  The number prior to the compound name is the retention time. Y axis represents relative ion 
abundance. 
There was significant production of methylthiolacetate, butanoic acid, dimethyl disulfide, dimethyl 
trisulfide and phenol by the F. nucleatum. Isobutane and toluene were associated with the largest 
negative fold changes.  
4.2.3 C. showae normalised against media  
The same analysis was then performed from data from C. showae and again produced the labels of 
“produced” and “utilised”.  When compared to F. nucleatum there is clearly more utilisation from 
the media than production, in the C. showae culture (Figure 24). 
Figure 24: Bar chart showing those compounds with the largest fold changes when C. showae is 
normalised against media. 
 
The number prior to the compound name is the retention time. Y axis represents relative ion abundance. 
When these two bar charts are combined it is clear that F. nucleatum is a net “producer” of volatile 
organic compounds whilst C. showae is a net “utiliser” (Figure 25), with the utilisation pattern of the 




Figure 25: Bar chart demonstrating the relative abundance of those volatile organic compounds 
with the largest fold changes when F. nucleatum and C. showae are normalised against the media. 
 
The number prior to the compound name is the retention time. Y axis represents relative ion abundance. 
 
This point is further emphasised when the chromatograms are compared by overlaying them (Figure 
26); there is a clear dominance, in terms of qualitative and quantitative production, in the F. 














4.3 Direct Volatile Organic Compound Analysis 
4.3.1 Direct Comparison of F. nucleatum and media alone  
No normalisation took place for this element of the analysis.  There was no significant difference in 
the number of VOCs identified between the F. nucleatum and media alone groups (p=0.5) (Figure 
27). 
Figure 27: Boxplot demonstrating the number of compounds identified in the F. nucleatum group 
and media alone group. 
 
Categorical analysis looking at prevalence of a VOCs showed 7 to be significant different (p= <0.05) 
(Table 19). 
Table 19: Volatile organic compounds identified to be significantly different following assessment 
of frequency. 










2-Pentanone 0 6 4 0 0.004 
Butanoic acid 6 0 0 4 0.004 
Methylcyclohexane 0 6 3 1 0.033 
Tetrachloroethylene 0 6 3 1 0.033 
4-methyl-2-pentanone 1 5 4 0 0.047 
2,4,6-trimethyldecane 1 5 4 0 0.047 
1-Propanol 5 1 0 4 0.047 
F. nucleatum culture n=6 and media culture n=4 
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Figure 28: Principal component analysis comparing F. nucleatum and media alone, based on 
prevalence. 
 
Coloured squares represent a centroid samples calculated from the mean of PC1 and PC2.
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4.3.2 Direct Comparison of C. showae and media alone 
There was no difference in the number of VOCs identified between the two groups (Figure 29). 
Figure 29: Boxplot demonstrating the number of compounds identified in the C. showae group and 
media alone group. 
 
Analysis of frequency and abundance did not show any significant differences.   
 
4.3.3 Comparison of F. nucleatum, C. showae and media 
Principal component analysis showed clustering of C. showae and, to a lesser extent, F. nucleatum 
with the media alone lying between the two (Figure 31).    There was no difference in the number of 
VOCs identified between the 3 groups (Figure 30).  Further assessment of prevalence was in line with 
prior analysis (Table 19).  Butanoic acid, phenol, methylthiolacetate and sulphides were predominant 




Figure 30: Boxplot demonstrating the number of VOCs identified in the 3 groups, C. showae, F. 
nucleatum and media. 
 
Figure 31: Principal component analysis comparing based upon relative abundance comparing F. 
nucleatum, C. showae and media. 
 




Table 20: Table demonstrating the presence and absence of VOCs in C. showae, F. nucleatum and 
media that achieved a p value of <0.05. 
















2-pentanone 8 0 0 6 4 0 <0.0001 
Butanoic acid 0 8 6 0 0 4 <0.0001 
 4-methyl-2-pentanone 8 0 1 5 4 0 0.001 
1-propanol 1 7 5 1 0 4 0.01 
2,6-bis(1,1-dimethylethyl)-4-(1-
methylpropyl)-phenol  
8 0 5 1 1 3 0.01 
Methyl-cyclohexane, 5 3 0 6 3 1 0.02 
Dimethyldisulfide,  0 8 4 2 2 2 0.02 
Methylthiolacetate 0 8 4 2 1 3 0.02 
3-Methylthiobutyraldehyde 0 8 4 2 1 3 0.02 
Phenol 0 8 4 2 1 3 0.02 
Dimethyl trisulfide 0 8 3 3 0 4 0.03 
 2,4,6-trimethyl-decane 5 3 1 5 4 0 0.04 
Tetrachloroethylene 4 4 0 6 3 1 0.04 
 
 
Fisher t test conducted using presence and absence in C. showae and F. nucleatum cultures.
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4.3.4 Direct comparison of C. showae and F. nucleatum 
 The separation of the F. nucleatum from C. showae was shown by PCA when F. nucleatum and C. 
showae were compared without including media (Figure 32). 
Figure 32: Principal component analysis comparing based upon relative abundance comparing F. 
nucleatum and C. showae. 
 





Figure 33: Overlay representative chromatograms derived from F. nucleatum and C. showae 
 
The same differences were identified: there were significant differences in butanoic acid, phenol, 
methylthiolacetate and sulphides. 
 
4.4 Analysis of co-cultures to assess the potential impact of C. showae on F. nucleatum 
DNA sequencing data, by others, has shown that, after 24 hours of co-culture, there is a significant 
over-representation of F. nucleatum, even with an initial 6:1 ratio of C. showae to F. nucleatum.  
There was no difference in the number of VOCs identified in the F. nucleatum, 30 minute and 24 
hour co-cultures(Hold et al 2015, unpublished). 
 
 
Principal component analysis suggested a difference when comparing 30 min co-culture and 24 hour 
co-culture (Figure 34a).  When the same analysis is applied to F. nucleatum culture and 24 hour co-
culture, this degree of separation is lost and the samples appear to homogenise (Figure 34b). 
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Figure 34a and b: (a) Principal component analysis comparing based upon relative abundance 
comparing 30 minute and 24 hour co-culture. (b) Principal component analysis comparing based 
upon relative abundance comparing F. nucleatum and 24 hour co-culture. 
(a) 
(b) 




Butanoic acid, 3-methylthiobutyraldehyde, disulfide dimethyl and methylthioacetate are all most 
abundant in the F. nucleatum alone samples, and are lowest in the 30 min co-culture and recovering 
in the 24 hour co-culture.  Phenol is most abundant in the 24 hour co-culture and least in the 30 min 
co-culture (Figure 36).  Comparison of abundance using ANOVA was performed across the 3 groups 
and identified 3 VOCs to be significantly different (Table 21).  This data is also presented as box plots 
in Figure 35a, b and c. 
Table 21: VOCs identified as significantly different by ANOVA performed on F. nucleatum alone, 30 
minute co-culture and 24 hour co-culture. 















Butanoic acid 19.04 16.75 18.22 <0.0001 
Phenol 20.64 19.23 21.19 0.0001 
3-Methylthiobutyraldehyde 20.22 19.02 21.02 0.008 
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Figure 35a, b and c: Box plots representing the relative ion abundance of the 3 VOCs identified as 
significantly different by ANOVA.  The features that provide the significance are provided as text 
to the right of each plot. 
 
Key- Overnight represents the 24 hour co-culture of F. nucleatum and C. showae, 30 min represents 




Figure 36: Bar charts for those VOCs found to have significantly different abundances when comparing 24 hour F. nucleatum alone, 30 minute co-culture 
and 24 hour co-culture. 
 
Y axis presents log transformed relative ion abundance, Fuso= Fusobacterium nucleatum culture, 30 min and 24 hour= duration of co-culture. 
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When comparing the abundance of F. nucleatum alone and the 30 minute co-culture, two additional 
VOCs were significantly different: disulfide dimethyl (p=0.013) and methylthioacetate (p=0.04) 
(Figure 37a and b). 
Figure 37a and b: Box plots for methylthiolacetate and dimethyldisulfide. 
 
Y axis is log transformed relative ion abundance. 
 
When comparing the F. nucleatum and 24 hour co-culture for prevalence and abundance, no 
significant differences were found. 
 
4.5 Discussion 
There is a clear difference in the metabolic activity of F. nucleatum and C. showae as shown by the 
VOCs identified during this study.  When the VOCs are normalised against the VOCs within the media 
there is clear evidence that F. nucleatum is a net producer of compounds whilst C. showae is a 
utiliser.  This is mirrored when there is comparison across the VOCs produced by F. nucleatum alone, 
the 30 minute co-culture and the 24 hour co-culture.  Throughout the different elements of the 
analysis the same VOCs were significant, namely, butanoic acid, phenol, methylthiolacetate, 
sulphides and 3-methylthiobutyraldehyde.  These are more prominent and/or abundant when the 
representation of F. nucleatum is greatest. 
It has been suggested that worldwide approximately 20% of cancers are related to infectious agents, 
for example human papilloma virus and cervical cancer, along with Helicobacter pylori and gastric 
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cancer [344].  Of the estimated 3.7 x 1030 microbes living on earth, only 10 are designated by the 
International Agency for Cancer Research (IACR) as carcinogenic to humans[345].  Despite this there 
are also a number of other bacteria with robust data supporting their role in human carcinogenesis, 
with a number being implicated in the pathogenesis of colorectal cancer. Bacteria constitute about 
90% of all the cells in the human body and it has been estimated that bacterial genes outnumber 
human genes by two orders of magnitude or more[346].  The bacterial density of the large bowel 
(~108 cells per ml) is much greater than that of the small bowel (~102 cells per ml), this is paralleled 
by an approximate 12-fold increase in cancer risk for the large bowel compared to the small bowel 
[343]. 
 
Figure 38: Adenoma-carcinoma sequence with associated genetic alterations leading to 
progression.  Image includes the points at which specific genetic mutations and alteration occur in 
the adenoma-carcinoma pathway. 
 
 
As previously described, the adenoma-carcinoma pathway is pivotal in the development and 
progression of colorectal cancer (Figure 38).  The key genetic abnormalities which occur during this 
process have been well-described, with some being used to predict outcome and response to 
treatment.  What is less-well understood is the role that the gut microbiota may play within the 
adenoma-carcinoma pathway.  Microbes can potentially have an oncogenic impact in a number of 
different ways, from DNA integration, affecting genomic instability and resistance to cell death, 
enhancing proliferative signalling and receptor engagement resulting in pathway signalling[347].   
Toxins produced by certain bacteria residing in the large bowel that act as defence strategies for the 
individual bacteria can cause DNA damage, either as a direct consequence of the toxin or indirectly 
through the formation of oxygen and nitrogen reactive species (ROS and NOS), examples of such 
toxins as Bacteroides fragilis toxin (Bft) produced by B. fragilis and cytolethal distending toxin (CDT) 
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produced by several Proteobacteria, including Campylobacter spp[348,349].  CDT is an example of a 
toxin that causes direct DNA damage.  Bft acts indirectly by eliciting high levels of ROS.  Chronically 
high levels of ROS can outpace a hosts DNA repair ability leading to DNA damage and 
mutations[347]. 
Along with the effects of toxins, several microbes can engage directly with host cell pathways, which 
in turn result in carcinogenesis.  Fusobacterium nucleatum is able to evoke such a response.  It 
expresses FadA, a bacterial cell surface adhesion component that binds to host E-cadherin, leading 
to -catenin activation and cell proliferation.  This further emphasises the point that a loss of 
appropriate boundaries and barrier maintenance between host and microbe is a critical step in the 
development of some tumours[347,350].  F. nucleatum has also been implicated in the chronic 
inflammation pathways, particularly through its activation of NF-Kappa B.  Once the gut barrier is 
breached, innate and adaptive immune responses are activated, resulting in an inflammatory 
response.  Numerous cytokines and chemokines are released, including IL-23, IL-6, IL-8 and TNF-
alpha.  Subsequent pathway activations contribute to tumour growth and progression.  Evidence 
suggests that there is preferential selection of bacterial which can thrive in an environment of 
inflammation and invasion[347,351]. 
Deep-sequencing technology has allowed  further exploration of the role that the gut microbiota 
plays in the development and progression of colorectal cancer and qualitative and quantitative 
analysis of microbes found on tumour and healthy tissue[299,352,353].  One of the most striking 
features of such work is the enrichment of Fusobacterium spp. in the on-tumour samples.  
Histological analysis shows that the bacteria can invade the cancer cells and actually be transported 
with the cell during metastatic spread.  It is clear that such bacteria play a key role but the question 
of when and how has led to the development of the bacterial driver-passenger model of colorectal 





Figure 39: A bacterial driver-passenger model of colorectal cancer 
 
 
First, certain indigenous intestinal bacteria drive the epithelial DNA damage that contributes to the 
initiation of colorectal cancer (termed bacterial drivers). Second, tumour development induces 
intestinal niche alterations that favour the proliferation of opportunistic bacteria (termed bacterial 
passengers). It should be noted that this driver–passenger model implies that, in contrast to driver 
mutations in the genomes of cancerous cells, bacterial drivers may disappear from cancerous tissue 
as they are outcompeted by passenger bacteria with a growth advantage in the tumour 
microenvironment[343].  Therefore sequencing analysis of on-tumour bacteria appears to be 
dominated by the passenger bacteria. 
4.5.1 Bacterial Drivers 
A number of bacteria have been suggested as candidate bacterial drivers of colorectal cancer.  Many 
of these bacteria have the production of DNA-damaging compounds in common.  Organisms with 
such features include Enterococcus faecalis, which produces extracellular superoxide; this is 
converted to hydrogen peroxide, leading to DNA damage in colonocytes [354,355].  Certain strains of 
Escherichia coli harbour the polyketide synthetase island which encodes a genotoxin called 
colibactin.  This toxin can induce single-strand DNA breaks, subsequent activation of DNA damage 
induced pathways increases the mutation rate in infected cells[356].  Others include B. fragilis and 
its production of Bacteroides fragilis toxin (Bft) and Campylobacter showae related synthesis of 
cytolethal distending toxin.   
The direct action of such bacteria and their toxins is augmented by the induction of chronic 
inflammation, predominately driven by IL-17 from T-helper cells in the lamina propria.  Subsequent 
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activation of STAT3 and IL-6 appears to have a central role in the development and progression of 
colorectal cancer, via their pro-proliferative, anti-apoptotic and pro-angiogenic properties[343,357].  
Increased levels of such pro-inflammatory mediators, including IL-6 and IL-8 have been reported in 
studies examining the role of Campylobacter spp in the carcinogenesis of colorectal cancer[358].  
Such species of bacteria are thought to be relatively rare in healthy human colonic tissue, but have 
been shown to be over-expressed in non-cancerous mucosa of those with colorectal cancer.  
Campylobacter spp have also been reported to be over-represented in patients with inflammatory 
bowel disease[349].  Therefore, persistent low-grade colonization with such organisms could 
increase an individual’s susceptibility to colorectal cancer by inducing an asymptomatic but chronic 
inflammatory response in the colonic mucosa. 
4.5.2 Candidate bacterial passengers 
Bacterial passengers of colorectal cancer are defined as gut bacteria that are relatively poor 
colonizers of a healthy intestinal tract but have a competitive advantage in the tumour 
microenvironment, allowing them to outcompete bacterial drivers of CRC[343].  A series of studies 
have highlighted Fusobacterium nucleatum as the most common passenger bacterium, being 
significantly over-represented on cancer tissue[299,300,353].  This over-representation does not 
however prove causality.  Rubinstein et al demonstrated the importance of the adhesion molecule 
FadA for the stimulation of colorectal cancer.  FadA binds vascular endothelial-cadherin on 
endothelial cells, causing increased endothelial cell permeability thus allowing bacteria to penetrate, 
a likely mechanism used by F. nucleatum for systemic dissemination.  This demonstrates that F. 
nucleatum binds to, and invades, both normal and cancerous epithelial cells via FadA binding to 
epithelial (E)-cadherin. This binding leads to growth stimulation of human colorectal cancer cells but 
not the non-cancerous cells. FadA binding to E-cadherin on colorectal cancer cells activates -
catenin-regulated transcription, resulting in increased expression of proto-oncogenes cyclin D1 and 
c-Myc, Wnt and inflammatory genes NF-kappa B, IL-6, IL-8, and IL-18[350,359].  Kostic et al showed 
that F. nucleatum was able to induce tumour cell proliferation and selectively recruit tumour-
infiltrating myeloid cells to promote tumourigenesis in APC+/- mice.  Supporting its role further 
along the adenoma-carcinoma pathway, rather than initiating the process like the driver 
bacteria[352].  F. nucleatum does not induce colitis or enteritis, therefore it is not able to play a role 
in inflammation-associated intestinal carcinogenesis, which supports its position as a passenger 
bacteria in the model. 
The ongoing development and progression of colorectal cancer is therefore beneficial to F. 
nucleatum as it out-competes other colonic microbes in such a setting.  It is an efficient producer of 
butyrate via the fermentation of fibre.  Much evidence exists to support the beneficial impact of 
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SCFAs in the colon, acting as an energy source for colonocytes and having an anti-inflammatory 
effect.  However, in the context of this driver-passenger model butyrate may convey a negative 
impact.  Belcheva et al, using a murine model with Msh and APC mutations, demonstrated enhanced 
tumourigenesis in the presence of butyrate.  This may be one way in which F. nucleatum maintains 
its preferential environment[360].  During our study, we found a significant production of butanoic 
acid in those samples containing pure F. nucleatum and 24 hour co-culture.  The presence of 
butyrate during chronic inflammation has been shown to induce apoptosis and, therefore, to reduce 
tumour development, suggesting that F. nucleatum has no in the initiation of the adenoma-
carcinoma pathways.  However, it may promote its continuation once the pathway is initiated and in 
doing preferentially selects its own existence.Other compounds that were found to be significantly 
more abundant in the F. nucleatum dominated samples were phenol and two sulphides.  Phenol has 
been demonstrated to promote carcinogenesis in the colon and has been shown to be most 
abundant in the distal colon where tumour development in most common[287].  Sulphides have 
been shown to be endogenously produced by colorectal cancer cell via cystathionine b-synthase 
(CBS).  Hydrogen sulphides follow a biphasic dose-response: The effects of some sulphides range 
from physiological, cytoprotective effects, which occur at low concentrations, to cytotoxic effects, 
which are typically apparent only at higher concentrations[361].  Sulphides have been demonstrated 
to promote angiogenesis, the proliferation of endothelial cells, fibroblasts, hepatocytes, and various 
cancer cells[362].  Thus their presence would support the tumour microenvironment and thus the 
over-population of F. nucleatum.  Inhibition of sulphide production by colorectal cancer cells has 
been shown to reduce angiogenesis and overall tumour growth, potentially leading to new 
therapeutic targets[361]. 
 
It is unclear from this study why the representation of F. nucleatum and C. showae changes over the 
time of their co-culture.  Given the net utilising properties of C. showae it may be that it simply uses 
up energy stores etc and therefore cannot survive. The human gut would, potentially, act as a 
constant stream of nutrition and energy for colonising bacteria, an environment that is not mimicked 
by such culturing.  Furthermore, if the mix of metabolites produced by the F. nucleatum is toxic it 
may lead to the death of C. showae.  This hypothesis may explain how F. nucleatum is able to 






Co-culture of F. nucleatum and C. showae alters the production of VOCs when compared to isolated 
culture of the bacteria.  When the co-culture is for 24 hours there is a large shift towards 
representation by F. nucleatum, this is mirrored by the identification of VOCs.  F. nucleatum has 
been suggested as a passenger bacterium, as part of the driver-passenger model of colorectal 
carcinogenesis.  Many of the VOCs identified during this study have been shown to preferentially 
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Colorectal cancer is a major cause of mortality and morbidity in Europe and North America, with an 
estimated European incidence of 43.5 per 100,000 and a mortality of 19.5 per 100,000 in 2012[1].  
The incidence of CRC has increased by 6% in the last decade and it is now the third most common 
malignancy in the UK. It leads to approximately 15,000 deaths per annum in the UK, with a 50-55% 5 
year mortality rate[2].  Colorectal cancer is the subject of national screening programmes in many 
countries; these aim to detect cancer in its early stages, including pre-malignant adenomatous 
polyps.  There is clear evidence that such programmes reduce the risk of death from colorectal 
cancer through detection of tumours at an earlier,  a more treatable stage and through removal of 
these precancerous adenomas[363]. 
 
5.1.1 Aim 
The aim of this study was to determine if the headspace volatile organic compounds (VOCs) 
detected in faecal samples from patients with neoplasia and no neoplasia in the colon are different 
from each other and whether faecal VOC profilemay be used as a biomarker for the diagnosis and/or 




SPME headspace extraction, followed by GCMS, was used to assess VOCs emitted from 450mg 
aliquots of faeces of symptomatic and Bowel Cancer Screening Programme (BCSP) patients 
undergoing colonoscopy.  Patients were assigned to one of three groups following colonoscopy: 
adenoma, cancer or non-neoplastic.  A full description of the methods can be found in Chapter 2. 
5.2 Results 
5.2.1 Patient demographics 
 
There were a total of 133 patients who were recruited to the study.  The average age was 64.3 years, 
56% of patients were male.  The mean age increased in patients with no neoplasia, adenoma and 
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cancer respectively, p=0.02.  None of the participants reported being a smoker or a vegetarian.  Self-
reported ethnicity was used, all but one patient was said to be white British.  Participation in the 
BCSP provided the largest proportion of referrals for colonoscopy (31.5%).   Full demographics and 
clinical characteristics can be seen in Table 20: 11 patients were from Sheffield, all of whom had a 
confirmed diagnosis of colorectal cancer but no other clinical information was available for these 
patients.   




Number 137 60 56 21 









Male 69 25 36 7 
Female 57 34 20 3 
Smoker (Yes) 0 0 0 0 
Indication for colonoscopy  
BCSP 38 13 22 3 
IDA 27 16 6 5 
Change in bowel habit-diarrhoea 16 11 4 1 
Surveillance previous neoplasia/FH 35 10 24 1 
IBD assessment/surveillance 9 9 0 0 
GI bleeding 1 1 0 0 
Unknown 11 0 0 11 
 
Table includes diagnosis and indications for original colonoscopy, of patients recruited in Liverpool, Plymouth 
and Sheffield. N.B. 11 of the cancer samples had no demographic information available.  
A third cohort of patients was supplied from Plymouth: all those were undergoing colonoscopy as 
part of their investigations for iron deficiency anaemia.  Samples were produced, handled and stored 
in line with the methodology employed in Liverpool.  This cohort consisted of 12 adenomatous polyp 
patients and 4 with adenocarcinoma.  These samples were not used to build the compound library 
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and were used as part of the validation process.  The mean age of these samples was 73 years.  Only 
when specified in this chapter were these samples utilised in the analysis. 
 
5.2.2 VOC characterisation 
A total of 162 VOCs were identified across all samples.  The mean number of VOCs identified in the 
entire cohort was 56.7, with no significant difference in those with or without neoplasia, p=0.2, 
(Table 23, Figure 40). 
Table 23: Mean number of VOCs identified in patients with and without colonic neoplasia. 
 No- neoplasia Neoplasia 
Number of patients 60 73 
Mean number of VOCs (SD) 58.1 (15.6) 55.2 (12.1) 
Coefficient of variation (CV) 0.2 0.2 
 
 
Figure 40: Box and whisker plot representing the number of VOCs identified in those with and 














































5.3 Univariate analysis in order to identify potential biomarker candidate/s 
Three technical processes were employed in order to identify and compare VOCs in order to identify 
compounds that could be taken forward for biomarker assessment.  A combination of 
Metab/R[320], Metaboanalyst[324] and XCMS were used to assess fold change, prevalence and 
relative abundance of VOCs emitted from the samples.  When Metaboanalyst was used the data was 
log transformed and normalised by median.  These methods allow for the application of ANOVA, 
Student’s t test and Fisher’s exact test.  A number of different comparisons were subsequently 
performed, these were: 
 No neoplasia (control) versus neoplasia 
 No neoplasia versus neoplasia in the form of adenomatous polyps 
 No neoplasia versus neoplasia in the form of colonic adenocarcinoma 
 No neoplasia versus a single adenomatous polyps > 1cm is size 
 No neoplasia versus patients with > 4 individual adenomatous polyps of any size 
 No neoplasia versus neoplasia in the form of adenomatous polyps  
 
The use of multiple independent analytical systems ensured robust identification of the potential 
VOC biomarkers.  Q values were generated to account for false discovery.  Results from ANOVA of 












Table 24: VOCs potentially associated with no neoplasia, adenoma or cancer.   
VOC (inc RT) p value q value  
27.19_Pentane, 2,3,4-trimethyl- 0.001 0.09 
32.25_menthol 0.001 0.09 
19.60_Butanoic acid, 3-methyl-, ethyl ester 0.001 0.09 
20.53_p-Xylene 0.005 0.18 
28.53_Benzeneacetaldehyde 0.006 0.18 
25.66_Propanoic acid, 2-methyl-, 2-methylbutyl ester 0.006 0.18 
14.07_Propanoic acid, anhydride 0.01 0.38 
18.18_Acetic acid, butyl ester 0.02 0.51 
27.52_Butanoic acid, 4-pentenyl ester 0.03 0.51 
7.59_Isopropyl alcohol 0.03 0.51 
22.11_Bicyclo[3.1.0]hex-2-ene, 4-methyl-1-(1-methylethyl)- 0.03 0.51 
24.45_2,6-Octadiene, 2,6-dimethyl- 0.03 0.51 
13.28_1-Butanol 0.04 0.51 
22.06_alpha-Phellandrene 0.04 0.51 
 
ANOVA was used to compare no neoplasia, adenoma and cancer.  q values representative of false discovery 
rate.  Analysis was performed using Metaboanalyst.  RT= Retention time. 
 
A number of the compounds found in Table 3 were seen to be significantly different (p=<0.05) across 
the other comparisons and modes of analysis.  In particular, these were benzeneacetaldehyde, 2,3,4-
trimethyl-pentane, menthol, isopropyl alcohol, butanoic acid based compounds, esters of acetic acid 
and sulphides. However, none remained significant after correction for multiple comparisons. 
 
Those VOCs identified to be significant different when comparing no neoplasia to adenoma and 





Table 25: VOCs potentially associated with no neoplasia or adenoma.   
 
VOC (RT) p value q value 
16.69_Methyl isovalerate 0.01 0.73 
27.52_Butanoic acid, 4-pentenyl ester 0.02 0.73 
30.30_Pentanoic acid, 3-methylbutyl ester 0.02 0.73 
27.19_Pentane, 2,3,4-trimethyl- 0.03 0.73 
28.53_Benzeneacetaldehyde 0.03 0.73 
30.78_p-Cresol 0.03 0.73 
22.06_alpha-Phellandrene 0.03 0.73 
 
Table generated from Student’s t test comparing no neoplasia and adenoma.  q value representative of false 
discovery rate.  Analysis performed using Metaboanalyst.  RT= Retention time 
Table 26: VOCs with p value <0.05 when comparing no neoplasia and cancer.  False discovery rate 
applied to correct for multiple comparisons, represented as q value. 
 
VOC (RT) p value q value 
7.59_Isopropyl alcohol <0.0001 0.004 
17.98_2-Hexanone 0.01 0.77 
19.60_Butanoic acid, 3-methyl-, ethyl ester 0.03 0.77 
19.07_Butanoic acid, 1-methylethyl ester 0.03 0.77 
22.77_Pentanoic acid, 1-methylethyl ester 0.03 0.77 
20.53_p-Xylene 0.03 0.77 
15.67_Propanoic acid, 1-methylethyl ester 0.04 0.77 
32.25_menthol 0.05 0.77 
 
Table generated from Student’s t test comparing no neoplasia and cancer.  q value representative of false 
discovery rate.  Analysis performed using Metaboanalyst.  RT= Retention time. 
After correction for false discovery rate isopropyl alcohol shows the most promise for the detection 
of neoplasia, particularly adenocarcinoma. 
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Figure 41: Box and whisker plot for isopropyl alcohol concentration found in faecal samples 
derived from patient with adenocarcinoma of the colon and no colonic neoplasia. 
 
Normal represents those without colonic neoplasia.  The adenocarcinoma cohort includes those cancer 
samples from Plymouth.  
5.4 Analysis of potential biomarkers for colorectal cancer identified from univariate analysis  
 
Initially, PLS-DA was employed to assess the ability to distinguish between the presence and absence 
of colonic neoplasia.  This failed to show a significant degree of separation (Figure 42).  ROC analysis 
did not achieve an AUROC curve great enough to be considered adequate for a diagnostic tool.  
Benzeneacetaldehyde achieved the greatest AUROC, 0.67.  Analysis was then focused upon higher 
risk neoplastic disease, namely adenocarcinoma, a single adenomatous polyp > 1cm in size and 

































Figure 42: Partial least squared discriminant analysis for all identified VOCs found in those with 
and without colonic neoplasia. 
 
Normal refers to those without neoplasia.  Analysis based upon all VOCs found. 
 
5.4.1 VOCs as a biomarker for colonic adenocarcinoma 
 
Isopropyl alcohol was further investigated because of the q value found earlier.  PLS-DA comparing 
those without neoplasia and adenocarcinoma (cancer) showed a degree of separation that 
suggested some diagnostic utility (Figure 43).  ROC analysis illustrated the potential to diagnosis 
adenocarcinoma of the colon using isopropyl alcohol, with an AUROC of 0.76 (Table 27).  When 
considering isopropyl alcohol in isolation, assessment of sensitivity and specificity can be made 
according to differing cut-offs.  The optimal cut-off gave a sensitivity of 83% and specificity of 71% 




Figure 43: PLS-DA comparing those with adenocarcinoma of the colon and no colonic neoplasia. 
 










Table 27: AUROC results for the VOCs emitted when comparing those with adenocarcinoma of the 
colon and no colonic neoplasia. 
VOC (RT) AUROC p value 
7.59_Isopropyl alcohol 0.76 <0.0001 
17.98_2-Hexanone 0.66 0.01 
20.53_p-Xylene 0.66 0.03 
22.77_Pentanoic acid, 1-methylethyl ester 0.65 0.03 
19.07_Butanoic acid, 1-methylethyl ester 0.65 0.03 
29.04_2-Nonanone 0.64 0.05 
19.60_Butanoic acid, 3-methyl-, ethyl ester 0.63 0.02 
32.25_menthol 0.62 0.04 
 




Figure 44: ROC curve for isopropyl alcohol when comparing those with adenocarcinoma of the 
colon and no colonic neoplasia. 
 
The red circle represents optimal cut-off generating sensitivity of 83% and specificity of 71%.  
Calculating ratios of all possible metabolite pairs and then choosing top ranked ratios, based on p 
values, allowed for further biomarker assessment.  Only those achieving an AUROC greater than 










Table 28: AUROC results for the VOCs emitted when using a comparison of ratios for those with 
adenocarcinoma of the colon and no colonic neoplasia. 






0.82 0.71-0.92 81 76 
32.25_menthol/7.59_Isopropyl alcohol 0.82 0.7-0.91 85 71 
29.04_2-Nonanone/7.59_Isopropyl alcohol 0.81 0.7-0.91 88 57 
18.20_Propanoic acid, 2-methyl-
/7.59_Isopropyl alcohol 
0.81 0.7-0.91 80 76 
24.13_Decane/7.59_Isopropyl alcohol 0.81 0.68-0.9 81 71 
22.01_Acetic acid, pentyl 
ester/7.59_Isopropyl alcohol 
0.8 0.69-0.89 83 71 
28.53_Benzeneacetaldehyde/7.59_Isopropy
l alcohol 
0.79 0.65-0.91 86 76 
 
 
5.4.2 VOCs as a biomarker for colonic adenocarcinoma- Qualitative analysis 
 
Logistic regression analysis for compound presence, identified 3 VOCs as potential biomarkers.  
These were isopropyl alcohol, 2-hexanone and butanoic acid, 3-methyl-,ethyl ester.  Using all 3 VOCs 
as a biomarker panel achieves an AUROC of 0.86 (Figure 45).  Using this model, there is a 6-fold 
increased chance of colorectal cancer if all 3 VOCs are present in a patient’s stool sample. 
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Figure 45: ROC curve using the qualitative biomarker panel of isopropyl alcohol, 2-hexanone and 
butanoic acid, 3-methyl-,ethyl ester for the diagnosis of colorectal cancer. 
 
 
5.4.2.1 Validation of quantitative biomarker model for colorectal cancer 
 
A hold-out technique was applied to the 81 samples (21 cancer and 60 controls) in order to validate 
the combination of butanoic acid, 3-methyl-/isopropyl alcohol as a biomarker for colorectal cancer.  
Fifty percent of each cohort were held back, the remaining samples were then subjected to testing 
with the butanoic acid, 3-methyl-/isopropyl alcohol combination via logistic regression and a 10-fold 
cross validation method (Figure 50).  When the model is then applied to those samples held out, the 
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Figure 46: ROC curve using logistic regression and 10-fold cross-validation, based on the 




5.4.3 VOCs as a biomarker for adenomatous polyps > 1cm in size - quantitative analysis 
 
PLS-DA showed separation between those without neoplasia and those with an adenomatous polyp 
> 1cm in size (Figure 47).  Subsequent univariate ROC analysis demonstrated an AUROC of 0.7 for 
2,3,4-trimethylpentane, with a potential sensitivity of 78% and specificity of 68% (Table 29, Figure 
48).  These compounds were then taken forward for further biomaker assessment using the 




Figure 47: PLS-DA comparing those with no colonic neoplasia and a single adenomatous polyp > 
1cm in size 
 











Table 29: AUROC result for the VOCs emitted when comparing no colonic neoplasia and a single 
adenomatous polyp > 1cm in size. 
VOC (RT) AUROC p value 
27.19_Pentane, 2,3,4-trimethyl- 0.70 <0.0001 
27.52_Butanoic acid, 4-pentenyl ester 0.67 <0.0001 
28.53_Benzeneacetaldehyde 0.70 0.02 
27.06_Butanoic acid, 3-methylbutyl ester 0.67 0.02 
32.25_menthol 0.66 0.01 
35.31_2-Undecanone 0.66 0.01 
26.96_Pentanoic acid, 2-methylpropyl ester 0.66 0.01 
29.39_Nonanal 0.65 0.03 
28.33_Pentanoic acid, butyl ester 0.65 0.01 
 
Those with an AUROC of >0.6 have been included in the table. 
 
Figure 48: ROC curve for Pentane, 2,3,4-trimethyl- following univariate analysis, when comparing 
those with no colonic neoplasia and a single adenomatous polyp > 1cm in size. 
 
The red circles represent the optimal cut off point giving sensitivity of 78% and specificity of 68%.   
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Following the comparison of abundance ratios, the greatest AUROC achieved was 0.78, this was the 
combination of benzeneacetaldehyde and 2-undecanone, demonstrating a sensitivity of 76% and 
specificity of 72% (Table 30).  When combined with a number of other VOCs 2,3,4-trimethylpentane 
was noted to have an improved AUROC. 
 
Table 30: AUROC result for the VOCs emitted when using a comparison of ratios for those with no 
colonic neoplasia and those with a single adenomatous polyp >1cm in size. 






0.78 0.68-0.87 76 72 
27.19_Pentane, 2,3,4-trimethyl-
/32.25_menthol 
0.77 0.67-0.86 80 64 
19.60_Butanoic acid, 3-methyl-, ethyl 
ester/ 27.06_Butanoic acid, 3-
methylbutyl ester 
0.76 0.65-0.85 81 56 
29.39_Nonanal/35.31_2-Undecanone 0.76 0.65-0.84 76 52 
32.25_menthol/35.31_2-Undecanone 0.75 0.63-0.84 68 72 
19.60_Butanoic acid, 3-methyl-, ethyl 
ester/ 27.19_Pentane, 2,3,4-trimethyl- 
0.74 0.63-0.84 68 60 
 
 
5.4.4 VOCs as a biomarker for > 4 individual adenomatous colonic polyps- quantitative analysis 
 
Univariate analysis was again performed, including correction for false discovery rate, in order to 
identify potential candidate biomarkers (p=<0.05).  Five of the nine VOCs identified as potential 
candidates in the analysis of polyps >1cm were again identified in this sub-analysis.  These were 
pentane, 2,3,4-trimethyl-, benzeneacetaldehyde, butanoic acid, 4-pentenyl ester, butanoic acid, 3-
methylbutyl ester and menthol.  After false discovery rate correction had been applied none of these 
VOCs achieved a q value of <0.05, despite this there did appear to be a good degree of separation on 
the PLS-DA (Figure 53).  Hexanoic acid, ethyl ester demonstrated the most potential, as it had the 
lowest p and q values (0.001 and 0.09, respectively) (Table 31). 
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Table 31: VOCs with p value <0.05 when comparing no neoplasia and those with > 4 individual 
polyps of any size.   
 
VOC (RT) p value FDR 
25.03_Hexanoic acid, ethyl ester 0.001 0.09 
27.19_Pentane, 2,3,4-trimethyl- 0.004 0.26 
31.50_Hexanoic acid, butyl ester 0.01 0.26 
28.53_Benzeneacetaldehyde 0.01 0.26 
28.72_Propanoic acid, hexyl ester 0.01 0.26 
27.52_Butanoic acid, 4-pentenyl ester 0.01 0.26 
25.61_Acetic acid, hexyl ester 0.01 0.26 
25.49_Benzaldehyde 0.02 0.26 
33.32_Isopentyl hexanoate 0.02 0.26 
18.57_Methyl valerate 0.02 0.26 
27.06_Butanoic acid, 3-methylbutyl ester 0.02 0.26 
23.39_Methional 0.03 0.34 
26.33_Hexanoic acid 0.03 0.34 
30.32_Ethanone, 1-(2-methyl-1-cyclopenten-1-yl)- 0.03 0.34 
30.30_Pentanoic acid, 3-methylbutyl ester 0.04 0.35 
32.25_menthol 0.04 0.35 
12.47_Butanal, 3-methyl- 0.04 0.36 
17.98_2-Hexanone 0.04 0.36 
 
Table generated from Students t test, q value generated for false discovery rate.  Analysis performed using 




Figure 49: PLS-DA using all the identified VOCs, comparing those with no neoplasia against those 
with > 4 individual polyps of any size. 
 
 
Using univariate ROC analysis, 6 VOCs achieved an AUROC of >0.7, with two being >0.75.  These 
were hexanoic acid ethyl ester (0.81), butanal, 3-methyl- (0.75), pentane, 2,3,4-trimethyl- (0.74), 
methyl valerate (0.73), hexanoic acid (0.72), benzeneacetaldehyde (0.71).  Hexanoic acid ethyl ester 
had the greatest AUROC, achieving a sensitivity of 85% and specificity of 70% (Figure 50). 
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Figure 50: ROC curve for hexanoic acid ethyl ester 
 
Box and whisker plot demonstrating the greater abundance of hexanoic acid ethyl ester in those with > 4 
individual adenomatous polyps. 
 
Paying particular attention to hexanoic acid ethyl ester, again further assessment of biomarker 
potential was conducted with ratio comparisons.  Only those achieving an AUROC of greater than, or 









Table 32: AUROC result for the VOCs emitted when using a comparison of ratios for those with no 
colonic neoplasia and those with > 4 individual polyps of any size. 






19.60_Butanoic acid, 3-methyl-, ethyl ester/ 




25.03_Hexanoic acid, ethyl ester/ 














25.03_Hexanoic acid, ethyl ester/32.25_menthol 0.84 0.73-
0.93 
78 70 
12.47_Butanal, 3-methyl-/17.98_2-Hexanone 0.84 0.71-
0.94 
78 80 


















Correctly identifying patients to undergo colonoscopy, as part of population based screening, is vital 
in order to maximise pathology capture and to minimise unnecessary examinations.  There is a clear 
link to improved outcomes from colorectal cancer by the identification of earlier stage colorectal 
cancer and pre-malignant adenomatous colonic polyps[364].  This study has demonstrated the utility 
of VOCs emitted from faeces to act as a biomarker for colonic neoplasia, in particular, 
adenocarcinoma and adenomatous polyps of increasing size and number.      
Using a variety of methods and substrates, other studies have suggested a utility of VOC analysis for 
the diagnosis of colorectal cancer.  One such study, from 2015, used selected ion flow tube mass 
spectrometry (SIFT-MS) to analysis VOCs emitted from faeces of FOBt positive patients,.  Comparing 
patients with no neoplasia and high grade neoplasia, ions probably arising from hydrogen sulphide, 
dimethyl sulphide and dimethyl disulphide were significantly higher in samples from high risk 
compared to low risk subjects.  The authors reported overall  specificity of 78% and 72% 
sensitivity[365].  Two separate studies, from 2014 and 2013, reported the analysis of VOCs found in 
urine and breath, respectively.  The study examining urine used Field Asymmetric Ion Mobility 
Spectrometer (FAIMS):  133 patients were included; 83 colorectal cancer patients and 50 healthy 
controls.  Sensitivity and specificity for CRC detection with FAIMS were 88% and 60% 
respectively[312].  A third technology, in the form of thermal-desorber gas chromatography–mass 
spectrometry, was used to assess VOCs in the study examining breath.  Assessing the pattern of 15 
compounds showed a sensitivity of 86%, a specificity of 83% and AUROC of 0·85[311].  More 
recently, using the same technique, this group described the ability of exhaled VOCs to discriminate 
between colorectal cancer patients before and after curative surgery[366].  Another study from 
2014 reported the utility of a pattern recognition–based detection technique, using VOCs found in 
faeces.  This study did not attempt to identify the individual compounds but focused upon differing 
patterns.  It attempted to identify established colorectal cancer and pre-malignant adenomatous 
lesions.  Faecal VOC profiles of patients with colorectal cancer differed significantly from controls 
(AUROC, 0.92; sensitivity, 0.85; and specificity, 0.87).  Patients with advanced adenomas could also 
be distinguished from controls (AUROC, 0.79; sensitivity, 0.62; and specificity, 0.86).   
Unlike in our work, few studies have attempted to identify the individual compounds responsible for 
generating the differentiation.  Most rely on sensor technology that recognises patterns rather than 
individual compounds.  Identification of the VOCs influencing diagnostic separation allows for 
biological plausibility to be explored, improving stringency.  We also examined the potential of VOCs 
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for the identification of pre-malignant adenomatous polyps, making our study unique.  All of the 
studies described here are feasibility studies and do not include validation sets, potentially limiting 
their clinical application.  We performed validation of our set with cross-validation methodology.  In 
doing so, we can report diagnostic accuracy for colorectal cancer that is very similar to other studies, 
but has been through a validation process, AUROC 0.82, sensitivity 87.9% (95% CI 0.87-0.99) and 
specificity 84.6% (95% CI 0.65-1.0).  Moreover, a validated and superior diagnostic utility for pre-
malignant adenomatous colonic polyps can be seen in our results.  
Population-based screening or a point of care test are the most likely clinical application of such VOC 
analysis.  Despite their relatively low patient acceptance rates, faecal based techniques are currently 
the most commonly employed i.e. FOBt, either gFOBt or FIT.  The gFOBt currently used in the UK 
BCSP has a sensitivity of 36% and a specificity of 94% for the detection of colorectal cancer[94,95].  
To date, there are no controlled trials that demonstrate that FIT are superior to gFOBt or to no 
screening in terms of reducing colorectal cancer-related mortality in average risk persons. However, 
a recent observational study from Italy demonstrated a reduction in colorectal cancer-related 
mortality in regions where screening with FIT was adopted compared with regions where screening 
had not yet been implemented[367,368]  The superiority of FIT over gFOBt is now widely recognised 
and the European Quality Assurance Guideline on Colorectal Cancer Screening published in 2011 
recommends FIT in preference to gFOBt[369,370]. Various countries have adopted FIT into their 
colorectal cancer screening programmes and the BCSP plans to replace gFOBt with FIT[371].  
Comparing the result of our study it would appear that VOCs have a greater diagnostic ability than 
FOBt for the identification of colorectal cancer and pre-malignant adenomatous polyps.  It also 
appears to have a superior performance when compared to faecal tM2-PK[194], discussed in 
Chapter 7.       
Many of the previous attempts to explore VOCs as a biomarker for colorectal neoplasia have used a 
pattern recognition system rather than the identification of individual VOCs.  Throughout the 
different elements of our analysis, including factor analysis, key VOCs became evident.  In particular 
these were isopropyl alcohol and butanoic acid based compounds. 
The International Agency for Research on Cancer (IARC), part of the World Health Organization 
(WHO), have classified isopropyl alcohol as a Group 1 carcinogen, meaning there is clear evidence 
that is carcinogenic to humans[372].  It is clear that isopropyl alcohol is more prevalent and 
abundant in the faeces of patients with colorectal cancer.  Endogenous isopropyl alcohol may arise 
from the metabolism of non-absorbable carbohydrates (Figure 51 and 52).  Fermentation of non-
absorbable carbohydrates, by colonic bacteria, is a key source of SCFA such as butyrate, acetate and 
 141 
 
propanoate.  Along with the metabolism of pyruvate these metabolic pathways are a source of 
acetate and subsequently acetone.   Acetone is converted to isopropyl alcohol by alcohol 
dehydrogenase, making it a by-product of SCFA metabolism.  Many studies have shown the 
protective effect of SCFA against colorectal cancer, with more recent studies demonstrating the 
potential negative impact of butyrate as the adenoma-carcinoma pathway progresses.  One such 
study, using a murine model with Msh and APC mutations, demonstrated enhanced tumourigenesis 
in the presence of butyrate[360].  If the tumour microenviroment preferentially selects butyrate 
producing organisms in order to promote its ongoing existence, as is suggested by the driver-
passenger model[343], then there will be an increase in butyrate based compounds together with 
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Figure 51: Schematic representation of the products of fermentation of non-absorbable 









Chapter 4 describes the VOCs identified in the headspace gas of the culture medium of 
Fusobacterium nucleatum and Campylobacter showae.  Both of these bacteria have been implicated 
in the development of colorectal cancer, via the driver-passenger model[343].  In this study F. 
nucleatum was identified as a net producer of VOCs, and was specifically found to be a net producer 
of isopropyl alcohol and butanoic acid.  F. nucleatum has been demonstrated to be over-represented 
in colorectal cancer[253,299,300,352,353].  Invasive strains of Fusobacterium nucleatum accelerate 
the onset of colonic tumours and drive the transition to a pro-inflammatory microenvironment that 








Figure 52: Pathway for the production of isopropyl alcohol from pyruvate in the human 
colon.  Adapted from associated KEGG pathway. 
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previously described isopropyl alcohol is a recognised carcinogen.  Butanoic acid has been shown to 
promote ongoing tumour growth once it has developed[360] thereby potentially explaining why 
there is an increase in isopropyl alcohol and butanoic acid based compounds in those with colorectal 
cancer. Enterobacteriaceae have been implicated in the development of colorectal cancer via the 
production of DNA damaging genotoxins and may thereby actively contribute to the accumulation of 
mutations that characterize the adenoma-carcinoma sequence[253,373].  Serratia spp belong to this 
family and have been demonstrated to produce isopropyl alcohol[374,375], thus providing another 
potential source of the VOCs seen within our samples. 
It appears from our data that the “signal” from the neoplastic disease becomes stronger as the 
disease burden increases, either in terms of the size, the number of adenomatous polyps or, as the 
adenomatous polyp/s become established, carcinoma.  This seems most likely to be a product of 
increasing surface area and overall tissue bulk,but both of these factors will alter the ratio between 
normal (non-neoplastic) colonic mucosa and abnormal (neoplastic) mucosa, making the VOCs signal 
more detectable.  The associated dysbiosis would potentially become more pronounced as the 
disease burden increases.  A number of studies have examined the composition of the microbiota in 
patients with colorectal cancer[253,299,300,343,376].  Along with F. nucleatum other bacterial 
species have been noted to differ significantly in both advanced adenomatous disease and colorectal 
cancer[353].  Wu et al described the 16S rRNA patterns seen in 19 patients with colorectal cancer 
and 20 healthy controls.    They observed significant elevation of several bacterial groups, such as 
Bacteroides and Fusobacterium species in the colorectal group. Furthermore, there was a positive 
correlation between Bacteroides prevalence and colorectal staging (TNM classification), suggesting 
increasing dysbiosis with tumour progression[377].  The presence of F. nucleatum in colorectal 
cancer tissue has also been noted in more advanced colorectal cancer, particularly those with lymph 
node metastasis, supporting the positive correlation[299,377]. 
 
5.5.1 Conclusion 
VOC analysis has a superior diagnostic ability for the identification of colorectal adenocarcinoma, 
when compared to other faecal based biomarkers, including those currently employed in UK 
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Greater levels of population participation in colorectal cancer screening programmes are associated 
with reduced mortality and greater cost-effectiveness[102].  Worldwide and in the UK there is a 
large degree of variation in uptake of screening and completion of the stool based testing[103].  
There are complex issues behind adherence and uptake of screening programmes, such factors have 
been reported to include those factors specific to the tests themselves, such as embarrassment and 
reluctance to handle stool[104].  Urine testing has been reported to be more socially acceptable and 




The aim of this study was to determine if the headspace volatile organic compounds (VOCs) 
detected in urine samples from patients with neoplastic and no neoplasia in the colon was different, 
allowing for the assessment of utility of faecal VOCs as a biomarker for the diagnosis and/or 
monitoring of colorectal neoplasia. 
6.1.2 Method 
 
SPME headspace extraction followed by GCMS was used to assess VOCs found in the urine of 
symptomatic and Bowel Cancer Screening Programme (BCSP) patients undergoing colonoscopy.  
Four millilitres of urine that had been subjected to 24 hours of freeze drying was used and the 
subsequent diagnosis classified as adenoma, cancer or non-neoplastic, after the colonoscopy.  A full 










6.2.1 Cohort demographics 
 
Eighty six recruited patients supplied urine samples.  The mean age of the entire cohort was 65 
years, with no difference in the mean age of those with and without colonic neoplasia.  Fifty seven 
percent of patients were male. 
Table 33: Demographics and indication for colonoscopy. 




n= 86 38 (44) 48 (56) 
Mean age 65 65 65 
Gender  
Male 51 (60) 19 (50) 32 (67) 
Female 35 (40) 19 (50) 16 (33) 
Indication  
IDA 23 (27) 16 (42) 7 (14) 
Surveillance 34 (40) 7 (18) 27 (56) 
BCSP 10 (11) 2 (5) 8 (17) 
CIBH 15 (17) 10 (26) 5 (10) 
Other 4 (5) 3 (7) 1 (3) 
 
There were twice as many males with neoplasia than females, the majority of those with neoplasia 
were referred for surveillance following a previous diagnosis of colonic neoplasia or family history of 
colorectal cancer.  Apart  from those subject to  screening or surveillance, those referred with iron 
deficiency anaemia (IDA) were the most numerous, 14% of those found to have neoplasia were 






6.2.2 VOC Characterisation 
 
A total of 134 compounds were identified across all the samples.  There was no significant difference 
the number of VOCs identified between those with and without neoplasia, p=0.5, (Table 34). 
 
Table 34: Table containing the mean number of VOCs identified in those with and without 





Mean number of VOCs 37.8 39.8 
SD 14.8 14.2 
SEM 2.4 2.1 




Figure 53: Box and whisker plot demonstrating the number of VOCs identified in the urine of those 
with and without colonic neoplasia. 










































6.2.3 Comparisons and biomarker utility assessment 
 
The standard procedures described in Chapter 2, along with the online tool Metaboanalyst, were 
used to perform the statistical analysis and biomarker assessment.  This was able to provide analysis 
of prevalence and abundance.  Of those with neoplasia at colonoscopy, further sub-analysis was also 
performed according to the size and number of adenomatous polyps identified.  Overall the 3 
comparisons were made: 
 No neoplasia and neoplasia 
 No neoplasia and adenoma >1cm in size 
 149 
 
 No neoplasia and > 4 individual adenomas of any size 
 There was no significant difference in the number of VOCs identified between the three groups.  
When comparison of prevalence was made, only the comparison of no neoplasia and adenoma 
>1cm demonstrated any significant difference.  These compounds were pyrazine, 2,3-dimethyl- 
(p=0.01) and 6-hepten-3-one, 4-methyl- (p=0.04).  No compounds were seen to be significantly 
different when assessed for abundance across the 3 different comparisons.  Principal component 
analysis and partial least squared discriminant analysis failed to show any meaningful separation.  
ROC analysis looking at diagnostic utility failed to demonstrate an AUROC of >0.65 across any of the 




This pilot study failed to demonstrate the diagnostic utility of VOCs emitted from urine as a 
biomarker for colorectal neoplasia.  Across the cohort we were able to detect and measure a 
significant number of VOCs.  There are a number of reasons why this lack of diagnostic utility may 
have been seen.  When comparing the surface area of a single adenomatous polyp to that of the 
remaining colonic mucosa in which it lies, it is easy to see how small  an impact on the overall VOC 
emission this may have.  Other studies that have suggested a diagnostic utility looked specifically at 
patients with established colorectal cancer, those that examined adenomatous polyps saw a fall in 
diagnostic ability.  Moreover many of these were not assessing urine but faeces[378].  There is clear 
evidence that VOCs are able to differentiate, IBD, IBS and infective diarrhoea, but these disease 
states involve larger proportions of the colon than neoplastic disease[379,380].  This is supported by 
our only finding a significant difference when there was a single adenoma > 1cm.   
The production of VOC within the colon is predominately from colonic bacteria.  As such, they 
represent the complex interaction of colonic cells, human gut microflora and invading 
pathogens[380].  These have been shown to be measurable in urine[309], thought to be possible as 
a result of gut permeability and the gut-liver axis, a feature which can vary between disease 
states[381].  This has been shown to increase with colonic neoplasia, with increased permeability by 
the formation of advanced adenomatous polyps and more so with established colorectal 
cancer[382].  There was only a relatively small number of patients in this study who had established 
colorectal cancer or advanced neoplasia.  This may explain the lack of diagnostic utility seen.  It may 
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also again be related to surface area and the ratio between normal and abnormal tissue, meaning 
that there is much greater tissue, with normal permeability, thus, not allowing for differentiation on 
the basis of identified VOCs.  The patients included in this study were recruited via the BCSP and also 
symptomatic patients attending for colonoscopy.  Therefore, of the 48 non-neoplastic patients, a 
number had other colonic pathology, including Crohn’s disease, ulcerative colitis and diverticulosis.  
The potential for increased gut permeability in the control group was enhanced, suggesting a 
potential mode for VOC presence in the urine being similar to that seen in neoplasia. 
Dietary intake has a significant effect upon VOC production, particularly fermentation and the 
production of short chain fatty acids[277].  All the patients included in this study provided their 
samples within 48 hours of their intended colonoscopy.  They were all advised to follow a pre-
colonoscopy diet, as is the standard practice therefore, there is the potential for similar VOC 
production as their diets were standardised.  The composition of the microbiome can change 
according to disease states, but if the patients were consuming a similar diet then it has the 
potential to homogenise the VOC pattern.  The dietary modification itself also has the potential to 
alter the gut microbiome composite[383].  Pre-colonoscopy diets advise the patients to stop 
consuming items that are high in fibre, such as fruits and cereals, and to increase their fluid intake.  
This will significantly reduce the production of SCFA such as butyrate, which, in turn, can have an 
impact upon the microbiome and overall VOC production[15]. 
When assessing VOCs in the faeces of these patients a series of differences was identified, this was 
not the case when assessing the VOCs in urine.  Many of the VOCs identified, including those 
deemed significantly different, originate from colonic fermentation e.g. SCFAs.    These compounds 
are promptly absorbed within the colon.  They are metabolised in 3 main areas, firstly by the colonic 
epithelium as a major source of energy.  Secondly, liver cells metabolise residual SCFAs for 
gluconeogenesis.  Finally, skeletal muscle tissue can metabolise SCFAs as an energy source.  Residual 
SCFAs are excreted in the faeces[384]therefore renal excretion and urinary detection is very limited.  
Patients were asked to provide urine samples up to 48 hours before their intended colonoscopy, it is 
feasible that VOCs were lost from the samples during this time.  Urine samples collected as part of 
the HCC study were frozen within in maximum of 2-3 hours of being produced, potentially  
preserving VOCs in these samples and allowing for improved detection. 
6.4 Conclusion 
Using the methodology applied to this cohort of samples, there does not appear to be a role for the 
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There is a well-described relationship between adenoma detection rates and future mortality from 
colorectal cancer. Therefore, detecting and removing adenomatous polyps is a pertinent medical 
issue. Colorectal cancer remains a leading cause of mortality and morbidity worldwide. Colorectal 
cancer screening programmes have been shown to reduce this mortality: many using faecal occult 
blood testing (FOBt) prior to colonoscopy as the initial screening tool. Other faecal-based diagnostic 
tools have been proposed, including, tumour M2-pyruvate kinase (tM2-PK).  
7.1.1 Aim 
In the current study, we have used this assay in a novel, secondary care cohort of patients derived 
from (1) the England Bowel Cancer Screening Programme and (2) symptomatic patients in an 
attempt to determine whether this assay has a role in diverse settings or as an adjunct to existing 
FOBt based screening. 
7.1.2 Method 
Patients undergoing colonoscopy in our centre were eligible for inclusion in this prospective study. 
Patients provided faecal samples immediately prior to bowel preparation. Faecal tM2-PK 
concentrations were measured using a proprietary ELISA by an investigator blinded to the patients’ 
diagnoses. Sensitivity, specificity, positive predictive value, negative predictive values and ROC 
analyses were calculated.  Kruskal-Wallis and Dunn’s post-hoc analyses were applied to numerical 
data. 
7.2 Results 
7.2.1 Patient demographics 
 
Ninety six patients returned samples within the allotted time. Thirty six patients were participating in 
the BCSP and, therefore, had a prior, positive g-FOBt. The remaining 60 were symptomatic patients 
outside  the BCSP and had an unknown FOBt status: the indications for their procedures were iron 
deficiency anaemia (n=18), change in bowel habit (n=15), surveillance or intervention for known 
polyps (n=20), family history of colorectal cancer and abnormal radiology (n=7). 52 of the cohort 
were male and 44 female. The median age was 68 years. Faecal tM2-PK levels were significantly 
higher in males (15.37 U/mL (95% CI 10.8-19.8) vs 8.034 U/mL (95% CI 5.01-10.9), p=0.01 by 2-tailed 
Student’s t-test) (Figure 54A). To characterise whether patient’s age influenced faecal tM2-PK 
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concentration, the cohort was divided into quintiles according to their age at the time of sampling. 
No significant differences in mean faecal tM2-PK were identified between any two quintiles (Kruskal-







Figure 54: A) Bar chart representing concentration of tM2-PK according to gender of patient (*p<.05, by Student’s t-test). B) Bar chart representing 
concentration of tM2-PK according to age of patients separated by quintiles. C) Box and whisker plot demonstrating tM2-PK concentration stratified by 









7.2.2 Correlation of faecal tM2-PK and the progression of colonic neoplasia 
 
Median faecal tM2-PK concentration in individuals with non-neoplastic colonoscopy results was 3.8 
U/mL, in those with either adenomatous or malignant disease the concentration was significantly 
greater (median 7.7 U/mL and 24.4 U/mL, respectively: p=0.01 by Kruskal Wallis 1-way ANOVA and 
Dunn’s post-hoc analysis, Figure 54C).  
 
7.2.3 Assessment of diagnostic ability of faecal tM2-PK for colorectal neoplasia 
 
To assess the suitability of the faecal tM2-PK ELISA as a screening test in our cohort, we categorised 
patients into those with non-neoplastic disease and those with a burden of neoplastic disease by 
colonoscopy. We performed an ROC analysis on the basis of these two groups and showed that the 
assay may have limited overall utility with an area under the ROC curve of 0.66 (p=0.006) (Figure 
59A). 
The ELISA manufacturer proposed a cut-off value of 4.0 U/mL. Adopting this as a cut-off to define a 
positive tM2-PK test, the assay’s sensitivity to detect adenoma or carcinoma was 72.4 % (95 % CI; 
59.1-83.3 %), specificity 48.7 % (95 % CI; 32.4-65.2 %), positive predictive value 67.7 % (95 % CI; 54.7-
79.2 %) and negative predictive value 36.7 % (95 % CI; 36.7-71.2 %). Application of McNemar’s test 
did not show a significant difference between the tM2-PK results and the presence of neoplasia at 
colonoscopy (p=0.73), suggesting a limited relationship between the faecal tM2-PK value and 
findings at colonoscopy. There was a false positive rate of 20.6 % across the 96 samples. In total, 37 
% of samples were incorrectly categorised by tM2-PK testing. 
The same statistical analysis was performed using a series of different threshold levels (Table 35 and 
Figure 55B). The optimal cut-off value identified by the highest McNemar’s test was at 4.8: this gave 




Figure 55: A) ROC curve showing utility of faecal tM2-PK ELISA for detection of adenomatous 
disease in this cohort, shaded area represents 95 % confidence intervals. B) Surface plot 



















Table 35: Table showing the sensitivity and specificity of different faecal tM2-PK thresholds for the 
study cohort, with binomial method McNemar values for each of these thresholds. 
Threshold Sensitivity 
% 
95 % CI Specificity 
% 





3 75.86 62.83  to 
86.13  
41.03 25.57  to 
57.90  
1.286 0.2559 
3.2 74.14 60.96  to 
84.75  
41.03 25.57  to 
57.90  
1.257 0.2559 
3.4 74.14 60.96  to 
84.75  
43.59 27.81  to 
60.38  
1.314 0.324 
3.6 74.14 60.96  to 
84.75  
43.59 27.81  to 
60.38  
1.314 0.324 
3.8 74.14 60.96  to 
84.75  
48.72 32.42  to 
65.22  
1.446 0.6177 
4 72.41 59.10  to 
83.34  
48.72 32.42  to 
65.22  
1.412 0.7359 
4.2 72.41 59.10  to 
83.34  
48.72 32.42  to 
65.22  
1.412 0.7359 
4.4 72.41 59.10  to 
83.34  
51.28 34.78  to 
67.58  
1.486 0.7359 
4.6 72.41 59.10  to 
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Of the 50 patients with adenomatous disease 22 were found to have a single polyp greater than 1cm 
in size. The median faecal tM2-PK reading for this group was 5.7 U/mL (interquartile range 1.3-19.5). 
Of these patients, 59 % (n=13) had a faecal tM2-PK result above the 4.0 U/mL cut-off, representing a 
true positive result by the assay manufacturer’s criteria. There was no significant difference in the 
tM2-PK concentration detectable in the faeces of patients with polyps >1cm or <1cm, p=0.63 (Figure 
60A). There was also no significant difference in the tM2-PK concentration in faeces of those with <5 
or ≥5 adenomatous polyps (Figure 56B). 
 
Figure 56: A) Box and whisker plot showing faecal tM2-PK concentration stratified by size of 
largest adenoma. B) Box and whisker plot of faecal tM2-PK concentration stratified by the number 




7.2.4 Assessment of faecal tM2-PK as adjunct to gFOBt in BCSP 
 
When we isolated those individuals (n=36) referred for colonoscopy, as part of the BCSP, those with 
neoplasia (n=25) were found to have significantly greater faecal tM2-PKconcentration than those 
without neoplastic pathology (Figure 57A, p=0.03). A macroscopically normal colonoscopy was seen 
in all BCSP patients who did not otherwise have neoplastic disease (n=11). ROC analysis of the BCSP 
patients alone demonstrated an AUROC of 0.82 (p=0.002) (Figure 61B).  Sixty one percent of patients 
with a prior positive fFBOt also had a positive tM2-PK.  Of the BCSP with no neoplasia, 72% had a 
negative tM2-PK, whilst 76% of those with neoplasia had a positive tM2-PK. 
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This difference was not observed in the non-BCSP group; 29 of whom were classified as non-
neoplastic, of these 7 had IBD and/or diverticulosis. Within this subset, 6 had elevated (false 
positive) tM2-PK concentration. The remaining 22 subjects had a macroscopically normal 
colonoscopy, and 11 received a true negative faecal tM2-PK result, whilst 11 had falsely positive 
















Figure 57: A) Box and whisker plot demonstrating faecal tM2-PK concentration in patients recruited via BCSP or non-BCSP route, and with or without 
adenomatous pathology (*p<0.05, **p<0.01, by Kruskal Wallis 1-way ANOVA and Dunn’s post-hoc analysis). B) ROC curve demonstrating the diagnostic 
accuracy of faecal tM2-PK ELISA in patients recruited following colonoscopy referral from the BCSP. C) ROC curve demonstrating the diagnostic accuracy 









In our secondary care cohort, the faecal tM2-PK assay appears to have a sensitivity that is 
comparable to, and in some instances, superior to existing faecal markers used as part of colorectal 
cancer screening programmes. The present study demonstrates a superior sensitivity to that 
associated with g-FOBt. However, the main issues that will prevent its independent use are its 
comparatively low specificity, high false positive rate and time constraints for sample collection. Its 
use with existing FOBt methods does, however, seem appealing. Combining the two methods 
appears to rectify some of the flaws of each, and could improve the accuracy of an initial faecal 
biomarker screening tool.  One role may be the sequential use of gFOBt followed by tM2-PK. 
However, the introduction of this type of screening would represent additional time and financial 
burdens that may constrain the use of these investigations. Ultimately, in order to justify their use, a 





The faecal tM2-PK concentration observed in this study demonstrated an increasing trend as 
pathology progressed along the adenoma-carcinoma pathway, supporting potential utility for the 
assay to distinguish between absence and presence of neoplastic disease.  
Our cohort contained more males, with a median age of 68, and was therefore, representative of a 
potential colorectal cancer population. The faecal tM2-PK concentration was higher in males, with 
age apparently  having no impact on the abundance of this enzyme. In a clinical setting, this lack of 
variation with age could be deemed beneficial.  
Based on the manufacturer’s threshold value of 4 U/mL, we found that the assay’s sensitivity to 
detect any adenomatous pathology was 72 % with specificity of 48 %. This is consistent with the 
findings of a meta-analysis, from 2012, which examined seventeen studies and found the quoted 
sensitivities, for colorectal cancer, to range from 68-97 % and adenoma detection to range from 28-
76 %.Within the meta-analysis several of the studies focused solely on the detection of carcinoma, 
rather than adenomatous polyps.   
To optimise the diagnostic accuracy of a faecal tM2-PK assay ,within a future screening programme, 
the diagnostic threshold for the assay could be adjusted away from the manufacturer’s 
recommended threshold of 4 U/mL. To understand whether this process may have utility we applied 
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a series of thresholds to our data set and calculated binomial McNemar statistics to define the 
threshold with optimal diagnostic utility for our cohort. Using this methodology we demonstrated 
optimal utility with a threshold of 4.8 U/mL. This led to an improved sensitivity of 69.0 % and 
specificity of 56.4 % in our cohort. At this threshold 40.2 % of tests yielded  true positive results, 
22.7% a true negative, whilst 17.5 % were false positive results and 19.5 % were false negative 
results. One of the obvious frailties of this methodology is that with this statistical approach the 
consequences of false negative and false positive results are conferred equal weighting. This is 
clearly not the case in this clinical situation, where the consequences of a false negative result 
manifestly outweigh those of a false positive. 
Using the manufacturer’s recommended threshold of 4 U/mL the faecal tM2-PK assay had a lower 
false negative rate of 16.5 %, but an increased false positive rate of 20.6 % in our cohort. Whilst this 
threshold could reduce the number of patients with adenomatous disease that were not detected by 
the faecal tM2-PK assay, it would lead to an increased number of endoscopic procedures that 
yielded no adenomatous pathology being performed. This false positive rate is substantially higher 
than that reported by Tonus et al[194], but is consistent with a study from 2006 which reported a 
low specificity with high false positive rate [385], suggesting that it may be within the range 
expected in a clinical cohort. One study from the USA estimated that a 5–10 % false positive rate 
during colorectal screening would amount to an expense of US$6 billion if 100 % participation rate is 
assumed [386]. The current UK Bowel Cancer Screening Program reports a sensitivity of 36.5 % and 
specificity of 92.2 % for g-FOBt. The literature suggests that if a different screening tool were to be 
implemented, for example i-FOBt, a higher detection rate could be achieved e.g. a sensitivity of 70.9 
% and specificity of 96.3 % [387]. The consequence of a false negative test in bowel cancer screening 
is grave and, therefore, the lower specificity associated with tM2-PK testing will mean it is unlikely to 
replace either of these methods in colorectal screening or as a preliminary test in a secondary care 
based population. False positive results have been reported in inflammatory bowel disease, infective 
disease and diverticulosis[388,389], this is replicated in our cohort as those with non neoplastic 
pathology and no prior FOBt had a false positive rate of 50 %. 
The combination of FOBt with faecal tM2-PK ELISA has been proposed as a strategy to optimise the 
sensitivity and specificity for a screening programme. When we segregated our cohort into those 
recruited from the BCSP and those with other indications for colonoscopy we demonstrated greater 
diagnostic utility for tM2-PK ELISA in patients recruited from the bowel cancer screening population. 
This was associated with a significantly lower median tM2-PK concentration in the faeces of patients 
without adenomatous disease in the BCSP cohort compared to those without adenomatous disease 
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in the non-BCSP cohort. This suggests that the utility of faecal tM2-PK as a biomarker for colonic 
adenomatous disease may be limited to the relatively homogenous asymptomatic screening cohort, 
rather than the more heterogenous group of symptomatic patients.  
A study from 2014 assessed the utility of g-FOBt with faecal tM2-PK ELISA prior to potential 
colonoscopy. 1800 individuals were invited to participate, with a response rate of 54 % (n=978), 
culminating in over 800 analysable samples being returned and 186 colonoscopies being performed. 
Overall, positivity was significantly increased by the addition of tM2-PK (27 %). Had only i-FOBt been 
tested, 77 % (n=189) fewer patients would have had a positive faecal test and been identified for a 
screening colonoscopy and 70 % (n=35) fewer patients would have had polyps detected and 
removed[390]. This study also reported that 10 % (n=99) of tM2-PK samples could not be analysed, 
because of a lapse in the 48 hour window required for its processing. This is clearly an issue for a 
postal based screening programme as is currently in operation in the UK. A further study from Italy 
assessed the impact of combined testing on 280 samples. For colorectal cancer detection, i-FOBt was 
the test with the highest specificity and positive predictive value (0.89 and 0.53), whereas tM2-PK 
had the highest sensitivity and negative predictive value (0.87 and 0.96). It demonstrated a good 
ability of the combined test to identify colorectal cancer, with patients showing positivity to both 
markers, the risk of cancer was as high as 79 % [391]. Other assays have been assessed in 
combination with FOBt, including faecal calprotectin, which demonstrated sensitivity for the 
detection of colorectal cancer of 79 %, whereas the sensitivity for the combination of i-FOBt and 
tM2-PK was 93 % [392]. 
An analysis of 697 patients in the Cleveland Clinic Foundation Adenoma Registry showed that, 
compared with one to two small adenomas, risk is increased 10-fold after removal of multiple 
adenomas at least one of which is larger than 1 cm [393], and adenomas of >1cm diameter identify 
individuals at increased risk of colorectal cancer even if removed [394]. It is therefore clinically 
important to identify polyps of >1cm diameter. With increasing size, one might predict increased 
abundance of tM2-PK, however within our cohort this was not the case.  
There is a similar increase in risk for those with ≥5 individual polyps, even if they are all <1cm in size. 
The apparent utility of the tM2-PK assay to detect polyps irrelevant of size makes it appealing for use 
in a screening or surveillance programme. Another beneficial element of this finding is that polyps 
<1cm do not tend to bleed and, therefore, may be missed by FOBt [395]. The tM2-PK assay does not 
have this problem as it does not rely on the presence of blood and, therefore, has the potential to 
detect non-bleeding adenomatous disease. Moreover, in our cohort no difference in the abundance 
of tM2-PK was identified in those with 5 or more adenomas, compared to those with fewer. 
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The application of tM2-PK shows potentially beneficial outcomes when used in a homogenous 
clinical group, such as the BCSP. The interference from a heterogeneous population, such as our 
secondary care cohort appears to impact upon the diagnostic utility of faecal tM2-PK analysis. A 
dedicated randomised controlled study would be required to explore this potential combination 




In our secondary care cohort, the faecal tM2-PK assay appears to have a sensitivity that is 
comparable to, and in some instances, superior to existing faecal markers used as part of colorectal 
cancer screening programmes. The present study demonstrates a superior sensitivity to that 
associated with g-FOBt. However, the main issues that will prevent its independent use are its 
comparatively low specificity, high false positive rate and time constraints for sample collection. Its 
use with existing FOBt methods does however seem appealing. Combining the two methods appears 
to rectify some of the flaws of each, and could improve the accuracy of an initial faecal biomarker 
screening tool.  One role may be the sequential use of gFOBt followed by tM2-PK. However, the 
introduction of this type of screening would represent additional time and financial burdens that 
may constrain the use of these investigations. Ultimately, in order to justify their use, a reduction in 






























8.1 Concluding discussion 
 
The UK incidence of both colorectal cancer and HCC is increasing in the UK.  Screening and early 
diagnosis of gastrointestinal malignancies has the ability to improve outcomes by reducing morbidity 
and mortality[5,129].  In the UK screening for HCC and colorectal cancer is currently adopted.  There 
is clear evidence that the UK BCSP has reduced colorectal cancer associated mortality, namely via 
the identification of pre-malignant adenomatous polyps, leading to their removal and thus 
preventing formation of adenocarcinoma.  The evidence for such an impact of HCC screening in 
cirrhotic patients is less robust, but is supported by national and international guidance[127,129].    
Both programmes have areas that could be improved.  For the BCSP, the FOBt used as a pre-screen 
to colonoscopy leads to a high false positive rate and thus potentially unnecessary colonoscopy.  This 
has significant financial implications for the screening programme and NHS.  Screening for HCC is 
currently based upon periodic USS assessment.  Therefore, the process is not employing a point of 
care test or pre-screening test prior to the diagnostic test.  As evidenced by my work and other work 
in the published literature, VOCs appear to have the potential to supplement both programmes in 
order to improve the overall diagnostic accuracy and thus overall impact, whilst limiting 
expenditure[306,311,312,365].   
A point of care test either used in general practice or as part of population based screening, 
conducted via a sensor based technology appears to be the most appropriate application of VOCs as 
a biomarker for gastrointestinal neoplasia[396].  For both colorectal cancer and HCC such technology 
would be best placed to select those required to undergo further investigations, i.e. colonoscopy for 
colorectal cancer and USS for HCC.  Using such “pre-screen” methods with improved sensitivity 
would limit the number of false positives that lead to unnecessary costly investigation.  Obviously 
this should not be at the expense of inferior specificity as the consequence of a false negative is a 
missed cancer and therefore could have grave implications. 
Other faecal based assays are available for the diagnosis of colorectal cancer, for example the faecal 
tM2-PK assay that is described in chapter 7.  The main issues that will prevent its independent use 
are its comparatively low specificity, high false positive rate and time constraints for sample 
collection. Its use with existing FOBt methods does however seem appealing. Combining the two 
methods appears to rectify some of the flaws of each, and could improve the accuracy of an initial 
faecal biomarker screening tool.  One role may be the sequential use of gFOBt followed by tM2-PK.  




Ultimately, in order to justify the use of either VOCs or other screening tool a reduction in mortality 
and morbidity from colorectal cancer or HCC will have to be demonstrated. 
The genetic abnormalities associated with the development of colorectal cancer are well described.  
Less is known about the association between the host microbiota and the development of colorectal 
cancer.  It can be difficult to prove a causative role for specific bacteria, but attempts have been 
made through the description of such models as the bacterial driver-passenger model of colorectal 
cancer[343].  This model suggests that as the colonic mucosa becomes more neoplastic there is 
preferential selection of passenger bacteria that overpopulate the abnormal tissue.  Their actions, 
including their metabolic productions, promote the ongoing existence and growth of the neoplastic 
tissue[350,353].  
There are a number of limitations within the studies described that should be highlighted.  Regarding 
the investigation of VOCs emitted from stool as a biomarker for colorectal neoplasia the number of 
cancer samples were limited along with the clinical information relating to them.  Ideally there 
would have been a larger number of cancer samples across all 3 regions of recruitment.  This would 
allow for a better assessment of inter-regional variability of VOCs.  Staging of the cancer, either 
radiologically or histologically would have improved analysis.  This would have allowed the 
separation of potentially curable disease, much like that explored in the VOCs emitted from urine as 
a biomarker for HCC study.  A further point of improvement would have been to record the 
anatomical location of each cancer or polyp in order to ascertain if there is a difference between left 
and right sided disease.  This is of particular importance as the Bowel Scope screening programme is 
being rolled out across England. 
Additional testing of the gFOBt status of all the non-BCSP samples would allow for further analysis to 
be performed.  This would allow for a direct comparison of the diagnostic accuracy of VOCs and 
gFOBt in order to determine if VOCs are superior.  It would also further explore the whether the two 
approaches could be synergistic in the identification of neoplasia.  This would also allow for further 
exploration of the results seen in chapter 7.   
Recruitment for the HCC study took place in Liverpool only.  This was across two centres but still 
within a single geographic region, this could be considered as a weakness.  Moreover the majority of 
HCC samples were recruited from a single centre, as this acts as the regional referral hospital.  As 
discussed in chapter 3 the VOCs emitted from urine can be influenced by a number of factors 
including ethnicity and diet.  Therefore to improve this element future work should aim to recruit 
from a number of regions within the UK or even on an international scale.  It should also aim to 
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match its recruitment to the ethic profile of the UK, according to census data.  This should also be in 
conjunction with consideration to recruit pathology equally across centres in order to account of 
differences in disease/patient management. 
8.2 Future work 
There are a number of avenues to explore as a result of the work discussed.  This includes larger 
scale duplication studies, mechanistic exploration of the associated microbiota and origins of the 
VOCs identified and application of the methodology to other pertinent medical issues.   
A larger scale study would certainly be required for both the faecal colorectal cancer VOC study and 
the urinary HCC VOC study.  The larger colorectal study, would involve a number of sites across the 
UK in order to account for any geographical variability in diet and ethnic composition of the 
populations.  It would also involved recruitment of a much larger cohort, allowing for sub-analysis of 
adenoma size, histological appearance and anatomical location of colorectal cancer and adenomas.  
FOBt could also be conducted on all stool in order to directly compare the performance of VOCs to 
FOBt as a pre-screen to colonoscopy and whether combining the two could improve selection for 
colonoscopy.  The discovery study described in chapter 5 identified a 3 VOC biomarker panel.  A 
larger scale study would act to explore/confirm the application of this panel.  This could be through a 
tailored GCMS methodology, or via a new sensor technology, such as Odoreader© or new in-house 
collaborative sensor technology specifically designed to only identify the 3 VOCs.   Clearly the origins 
of significant VOCs needs exploration and explanation.  Bacterial genetic sequencing technologies 
can be employed in order to detect difference in the microbiota associated with the presence of 
adenoma and/or carcinoma, this can be performed on the stool provided.  Metabolic pathways and 
VOC production by specific pathogens can then be explored, as per chapter 4.  VOC analysis of 
colorectal cancer organoid culture may also allow for the assessment of the source of significant 
VOCs.  
A larger, multi-centred study for the use of urinary VOCs for the diagnosis of HCC would address 
geographical issues identified in the study conducted.  It would also allow for an increase in the 
range and number of underlying aetiologies, thus being more representative of a screening 
population.  Once again a panel of VOCs can be better explored with other sensor technologies.  It 
would also allow for the assessment of the model described, particularly those identifying as 
diagnostic for BCLC curative HCC.  Coupled to this larger study, VOC analysis of HCC tissue from 
resected tumours could be performed, allowing for the explanation of the origin of such compounds.  
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A prospective study, whereby urinary VOCs are coupled to USS surveillance would allow the 
assessment of the use of VOCs as a pre-screen tool to USS based screening. 
The methodologies used to explore colorectal cancer and HCC could be applied to other 
gastrointestinal issues.  One such issue is the early identification of intestinal anastomotic leak 
following surgical resection.  Patients undergoing intestinal resection with a primary anastomosis are 
at risk of anastomotic breakdown and leak of luminal content into the peritoneum.  This has been 
reported to be in the region of 5% of cases[397].  Particularly in oncological procedures, this results 
in worse outcomes and a reduced 5 year survival[398].  Typically in the immediate post operative 
period surgical drains are placed and remain in situ for 2-3 days post op.  As luminal content leaks 
into the peritoneum, so too does the gut microbiota, one could assume that the associated VOC 
profile in the drain fluid would alter to represent the presence of such bacteria.  Periodic VOC 
analysis of the drain fluid could be used to identify those who have leaked or ideally, in whom a leak 
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A non-invasive diagnostic indicator for 
Colorectal Cancer 
 
An invitation to you 
You are being invited to take part in a research study. You DO NOT have to take part and your 
treatment WILL NOT BE AFFECTED in any way by any involvement, or otherwise, in this project. 
Before you decide, it is important for you to understand why the research is being done and what it 
will involve. Please read the following information carefully and discuss it with friends, relatives or 
your GP/ward doctor as you wish. Please do not hesitate to contact us if there is any aspect of the 
research that is not clear or if you would like more information. The purpose of this document is to 
invite you to take part in medical research.   
 
Purpose of this study 
We intend to collect the gas that makes the smell from your stool and urine samples. Your samples 
will be used to investigate whether there are any changes in the chemicals contained in the faeces 
and urine which may be used to diagnose colorectal (large bowel) cancer or polyps (a potentially 
early form of the cancer). We are aware that patients with a wide variety of bowel and liver 
disorders experience unpleasant faecal odour. Recent evidence also suggests that dogs can detect a 
change in the smell from their owners, if they develop cancer.  
We have already found several chemicals that may be used to determine when the stool contains 
various bacteria and viruses. We will analyse the faecal and urine odours to determine whether 
particular smells are linked to colorectal cancer and colonic polyps.  
 
Nature of the research 
The chemicals making up faecal and urinary odours will be analysed from the space in the closed 
tube above the samples. The gas, stool, urine contents and any bacteria grown from the samples will 
not be retained after the completion of the research project. All samples will be entirely destroyed 
by incineration upon completion of the project. 
 
Why have you been chosen to participate? 
There a number of different types of patients being asked to participate in this study. 
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You may have been selected as you have a positive Faecal Occult Blood test. This means that the 
presence of a small amount of blood has been detected in your stool. Blood in the stool can be one 
sign of colorectal (large bowel) cancer or colonic polyps and you have been advised to attend for a 








You are having a colonoscopy for a change in bowel habit or iron deficiency anaemia.  Please note 




You are due to undergo an operation for a known/possible colorectal cancer.  Or you are under the 
care of the colorectal team.  
 
We would like a sample of your stool and urine.  
 
What is required of me? 
Please collect a sample of stool and urine before you take your bowel preparation (laxative) 
medication, using the equipment provided, and place it in the dedicated pots in the pack. Once you 
have given us the samples, we will ask you to fill in a form to give some more information about your 
age, ethnic origin and whether the stool sample comes from a stool that is normal for you. Please 
label the pots with your name and date of birth, enclose the sample pot in the small plastic bag 




Who is organising the study? 
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Professor Chris Probert, Professor in Gastroenterology, leads this study.  Dr Ashley Bond, Clinical 
Research Fellow, will handle sample collection, data handling and experiments on the samples to 
analyse the odour. Both are doctors employed by the University of Liverpool and Royal Liverpool 
University Hospital 
 
What will happen to me if I take part? 
After you pass the two specimens into the sample tubes and provide this to us at your colonoscopy, 
this will be frozen and we will analyse the odour to identify its chemical composition. No other input 
is required from you. Nothing additional will happen to you as part of this study. 
 
Do I have to donate this faecal sample?  
No. You are completely free to decline donation - this will not affect your treatment. 
 
Are there any risks or disadvantages in taking part in this study? 
No. 
 
What are the possible benefits of taking part? 
This research on faecal and urinary odours will help us to identify chemicals that will hopefully allow 
earlier diagnosis of colorectal cancer and therefore increase the potential for cure. There will be no 
direct benefit to you. 
 
Is my doctor being paid for including me in this study?  
No. 
 
What if something goes wrong? 
There are no potential side effects of using your faecal and urine samples in this study. 
 
Confidentiality - who will know I am taking part in the research? 
Prof. Probert, Dr Bond and the management of the NHS Bowel Cancer Screening Programme. All of 
the individuals mentioned above are bound by NHS confidentiality requirements and the Data 




Confidentiality – sample storage and data handling 
Details of your age, sex and selected questions which will have relevance to the interpretation of 
your sample results will be gathered on the attached form. These data, along with the sample, will 
then be catalogued and stored confidentially and anonymously. All data will be disposed of at the 
end of the project.  Please be advised we will follow up your medical records for comparison with 
the VOCS results 
 
Confidentiality - anonymity 
Your sample will be catalogued with unique identifier. This can only be traced back to you by 
Professor Probert or Dr. Bond, who will have access to the master list.   
 
Retention of tissue and faecal and samples  
Your sample will be used only for the research specified and will be destroyed by incineration upon 
completion of the research project. No tissue is being retained or stored for any other purpose. 
 
Local Ethical Committee Approval  
All research in the NHS is looked at by independent group of people called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity.  This study has been reviewed and 
given favourable opinion by the Royal Liverpool University Hospital and University of Liverpool 
Research and Development Departments, the local (Mersey) Research Ethics Committee and the 
Colorectal Cancer National Screening Programme to ensure that it meets the NHS national standards 
for research involving human patients.  South 
West-Central Bristol REC have reviewed and approved the study.  
 
 
What will happen to the results of the study?  
We will use the data obtained from your samples to try to devise a test for the early diagnosis of 
colorectal (large bowel) cancer.  The result of this study will be published in an appropriate journal, 
all results will be anonymised. 
 
Further information  




Department of Gastroenterology, 
University of Liverpool 
Tel: 0151 794 6822 
abond@liverpool.ac.uk 
PALS – Patient Advice and Liaison Service (independent of us) 
Tel: 0800 218 2333 
 
Thank you for reading this. 
We hope that you will be able to help us with our research.  
CS Probert and AD Bond 
General history about your health (please write your answers next to the questions): 
 
1. Are you a current smoker? 
 
 




3. Are you a vegetarian? 
 
 
4. Have you taken any antibiotics at any point over the last 6 months? 
 
5. Approximately how many units of alcohol do you drink each week? (1 pint of lager or 1 
normal 175ml  glass of red wine is approx 2.5 units) 
 
6. Place of birth/ethnicity 
 
 





CONSENT FORM The role of faecal and urinary Volatile Organic Compounds (VOCs) as a non-invasive 























I confirm that I have read and understand the information 
sheet for the above study (Version 2, date 25/11/14) and have 
had the opportunity to consider the information, ask questions 







I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason and 










I understand that relevant sections of my medical notes, and 
data collected during the study, may be looked at by individuals 
from regulatory authorities or from the NHS Trust where it is 
relevant to my taking part in this research. I give permission for 















A non-invasive diagnostic indicator for 
Hepatocellular carcinoma 
 
An invitation to you 
You are being invited to take part in a research study. You DO NOT have to take part and your 
treatment WILL NOT BE AFFECTED in any way by any involvement, or otherwise, in this project. 
Before you decide, it is important for you to understand why the research is being done and what it 
will involve. Please read the following information carefully.. . The purpose of this document is to 
invite you to take part in medical research.   
 
Purpose of this study 
We intend to collect the gas that makes the smell from your urine samples. Your samples will be 
used to investigate whether there are any changes in the chemicals contained in the urine which 
may be used to diagnose Hepatocellular (liver) cancer...  
We have already found several chemicals that may be used to determine when the urine contains a 
scent associated with liver disease and liver cancer. We will analyse the urine odour to determine 
whether particular smells are linked to liver cancer.  
 
Nature of the research 
The chemicals making up urine odour will be analysed from the space in the closed tube above the 
urine sample. The gas and urine contents from the samples will not be retained after the completion 
of the research project. All samples will be entirely destroyed by incineration upon completion of the 
project. 
 
Why have you been chosen to participate? 
You have been selected to participate as you have one of the one of the following conditions: 
1) Chronic liver disease without cirrhosis 
2) Chronic liver disease with cirrhosis 
3) A diagnosis of Hepatocellular carcinoma 
It is anticipated that we will use those without a cancer diagnosis as our control group 
 
What is required of me? 
 211 
 
All we require from you is a urine sample today during your clinic appointment and completion of 




Who is organising the study? 
Professor Chris Probert, Professor in Gastroenterology, leads this study.  Dr Ashley Bond, Clinical 
Research  Fellow, will handle sample collection, data handling and experiments on the sample to 
analyse the odour. Both are doctors employed by the University of Liverpool and Royal Liverpool 
University Hospital.  There will also be assistance from Dr Tim Cross at the Royal Liverpool University 
Hospital and Dr Nick Stern at University Hospital Aintree.  Dedicated nurse specialist and research 
nurse will discuss sample collection with you at each site. 
 
What will happen to me if I take part? 
After you provide the urine sample during the clinic appointment, this will be frozen and we will 
analyse the odour to identify its chemical composition. No other input is required from you. Nothing 
additional will happen to you as part of this study. 
 
Do I have to donate this urine sample?  
No. You are completely free to decline donation - this will not affect your treatment. 
 
Are there any risks or disadvantages in taking part in this study? 
No. 
 
What are the possible benefits of taking part? 
This research on urine odours will help us to identify chemicals that will hopefully allow earlier 
diagnosis of liver cancer and therefore increase the potential for cure. There will be no direct benefit 
to you. 
 





What if something goes wrong? 
There are no potential side effects of using your urine sample in this study. 
 
Confidentiality - who will know I am taking part in the research? 
Prof. Probert, Dr Bond. All of the individuals mentioned above are bound by NHS confidentiality 
requirements and the Data Protection Act.  
 
Confidentiality – sample storage and data handling 
Samples will be allocated an anonymous study number and all data will be anonymous.  
Only clinical information relevant to the study will be looked at by the investigators.All data 
will be disposed of at the end of the project. 
 
Confidentiality - anonymity 
Your sample will be catalogued with unique identifier. This can only be traced back to you by 
Professor Probert or Dr. Bond, who will have access to the master list.   
 
Retention of urine samples  
Your sample will be used only for the research specified and will be destroyed by incineration upon 
completion of the research project. No tissue is being retained or stored for any other purpose. 
 
Local Ethical Committee Approval  
All research in the NHS is looked at by independent group of people called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity.  This study has been reviewed and 
given favourable opinion by the NRES Committee South East Coast Brighton and Sussex. 
 
What will happen to the results of the study?  
We will use the data obtained from your samples to try to devise a test for the early diagnosis of 
hepatocellular carcinoma (liver cancer).  We intend to seek publication of the results in academic 
journals, you would have full access to these potential results. 
 
Further information  




Dr Ashley Bond 
Department of Gastroenterology, 
University of Liverpool 
Tel: 0151 794 6822 
Email: abond@liverpool.ac.uk 
 
PALS – Patient Advice and Liaison Service (independent of us) 
Tel: 0800 218 2333 
 
Thank you for reading this. 
We hope that you will be able to help us with our research.  
 
CS Probert and A Bond 
General history about your health (please write your answers next to the questions): 
 




2. Are you a vegetarian? 
 
 
3. Approximately how many units of alcohol do you drink each week? (1 pint of lager or 1 
normal 175ml  glass of red wine is approx 2.5 units) 
 
 
4. Place of birth/ethnicity 
 
 





The role of urinary volatile organic compounds as a non-invasive 
diagnostic biomarker for hepatocellular carcinoma. Principal Investigator:  
Professor Chris Probert                                               Please initial box                                                                       
 
_________________________________  _________________    _____________________ 
Patients name                                               Date                              Signature                                                                                                                                                                                                                           
                           
__________________________________ ___________________  ____________________ 






I confirm that I have read and understand the information sheet for 
the above study and have had the opportunity to consider the 








I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason and without my 










I understand that relevant sections of my medical notes, and data 
collected during the study, may be looked at by individuals from 
regulatory authorities or from the NHS Trust where it is relevant to my 
taking part in this research. I give permission for these individuals to 





























































































































































Example of Metaboanalyst 
data handling description 
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